Pharma & Biotech Sector Financials, Performance and Ratios
-
Sector Score
38.0 /100
Rank 13 out of 27 Sectors -
Advance/Decline
395/253
-
No. of Companies648
-
Avg. Market Cap8,641
-
Price to Earning Ratio4.82
-
Price to Earning Growth Ratio0.91
-
Price to Book Ratio36.00
-
Return on Equity6.09
-
Return on Capital Employed-
-
Return on Assets3.00
-
Dividend yield 1 year %0.64 %
-
Net Profit Growth Annual YoY %46.34 %
-
Net Profit Growth Qtr YoY %249.57 %
-
Net Profit Growth Qtr QoQ %-71.99 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Pharma & Biotech Sector Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Pharma & Biotech Peer comparison
Compare all stocks in Pharma & Biotech industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie |
|
398,270.4
|
225.4
|
L
 1.1%
H
221.7
227.1
|
L
 5.9%
H
209.0
230.5
|
L
 11.8%
H
202.0
230.5
|
L
 -2.0%
H
190.8
231.3
|
L
 18.8%
H
181.7
244.8
|
L
 63.8%
H
131.0
244.8
|
L
 100.7%
H
105.6
244.8
|
L
 265.2%
H
55.1
244.8
|
| Adc Therapeutics SA |
|
139.9
|
1.1
|
L
 12.2%
H
1.0
1.2
|
L
 -67.7%
H
0.8
3.4
|
L
 -68.6%
H
0.8
3.7
|
L
 -73.2%
H
0.8
5.0
|
L
 -70.0%
H
0.8
5.0
|
L
 -56%
H
0.4
6.0
|
L
 -94.9%
H
0.4
32
|
L
H
0.4
56.6
|
| Amneal Pharma Inc (Class A) |
|
4,686.4
|
14.7
|
L
 7.2%
H
13.8
14.7
|
L
 13.9%
H
12.5
14.7
|
L
 11.3%
H
11.8
14.7
|
L
 11.0%
H
11.7
14.7
|
L
 92.8%
H
7.5
15.4
|
L
 512.1%
H
2.3
15.4
|
L
 157.3%
H
1.2
15.4
|
L
 -56.4%
H
1.2
33.8
|
| Annovis Bio Inc |
|
75.3
|
1.8
|
L
 -1.1%
H
1.7
1.8
|
L
 -2.8%
H
1.7
2.1
|
L
 -22.4%
H
1.7
2.5
|
L
 -28.9%
H
1.5
3.0
|
L
 -44.9%
H
1.5
5.5
|
L
 -87.2%
H
1.1
22.5
|
L
 -97.6%
H
1.1
132
|
L
H
1.1
132
|
| Bausch Health Companies Inc |
|
1,930.9
|
5.2
|
L
 1.2%
H
5.1
5.3
|
L
 -2.6%
H
4.9
5.4
|
L
 -10.1%
H
4.9
5.8
|
L
 -3.9%
H
4.9
6.3
|
L
 8.6%
H
4.8
8.7
|
L
 -27.2%
H
4.0
11.5
|
L
 -83.5%
H
4.0
32.1
|
L
 -78.4%
H
4.0
34.8
|
| Bristol-Myers Squibb |
|
115,336.2
|
56.5
|
L
 1.6%
H
55.3
56.5
|
L
 2.8%
H
54.2
57.8
|
L
 0.6%
H
54.2
60.3
|
L
 -6.3%
H
54.2
62.2
|
L
 16.7%
H
42.5
62.9
|
L
 -13.5%
H
39.4
66.4
|
L
 -11.3%
H
39.4
81.4
|
L
 -23.1%
H
39.4
81.4
|
| Emergent Biosolutions Inc |
|
410.2
|
8.0
|
L
 -0.6%
H
7.6
8.2
|
L
 -6.4%
H
7.6
8.5
|
L
 -16.3%
H
7.6
9.7
|
L
 -4.1%
H
7.5
9.7
|
L
 19.9%
H
5.6
14.1
|
L
 -5.2%
H
1.4
15.1
|
L
 -87.6%
H
1.4
68.0
|
L
 -80.8%
H
1.4
137.6
|
| Elanco Animal Health Inc |
|
12,236.5
|
24.5
|
L
 3.5%
H
23.9
24.7
|
L
 3.5%
H
23.0
26.2
|
L
 3.6%
H
19.4
26.2
|
L
 4.9%
H
19.4
26.3
|
L
 76.3%
H
13.2
27.7
|
L
 162.0%
H
8.0
27.7
|
L
 -26.6%
H
7.9
37.5
|
L
H
7.9
37.6
|
| GSK PLC (ADR) |
|
102,767.9
|
51.3
|
L
 1.2%
H
50.4
51.3
|
L
 3.9%
H
48.6
52.0
|
L
 1.7%
H
48.6
52.1
|
L
 -6.0%
H
48.6
59.6
|
L
 24.4%
H
35.5
61.7
|
L
 47.6%
H
31.7
61.7
|
L
 29.7%
H
28.5
61.7
|
L
 18.4%
H
28.5
61.7
|
| Johnson & Johnson |
|
570,510.4
|
237
|
L
 2.1%
H
230.4
237.7
|
L
 6.0%
H
221.2
237.7
|
L
 7.1%
H
220.4
237.7
|
L
 -1.4%
H
220.4
247.2
|
L
 52.9%
H
149.0
251.7
|
L
 47.9%
H
140.7
251.7
|
L
 45.1%
H
140.7
251.7
|
L
 104.7%
H
109.2
251.7
|
| Eli Lilly |
|
1,020,758.6
|
1,144.7
|
L
 -0.4%
H
1137.8
1174.6
|
L
 5.8%
H
1052.2
1182.7
|
L
 20.7%
H
943.3
1182.7
|
L
 15.6%
H
850.5
1182.7
|
L
 48.7%
H
623.8
1182.7
|
L
 156.9%
H
434.3
1182.7
|
L
 418.7%
H
217
1182.7
|
L
 1428.1%
H
64.2
1182.7
|
| Merck & Company |
|
295,391.0
|
119.6
|
L
 0.1%
H
118
120.5
|
L
 3.9%
H
114.5
123.5
|
L
 7.4%
H
110.9
123.5
|
L
 3.3%
H
107.9
124
|
L
 51.5%
H
76.7
125.1
|
L
 8.4%
H
73.3
134.6
|
L
 65.2%
H
70.9
134.6
|
L
 117.5%
H
50.4
134.6
|
| Nuvation Bio Inc (Class A) |
|
1,716.6
|
4.9
|
L
 2.7%
H
4.6
5.6
|
L
 -0.6%
H
4.6
5.6
|
L
 2.9%
H
4.1
5.6
|
L
 7.4%
H
4.0
5.6
|
L
 98.8%
H
1.6
9.8
|
L
 185.0%
H
1.0
9.8
|
L
 -63.6%
H
1.0
13.5
|
L
H
1.0
15.2
|
| Novo Nordisk (ADR) |
|
186,861.9
|
42.2
|
L
 2.9%
H
41.1
42.3
|
L
 -4.3%
H
41
44.4
|
L
 -8.4%
H
41
47.8
|
L
 9.4%
H
35.1
47.8
|
L
 -43.5%
H
35.1
81.4
|
L
 -47.1%
H
35.1
148.2
|
L
 2.6%
H
35.1
148.2
|
L
 47.6%
H
15.5
148.2
|
| Novartis AG (ADR) |
|
284,534.7
|
149.1
|
L
 1.8%
H
147.0
149.7
|
L
 2.4%
H
142.3
149.7
|
L
 2.1%
H
142.3
152.5
|
L
 -6.9%
H
142.3
163.1
|
L
 26.4%
H
112.3
170.5
|
L
 48.2%
H
92.2
170.5
|
L
 66.3%
H
74.1
170.5
|
L
 107.2%
H
59.2
170.5
|
| Organon & Co. |
|
3,518.9
|
13.4
|
L
 0.1%
H
13.4
13.4
|
L
 0.3%
H
13.4
13.4
|
L
 0.5%
H
13.3
13.5
|
L
 104.3%
H
5.7
13.5
|
L
 40.2%
H
5.7
13.5
|
L
 -33.0%
H
5.7
24.1
|
L
 -53.6%
H
5.7
39.5
|
L
H
5.7
39.5
|
| Prestige Consumer Healthcare Inc |
|
2,305.1
|
48.7
|
L
 2.0%
H
47.9
49.8
|
L
 5.9%
H
44.8
49.8
|
L
 -7.4%
H
42.6
52.3
|
L
 -27.6%
H
42.6
67
|
L
 -42.8%
H
42.6
87.1
|
L
 -16.5%
H
42.6
90.0
|
L
 -3.8%
H
42.6
90.0
|
L
 -9.6%
H
26.3
90.0
|
| Pfizer |
|
146,475.7
|
25.7
|
L
 0.3%
H
25.5
25.9
|
L
 0.3%
H
25.3
26.2
|
L
 0.1%
H
25.2
26.5
|
L
 -5.0%
H
25.2
28.7
|
L
 10.1%
H
23.1
28.7
|
L
 -34.3%
H
20.9
40.4
|
L
 -33.8%
H
20.9
61.7
|
L
 -23.0%
H
20.9
61.7
|
| Perrigo Co PLC |
|
1,547.0
|
11.2
|
L
 -3.7%
H
10.9
11.6
|
L
 3.9%
H
10.2
12.0
|
L
 -4.5%
H
10.2
12.0
|
L
 4.3%
H
9.2
12.6
|
L
 -57.3%
H
9.2
28.4
|
L
 -66.8%
H
9.2
40.3
|
L
 -76.2%
H
9.2
50.9
|
L
 -88.9%
H
9.2
111
|
| Arcus Biosciences Inc |
|
2,973.3
|
23.6
|
L
 1.4%
H
22.6
24.3
|
L
 -7.9%
H
22.6
25.7
|
L
 -6.8%
H
22.6
26.2
|
L
 6.9%
H
20
28.7
|
L
 137.1%
H
7.9
28.7
|
L
 9.2%
H
6.5
28.7
|
L
 -4.5%
H
6.5
49.1
|
L
H
6.3
49.1
|
| Dr. Reddy`s Laboratories Ltd (ADR) |
|
11,133.2
|
13.4
|
L
 1.1%
H
13.2
13.4
|
L
 0.8%
H
13.0
13.4
|
L
 1.1%
H
12.2
13.9
|
L
 -7.2%
H
12.2
14.6
|
L
 -14.0%
H
12.2
16.2
|
L
 17.3%
H
11.3
74.9
|
L
 -7.3%
H
9.6
74.9
|
L
 42.7%
H
5.6
74.9
|
| Takeda pharma Co (ADR) |
|
49,653.4
|
15.7
|
L
 -0.1%
H
15.6
15.8
|
L
 3.5%
H
14.8
15.9
|
L
 -4.5%
H
14.8
16.8
|
L
 -12.1%
H
14.8
18.9
|
L
 5.1%
H
13.0
18.9
|
L
 -2.5%
H
12.6
18.9
|
L
 -6.3%
H
12.3
18.9
|
L
 -27.3%
H
12.3
30.6
|
| Teva- pharma Ind Ltd (ADR) |
|
40,114.5
|
34.5
|
L
 3.6%
H
32.9
34.5
|
L
 -0.6%
H
32.4
35.0
|
L
 -3.6%
H
32.4
36.4
|
L
 11.0%
H
27.9
37.0
|
L
 93.9%
H
15.0
37.3
|
L
 366.2%
H
7.3
37.3
|
L
 226.5%
H
6.8
37.3
|
L
 -36.2%
H
6.1
56.4
|
| Usana Health Sciences Inc |
|
351.0
|
19.0
|
L
 1.7%
H
18.4
19.3
|
L
 3.7%
H
17.4
19.3
|
L
 0.3%
H
16.9
19.5
|
L
 6.6%
H
16.6
21
|
L
 -35.3%
H
16.6
38.3
|
L
 -70.1%
H
16.6
69.6
|
L
 -81.6%
H
16.6
104.8
|
L
 -69.0%
H
16.6
138.0
|
| Zoetis (Class A) |
|
34,460.6
|
82.2
|
L
 4.3%
H
79.5
82.3
|
L
 6.0%
H
74.9
82.3
|
L
 -0.8%
H
72.4
82.3
|
L
 -32.3%
H
72.4
123.3
|
L
 -51.7%
H
72.4
169.5
|
L
 -50.0%
H
72.4
201.9
|
L
 -52.8%
H
72.4
249.3
|
L
 69.7%
H
45.3
249.3
|
| Biohaven Ltd |
|
1,669.7
|
11.1
|
L
 -0.3%
H
10.7
12
|
L
 -3.0%
H
9.9
12
|
L
 12.5%
H
8.2
12
|
L
 11.8%
H
8.0
12.1
|
L
 -34.9%
H
7.5
18.6
|
L
 -52.1%
H
7.5
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
| Whitehawk Therapeutics Inc |
|
208.7
|
4.2
|
L
 5.0%
H
4.0
4.3
|
L
 -6.0%
H
4.0
4.6
|
L
 6.3%
H
3.7
5.5
|
L
 12.5%
H
3.2
5.5
|
L
 125.7%
H
1.6
5.5
|
L
 -48.3%
H
1.2
8.5
|
L
 -85.8%
H
1.2
49.8
|
L
H
1.2
101.3
|
| AbCellera Biologics Inc |
|
1,618.5
|
5.3
|
L
 -2.2%
H
5.0
5.7
|
L
 -18.0%
H
5.0
6.7
|
L
 1.2%
H
3.9
6.8
|
L
 53.6%
H
3.2
6.8
|
L
 117.2%
H
2.5
6.8
|
L
 -26.0%
H
1.9
8.1
|
L
 -78.8%
H
1.9
26.6
|
L
H
1.9
71.9
|
| Abeona Therapeutics Inc |
|
310.6
|
5.5
|
L
 1.3%
H
5.2
5.5
|
L
 -3.2%
H
5.2
5.9
|
L
 -7.6%
H
5.1
6.0
|
L
 12.4%
H
4.2
6.1
|
L
 -19.1%
H
4
7.5
|
L
 27.0%
H
2.9
9.0
|
L
 -87.8%
H
2.2
47.3
|
L
 -93.1%
H
2.2
568.8
|
| Oruka Therapeutics Inc |
|
4,036.7
|
66.9
|
L
 4.5%
H
62.6
67.1
|
L
 21.7%
H
54.0
67.1
|
L
 3.6%
H
53.6
67.8
|
L
 103%
H
31.3
91
|
L
 432.0%
H
10.8
91
|
L
 169.4%
H
2.2
91
|
L
 49.5%
H
2.2
91
|
L
 -91.4%
H
2.2
777.6
|
| Acumen Pharma Inc |
|
158.2
|
2.2
|
L
 0.9%
H
2.2
2.3
|
L
 -12.8%
H
2.1
2.5
|
L
 -14.5%
H
2.1
2.7
|
L
 -33.8%
H
2.1
3.6
|
L
 82.5%
H
1.1
3.6
|
L
 -55.0%
H
0.9
11.3
|
L
H
0.9
27.0
|
L
H
0.9
27.0
|
| Arbutus Biopharma Corp |
|
839.5
|
4.3
|
L
 0.2%
H
4.2
4.4
|
L
 -5.1%
H
4.2
4.5
|
L
 -2.1%
H
4.1
4.8
|
L
 -6.2%
H
4.0
4.9
|
L
 22.1%
H
3.0
5.1
|
L
 67.3%
H
1.7
5.1
|
L
 23.5%
H
1.7
6.5
|
L
 5.7%
H
0.8
12.6
|
| ABVC BioPharma Inc |
|
34.3
|
1.3
|
L
 -1.5%
H
1.3
1.4
|
L
 -2.9%
H
1.2
1.5
|
L
 24.5%
H
1
1.5
|
L
 -1.5%
H
0.9
1.8
|
L
 -14.3%
H
0.9
5.5
|
L
 -79.0%
H
0.4
6.9
|
L
 -97.4%
H
0.4
116.9
|
L
 -99.6%
H
0.4
378
|
| Acadia Pharma Inc |
|
3,739.8
|
21.8
|
L
 0.7%
H
21.5
22.0
|
L
 1.5%
H
20.8
22.0
|
L
 -2.5%
H
20.3
22.5
|
L
 -1.4%
H
19.9
23.1
|
L
 -0.6%
H
19.7
28.4
|
L
 -13.0%
H
13.4
33.9
|
L
 -17.8%
H
12.2
33.9
|
L
 -47.4%
H
12.2
58.7
|
| Adicet Bio Inc |
|
68.3
|
7.3
|
L
 1.3%
H
7.0
7.6
|
L
 -16.7%
H
7.0
8.7
|
L
 -14.5%
H
7.0
9.5
|
L
 0.3%
H
6.0
9.5
|
L
 -39.6%
H
6.0
17.4
|
L
 -91.9%
H
6.0
91.8
|
L
 -96.2%
H
6.0
349.9
|
L
H
6.0
349.9
|
| Achieve Life Sciences Inc |
|
574.9
|
5.6
|
L
 2.2%
H
5.4
5.7
|
L
 5.7%
H
4.7
5.7
|
L
 7.5%
H
4.4
6.2
|
L
 31.2%
H
2.6
6.2
|
L
 46.2%
H
2
6.2
|
L
 -5.2%
H
1.8
6.5
|
L
 -36.1%
H
1.8
10.3
|
L
 -99.8%
H
1.8
2574
|
| AC Immune SA |
|
230.0
|
2.3
|
L
 3.2%
H
2.1
2.3
|
L
 -8.1%
H
2.1
2.5
|
L
 -21.0%
H
2.1
3.1
|
L
 -19%
H
2.1
3.5
|
L
 10.8%
H
1.7
4
|
L
 1.8%
H
1.4
5.1
|
L
 -68.5%
H
1.4
12.6
|
L
H
1.4
20.0
|
| Aclaris Therapeutics Inc |
|
600.6
|
4.3
|
L
 -1.4%
H
4.2
4.5
|
L
 -0.9%
H
4.2
4.8
|
L
 -12.8%
H
4.2
5.2
|
L
 40.5%
H
3.0
5.2
|
L
 181.1%
H
1.3
5.2
|
L
 -53.7%
H
0.6
11.1
|
L
 -77.1%
H
0.6
20.0
|
L
 -80.1%
H
0.6
33.3
|
| Acrivon Therapeutics Inc |
|
60.8
|
1.4
|
L
 0.7%
H
1.4
1.5
|
L
 -9.0%
H
1.4
1.6
|
L
 -28.3%
H
1.4
2.1
|
L
 -8.4%
H
1.3
2.2
|
L
 5.2%
H
1.2
3.6
|
L
 -88.5%
H
1.1
14.0
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
| Acelrx Pharma Inc |
|
13.9
|
0.8
|
L
 -3.5%
H
0.8
0.9
|
L
 3.8%
H
0.8
0.9
|
L
 -8.9%
H
0.8
0.9
|
L
 -5.8%
H
0.7
1.0
|
L
 60.8%
H
0.4
1.6
|
L
 -26.1%
H
0.4
1.6
|
L
 -97.5%
H
0.4
32.4
|
L
 -98.8%
H
0.4
115
|
| Grace Therapeutics Inc |
|
36.1
|
2.3
|
L
 1.3%
H
2.3
2.4
|
L
 -13.4%
H
2.3
2.7
|
L
 -0.4%
H
2.1
2.7
|
L
 -39.6%
H
1.8
5.2
|
L
 -21.6%
H
1.8
5.2
|
L
 -20.7%
H
1.7
5.2
|
L
 -91.8%
H
1.7
32.6
|
L
 -96.9%
H
1.7
161.1
|
| Acurx Pharma Inc |
|
6.9
|
1.6
|
L
 -0.6%
H
1.6
1.7
|
L
 -16.6%
H
1.6
1.9
|
L
 -23.0%
H
1.6
2.2
|
L
 19.3%
H
1.4
7.5
|
L
 -76.8%
H
1.3
21
|
L
 -97.1%
H
1.3
176.4
|
L
H
1.3
176.4
|
L
H
1.3
176.4
|
| Adial Pharma Inc |
|
4.6
|
2.1
|
L
 -3.6%
H
2.1
2.2
|
L
 -13.1%
H
2.1
2.5
|
L
 49.0%
H
1.3
2.6
|
L
 16.4%
H
1.3
2.6
|
L
 -85.1%
H
1.3
18.9
|
L
 -98.7%
H
1.3
350
|
L
 -99.9%
H
1.3
3175
|
L
H
1.3
5900
|
| Adma Biologics Inc |
|
1,882.0
|
8.1
|
L
 0.7%
H
8.0
8.3
|
L
 2.8%
H
7.5
8.3
|
L
 -0.6%
H
7.5
8.8
|
L
 -47.2%
H
7.2
16.4
|
L
 -60.6%
H
7.2
22.4
|
L
 104.5%
H
3.1
25.7
|
L
 348.6%
H
1.0
25.7
|
L
 9.0%
H
1.0
25.7
|
| Adaptive biotech Corp |
|
2,778.4
|
17.4
|
L
 4.0%
H
16.5
17.5
|
L
 14.0%
H
14.8
18.3
|
L
 25.7%
H
12.5
18.3
|
L
 16.8%
H
12
18.3
|
L
 72.1%
H
9.9
20.8
|
L
 135.5%
H
2.3
20.8
|
L
 -50.8%
H
2.3
43.4
|
L
H
2.3
71.3
|
| Aditxt Inc |
|
0.0
|
0.0
|
L
 -40%
H
0.0
0.0
|
L
 -72.7%
H
0.0
0.1
|
L
 -99.1%
H
0.0
3.0
|
L
 -100.0%
H
0.0
117.9
|
L
 -100%
H
0.0
53453.5
|
L
 -100.0%
H
0.0
10000000000
|
L
 -100.0%
H
0.0
10000000000
|
L
H
0.0
10000000000
|
| Agenus Inc |
|
129.5
|
3.1
|
L
 -1.0%
H
3.1
3.3
|
L
 -10.6%
H
3.1
3.5
|
L
 -18.6%
H
3.0
3.7
|
L
 5.1%
H
2.9
5.1
|
L
 -47.7%
H
2.7
7.3
|
L
 -92.4%
H
1.4
196
|
L
 -96.8%
H
1.4
196
|
L
 -96.3%
H
1.4
196
|
| Agios Pharma Inc |
|
1,673.5
|
28.1
|
L
 2.6%
H
26.9
28.5
|
L
 0.5%
H
26.4
29.4
|
L
 1.3%
H
26.4
30.5
|
L
 2.4%
H
24.3
36.4
|
L
 -18.0%
H
22.2
46
|
L
 5.8%
H
19.8
62.6
|
L
 -53.1%
H
16.8
62.6
|
L
 -57.4%
H
16.8
99.8
|
| Aeglea BioTherapeutics Inc |
|
309.5
|
76.4
|
L
 6.2%
H
70.9
77.1
|
L
 8.4%
H
68.5
79.5
|
L
 1.9%
H
64.7
79.5
|
L
 90.4%
H
39
79.5
|
L
 350.4%
H
13.9
79.5
|
L
 2259.3%
H
2.7
79.5
|
L
 -55.0%
H
2.7
212.5
|
L
 -57.9%
H
2.7
300
|
| Akebia Therapeutics Inc |
|
246.8
|
0.9
|
L
 -2.1%
H
0.9
1.0
|
L
 -9.8%
H
0.9
1.0
|
L
 -20.7%
H
0.9
1.2
|
L
 -27.6%
H
0.9
1.6
|
L
 -76.8%
H
0.9
4.1
|
L
 -26.4%
H
0.8
4.1
|
L
 -74.4%
H
0.2
4.3
|
L
 -89.4%
H
0.2
20.3
|
| Avalon GloboCare Corp |
|
4.3
|
0.4
|
L
 5.9%
H
0.3
0.4
|
L
 5.9%
H
0.3
0.4
|
L
 -10%
H
0.2
0.4
|
L
 -60.9%
H
0.2
0.9
|
L
 -89.4%
H
0.2
4.7
|
L
 -83.0%
H
0.2
11.7
|
L
 -97.0%
H
0.2
15.7
|
L
H
0.2
135
|
| Aldeyra Therapeutics Inc |
|
103.8
|
1.7
|
L
 -1.2%
H
1.7
1.8
|
L
 3.6%
H
1.6
2.0
|
L
 -0.6%
H
1.5
2.0
|
L
 -64.2%
H
1.1
5.6
|
L
 -35.3%
H
1.1
6.2
|
L
 -85.5%
H
1.1
12.0
|
L
 -86.7%
H
1.1
13.2
|
L
 -70.0%
H
1.1
16.7
|
| Alector Inc |
|
181.0
|
1.6
|
L
 -0.6%
H
1.6
1.7
|
L
 -21.3%
H
1.6
2.1
|
L
 -22.4%
H
1.6
2.4
|
L
 -18.5%
H
1.6
2.7
|
L
 9.4%
H
1.1
3.4
|
L
 -77.8%
H
0.9
9.1
|
L
 -91.4%
H
0.9
43.3
|
L
H
0.9
43.3
|
| Aligos Therapeutics Inc |
|
31.8
|
5.1
|
L
 3.6%
H
5.0
5.3
|
L
 -3.9%
H
4.8
5.6
|
L
 -20.2%
H
4.8
6.9
|
L
 -26.4%
H
4.8
9.0
|
L
 -28.6%
H
4.8
13.7
|
L
 -81.3%
H
3.8
46.3
|
L
 -99.3%
H
3.8
857.8
|
L
H
3.8
937.8
|
| Alkermes PLC |
|
7,382.1
|
44.3
|
L
 4.3%
H
43.0
44.9
|
L
 4.8%
H
40.6
44.9
|
L
 26.6%
H
35.2
44.9
|
L
 54.7%
H
27
44.9
|
L
 39.7%
H
25.2
44.9
|
L
 40.4%
H
22.0
44.9
|
L
 80.9%
H
21.2
44.9
|
L
 -2.9%
H
12.0
71.2
|
| Allogene Therapeutics Inc |
|
628.2
|
1.8
|
L
 -1.6%
H
1.8
1.9
|
L
 -15.4%
H
1.8
2.2
|
L
 -20.2%
H
1.8
2.4
|
L
 -20.9%
H
1.8
4.5
|
L
 28.2%
H
1.0
4.5
|
L
 -68.6%
H
0.9
6.1
|
L
 -92.6%
H
0.9
27.9
|
L
H
0.9
55
|
| Allarity Therapeutics Inc |
|
25.6
|
1.6
|
L
 1.9%
H
1.6
1.7
|
L
 -6.4%
H
1.6
1.7
|
L
 3.9%
H
1.3
1.8
|
L
 29.8%
H
1.0
1.8
|
L
 89.4%
H
0.8
2.1
|
L
 -98.9%
H
0.1
269.8
|
L
H
0.1
509600
|
L
H
0.1
509600
|
| Alnylam Pharma Inc |
|
39,745.4
|
297.7
|
L
 1.9%
H
294.0
302.9
|
L
 0.7%
H
283.1
310.5
|
L
 0.9%
H
283.1
310.5
|
L
 -7.2%
H
283.1
343.4
|
L
 -1.0%
H
283.1
495.6
|
L
 56.3%
H
142.0
495.6
|
L
 97.0%
H
117.6
495.6
|
L
 326.0%
H
31.4
495.6
|
| Rein Therapeutics Inc |
|
78.7
|
0.9
|
L
 -3.2%
H
0.9
1.0
|
L
 -14.0%
H
0.9
1.1
|
L
 -24.6%
H
0.9
1.2
|
L
 -23.3%
H
0.9
2.1
|
L
 -54%
H
0.9
2.2
|
L
 -41.4%
H
0.9
7.4
|
L
 -96.5%
H
0.9
28
|
L
H
0.9
309.6
|
| Altimmune Inc |
|
517.3
|
2.7
|
L
 -2.6%
H
2.6
2.8
|
L
 -11.6%
H
2.6
3
|
L
 -13.9%
H
2.6
3.2
|
L
 -24.9%
H
2.6
4.0
|
L
 -52.7%
H
2.6
7.7
|
L
 -35.0%
H
2.1
14.8
|
L
 -80.9%
H
2.1
23.5
|
L
 -99.6%
H
1.5
1050
|
| Alvotech |
|
1,298.1
|
4.2
|
L
 -1.9%
H
4.1
4.6
|
L
 29.2%
H
2.9
4.6
|
L
 27.6%
H
2.9
4.6
|
L
 3.7%
H
2.9
4.6
|
L
 -61.0%
H
2.9
10.8
|
L
 -49.5%
H
2.9
18
|
L
H
2.9
18
|
L
H
2.9
18
|
| Kalaris Therapeutics Inc |
|
97.1
|
4.1
|
L
 -2.2%
H
4.0
4.3
|
L
 -16.7%
H
4.0
5.0
|
L
 -19.7%
H
4.0
5.6
|
L
 -58.5%
H
4.0
10.2
|
L
 23.6%
H
2.1
11.9
|
L
 -29.0%
H
0.4
12.9
|
L
 -82.5%
H
0.4
26.4
|
L
H
0.4
49.0
|
| Alzamend Neuro Inc |
|
4.4
|
1.2
|
L
 -0.9%
H
1.1
1.2
|
L
 -1.7%
H
1.1
1.2
|
L
 7.5%
H
1
1.3
|
L
 -41.9%
H
0.8
2.4
|
L
 -68.2%
H
0.8
3.6
|
L
 -99.9%
H
0.8
972
|
L
H
0.8
45292.5
|
L
H
0.8
45292.5
|
| Amgen |
|
185,961.9
|
344.6
|
L
 -0.3%
H
342.6
349.6
|
L
 4.7%
H
322.3
356.5
|
L
 3.9%
H
321.0
356.5
|
L
 -6.8%
H
320.5
380.1
|
L
 18.7%
H
267.8
391.3
|
L
 56.1%
H
215.3
391.3
|
L
 45.5%
H
198.6
391.3
|
L
 118.1%
H
133.6
391.3
|
| Amylyx Pharma Inc |
|
1,506.6
|
13.6
|
L
 4.2%
H
13.1
13.9
|
L
 -3.7%
H
12.6
14.5
|
L
 -8.0%
H
12.4
15.2
|
L
 -2.2%
H
12.4
18.6
|
L
 154.2%
H
4.8
18.6
|
L
 -48.4%
H
1.6
26.3
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
| Amphastar Pharma Inc |
|
888.9
|
20.2
|
L
 4.0%
H
19.5
20.3
|
L
 9.5%
H
17.7
20.3
|
L
 6.1%
H
16.6
20.3
|
L
 4.2%
H
16.6
24.3
|
L
 -22.4%
H
16.6
31.3
|
L
 -56.1%
H
16.6
67.7
|
L
 3.8%
H
16.6
67.7
|
L
 24.4%
H
12.1
67.7
|
| AnaptysBio Inc |
|
1,502.5
|
51.6
|
L
 0.5%
H
50.6
53.3
|
L
 -2.8%
H
50.1
53.3
|
L
 -25.5%
H
50.1
70.5
|
L
 -6.8%
H
44
73.3
|
L
 117.9%
H
17.1
73.3
|
L
 181.8%
H
12.2
73.3
|
L
 113.7%
H
12.2
73.3
|
L
H
10
134
|
| ANI Pharma Inc |
|
1,846.1
|
81.2
|
L
 1.3%
H
80.8
82.3
|
L
 5.9%
H
73.5
82.3
|
L
 -0.8%
H
73.5
83.8
|
L
 9.7%
H
70.2
87.8
|
L
 31.1%
H
61.2
99.5
|
L
 62.9%
H
48.2
99.5
|
L
 131.4%
H
22.3
99.5
|
L
 45.5%
H
22.3
99.5
|
| Anixa Biosciences Inc |
|
80.5
|
2.4
|
L
 -2.4%
H
2.4
2.5
|
L
 -11.1%
H
2.4
2.7
|
L
 -20%
H
2.4
3.0
|
L
 -15.8%
H
2.4
3.2
|
L
 -13.0%
H
2.4
5.5
|
L
 -31.4%
H
2.1
5.5
|
L
 -44.3%
H
2.1
6.5
|
L
 -27.3%
H
0.6
8.1
|
| Annexon Inc |
|
852.0
|
5.2
|
L
 1.6%
H
5.0
5.3
|
L
 -6.8%
H
5.0
5.7
|
L
 -8.6%
H
4.8
5.9
|
L
 0.8%
H
4.8
6.6
|
L
 100%
H
1.9
7.2
|
L
 80.6%
H
1.3
8.4
|
L
 -77.0%
H
1.3
24.9
|
L
H
1.3
38.0
|
| AN2 Therapeutics Inc |
|
140.8
|
3.9
|
L
 1.6%
H
3.7
4
|
L
 -7.1%
H
3.7
4.5
|
L
 -12.3%
H
3.7
5.2
|
L
 37.2%
H
2.9
6.9
|
L
 246.0%
H
1
6.9
|
L
 -39.0%
H
0.9
22.2
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
| Applied Dna Sciences Inc |
|
3.8
|
0.5
|
L
 -1.9%
H
0.5
0.5
|
L
 -3.6%
H
0.5
0.6
|
L
 10.4%
H
0.4
0.6
|
L
 -24.3%
H
0.4
0.9
|
L
 -90.1%
H
0.4
7.2
|
L
 -100.0%
H
0.4
27900
|
L
 -100.0%
H
0.4
121500
|
L
 -100.0%
H
0.4
2167200
|
| Apollomics Inc (Class A) |
|
31.4
|
14.3
|
L
 2.1%
H
13.7
15.2
|
L
 -0.2%
H
13.0
15.2
|
L
 -7.4%
H
13.0
16
|
L
 -28.7%
H
12.6
20.5
|
L
 120%
H
3.7
42.1
|
L
 -97.3%
H
0.1
620
|
L
H
0.1
4900
|
L
H
0.1
4900
|
| Aptorum Grp Ltd (Class A) |
|
9.1
|
1.1
|
L
 -4.3%
H
1.0
1.2
|
L
 4.7%
H
0.9
1.4
|
L
 33.3%
H
0.8
1.4
|
L
 40%
H
0.8
1.4
|
L
 4.7%
H
0.7
4.5
|
L
 -63.9%
H
0.5
17.5
|
L
 -96.2%
H
0.5
35
|
L
H
0.5
332.8
|
| Aprea Therapeutics Inc |
|
9.2
|
0.7
|
L
 1.4%
H
0.7
0.8
|
L
 -9.8%
H
0.7
0.8
|
L
 -24.5%
H
0.7
1
|
L
 -17.8%
H
0.6
1.1
|
L
 -57.7%
H
0.6
2.2
|
L
 -78.7%
H
0.6
8.9
|
L
 -99.2%
H
0.6
156
|
L
H
0.6
1062.2
|
| Aptevo Therapeutics Inc |
|
5.9
|
4.8
|
L
 -2.7%
H
4.6
5.0
|
L
 -9.2%
H
4.6
5.5
|
L
 -4.2%
H
4.3
5.5
|
L
 -25.6%
H
3.8
6.7
|
L
 -94.7%
H
3.8
236.0
|
L
 -100.0%
H
3.8
1078387.2
|
L
 -100.0%
H
3.8
18613900.8
|
L
H
3.8
68020444.8
|
| AquaBounty Tech Inc |
|
4.8
|
0.9
|
L
 -3.1%
H
0.9
1
|
L
 -8.7%
H
0.9
1.1
|
L
H
0.9
1.1
|
L
 1.1%
H
0.9
1.2
|
L
 19.0%
H
0.7
3.0
|
L
 -87.4%
H
0.5
8.6
|
L
 -99.2%
H
0.5
130.6
|
L
H
0.5
610
|
| Aquestive Therapeutics Inc |
|
500.5
|
4.0
|
L
 2.1%
H
3.9
4.0
|
L
 -0.3%
H
3.9
4.2
|
L
 -7.6%
H
3.9
5.0
|
L
 -5.5%
H
3.8
5.0
|
L
 12.1%
H
2.9
7.6
|
L
 85.6%
H
1.3
7.6
|
L
 1.5%
H
0.6
7.6
|
L
H
0.6
20.7
|
| Arcturus Therapeutics Holdings Inc |
|
203.5
|
7.2
|
L
 0.6%
H
6.9
7.4
|
L
 -7.9%
H
6.9
8.2
|
L
 -22.3%
H
6.7
9.6
|
L
 0.7%
H
6.4
9.6
|
L
 -44.0%
H
5.9
24.2
|
L
 -74.8%
H
5.9
45
|
L
 -78.0%
H
5.9
65
|
L
 -81.5%
H
4.1
129.7
|
| Ardelyx Inc |
|
1,383.4
|
5.6
|
L
 1.1%
H
5.5
5.7
|
L
 -2.3%
H
5.3
5.7
|
L
 -17.4%
H
5.3
6.8
|
L
 -9.5%
H
5.1
7.4
|
L
 52.2%
H
3.5
8.4
|
L
 42.5%
H
3.2
10.1
|
L
 -21.8%
H
0.5
10.1
|
L
 -39.1%
H
0.5
16.3
|
| Arcutis Biotherapeutics Inc |
|
2,850.7
|
22.8
|
L
 5.8%
H
21.7
22.9
|
L
 6.2%
H
20.5
22.9
|
L
 7.7%
H
19.3
22.9
|
L
 -5.0%
H
19.3
25.5
|
L
 58.6%
H
12.7
31.8
|
L
 127.7%
H
1.8
31.8
|
L
 -18.4%
H
1.8
31.8
|
L
H
1.8
40.9
|
| Artelo Biosciences Inc |
|
4.6
|
1.3
|
L
H
1.3
1.4
|
L
 -7.0%
H
1.3
1.5
|
L
 -47.6%
H
1.2
2.6
|
L
 -61.1%
H
1.2
19.9
|
L
 -93.4%
H
1.2
85.8
|
L
 -96.4%
H
1.2
85.8
|
L
 -99.6%
H
1.2
359.1
|
L
H
1.2
46656
|
| Arvinas Inc |
|
465.2
|
7.2
|
L
 0.8%
H
7.0
7.4
|
L
 -16.0%
H
7.0
8.6
|
L
 -28.7%
H
7.0
10.4
|
L
 -47.0%
H
7.0
14.5
|
L
 -4.3%
H
6.1
14.5
|
L
 -70.3%
H
5.9
53.1
|
L
 -90.8%
H
5.9
108.5
|
L
H
5.9
108.5
|
| Arrowhead Pharma Inc |
|
10,329.0
|
73.3
|
L
 -0.7%
H
69.7
76.2
|
L
 -2.5%
H
69.3
76.2
|
L
 0.9%
H
69.3
82.3
|
L
 22.6%
H
54.0
82.3
|
L
 336.2%
H
14.3
82.3
|
L
 105.4%
H
9.6
82.3
|
L
 -9.6%
H
9.6
93.7
|
L
 1106.1%
H
1.2
93.7
|
| Assembly Biosciences Inc |
|
450.2
|
22.7
|
L
 0.7%
H
22.2
23.8
|
L
 -15.6%
H
22.2
27.2
|
L
 -23.6%
H
22.2
32.5
|
L
 -19.6%
H
22.2
32.5
|
L
 39.9%
H
15.5
39.7
|
L
 69.8%
H
7.7
39.7
|
L
 -53.8%
H
7.7
56.3
|
L
 -70.8%
H
7.7
808.3
|
| ASP Isotopes Inc |
|
805.8
|
6.4
|
L
 -6.3%
H
6.1
7.1
|
L
 -20.1%
H
6.1
8.5
|
L
 19.0%
H
4.8
8.5
|
L
 15.3%
H
3.9
8.5
|
L
 -31.6%
H
3.9
14.5
|
L
 1423.8%
H
0.3
14.5
|
L
H
0.3
14.5
|
L
H
0.3
14.5
|
| Assertio Holdings Inc |
|
151.6
|
23.5
|
L
 0.1%
H
23.4
23.5
|
L
 0.1%
H
23.4
23.5
|
L
 4.3%
H
22.1
23.5
|
L
 100.2%
H
11.1
23.5
|
L
 136.3%
H
8.6
23.5
|
L
 -74.0%
H
7.7
96.2
|
L
 -15.9%
H
7.7
120.2
|
L
 -98.1%
H
7.7
1621.2
|
| ATAI Life Sciences N.V. |
|
1,432.2
|
3.9
|
L
 2.1%
H
3.8
4
|
L
 -19.3%
H
3.8
5
|
L
 -3.5%
H
3.8
5
|
L
 14.8%
H
3.3
5.5
|
L
 61.4%
H
2
6.8
|
L
 117.3%
H
1.0
6.8
|
L
H
1.0
22.9
|
L
H
1.0
22.9
|
| LeonaBio Inc |
|
79.5
|
8.5
|
L
 -1.5%
H
8.4
8.9
|
L
 -8.9%
H
8.2
10.0
|
L
 -15.7%
H
8.2
11.4
|
L
 59.6%
H
5.3
14.2
|
L
 135%
H
2.9
14.2
|
L
 -75.9%
H
2.2
43.0
|
L
 -95.9%
H
2.2
208.6
|
L
H
2.2
347.9
|
| ETHZilla Corp |
|
75.9
|
5.2
|
L
 -1.7%
H
5.2
5.8
|
L
 14.2%
H
4.5
5.8
|
L
 13.2%
H
3.6
5.8
|
L
 80.6%
H
1.8
5.9
|
L
 -49.8%
H
1.8
174.6
|
L
 -97.7%
H
1.8
237.5
|
L
 -100.0%
H
1.8
44612
|
L
H
1.8
49571
|
| Atossa Therapeutics Inc |
|
38.0
|
4.4
|
L
 -3.1%
H
4.4
4.6
|
L
 -13.7%
H
4.4
5.1
|
L
 -21.3%
H
4.4
5.7
|
L
 -2.7%
H
4.4
6.3
|
L
 -67.3%
H
3.8
19.4
|
L
 -69.7%
H
3.8
34.7
|
L
 -95.2%
H
3.8
147
|
L
 -99.5%
H
3.8
961.0
|
| Atara Biotherapeutics Inc |
|
88.0
|
9.8
|
L
 2.0%
H
9.4
10.2
|
L
 -5.0%
H
9.4
10.5
|
L
 17.2%
H
7.9
11.4
|
L
 89.0%
H
4.3
12.5
|
L
 5.9%
H
3.9
19.1
|
L
 -79.2%
H
0.4
63.4
|
L
 -97.2%
H
0.4
501
|
L
 -98.1%
H
0.4
1361.3
|
| Aurinia Pharma Inc |
|
2,029.3
|
15.8
|
L
 0.8%
H
15.5
16.1
|
L
 3.1%
H
15
16.7
|
L
 3.6%
H
15.0
16.7
|
L
 10.2%
H
13.8
16.9
|
L
 92.7%
H
7.3
16.9
|
L
 51.6%
H
4.7
16.9
|
L
 26.4%
H
4.1
34.0
|
L
 447.9%
H
1.7
34.0
|
| Aura Biosciences Inc |
|
656.5
|
6.4
|
L
 -2.0%
H
6.3
6.7
|
L
 -11.7%
H
6.3
7.3
|
L
 -24.4%
H
6.3
8.5
|
L
 13.4%
H
5.3
9.5
|
L
 -2.3%
H
4.7
9.5
|
L
 -49.8%
H
4.3
12.9
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
| Atea Pharma Inc |
|
348.9
|
4.4
|
L
 0.9%
H
4.3
4.5
|
L
 -0.5%
H
4.2
4.5
|
L
 -19.7%
H
4.0
5.6
|
L
 -26.0%
H
4.0
6.5
|
L
 37.1%
H
2.8
6.5
|
L
 2.1%
H
2.5
6.5
|
L
 -81.5%
H
2.5
46.9
|
L
H
2.5
94.2
|
| Tectonic Therapeutic Inc |
|
538.9
|
28.6
|
L
 -1.9%
H
27.2
30.5
|
L
 -1.1%
H
27
30.5
|
L
 -1.5%
H
26.7
32.3
|
L
 -20.4%
H
26.3
35.8
|
L
 23.9%
H
14.4
36.0
|
L
 98.3%
H
1.4
61.1
|
L
 -74.9%
H
1.4
132
|
L
H
1.4
644.4
|
| Jade Biosciences Inc |
|
926.3
|
15.2
|
L
 1.6%
H
14.3
15.4
|
L
 -18.1%
H
14.3
19.4
|
L
 -41.0%
H
14.3
26.8
|
L
 8.3%
H
12.9
28
|
L
 111.7%
H
6.6
28
|
L
 -97.4%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
L
H
6.6
1134.5
|
| Avalo Therapeutics Inc |
|
678.1
|
12.9
|
L
 1.3%
H
12.5
13.4
|
L
 -18.1%
H
12.5
15.6
|
L
 -40.2%
H
12.5
22.0
|
L
 -25.5%
H
12.5
24.3
|
L
 214.6%
H
4.2
24.3
|
L
 210.8%
H
0.0
34.5
|
L
 -67.7%
H
0.0
44.4
|
L
 -53.1%
H
0.0
91.8
|
| Anavex Life Sciences Corp |
|
235.4
|
2.5
|
L
 -3.1%
H
2.5
2.7
|
L
 -14.8%
H
2.5
3.0
|
L
 -21.1%
H
2.5
3.4
|
L
 -45.4%
H
2.5
4.9
|
L
 -69.3%
H
2.5
14.0
|
L
 -72.5%
H
2.5
14.4
|
L
 -83.3%
H
2.5
31.5
|
L
 -41.6%
H
1.3
31.5
|
| Axsome Therapeutics Inc |
|
12,640.6
|
245.6
|
L
 4.5%
H
236.4
246.4
|
L
 6.7%
H
217.2
246.4
|
L
 13%
H
213.2
246.4
|
L
 51.3%
H
152.3
246.4
|
L
 119.5%
H
96.1
246.4
|
L
 226.5%
H
55.0
246.4
|
L
 275.6%
H
19.4
246.4
|
L
 2866.7%
H
1.9
246.4
|
| Aytu BioPharma Inc |
|
24.7
|
2.3
|
L
 0.4%
H
2.2
2.4
|
L
 7.0%
H
2.0
2.4
|
L
 -8%
H
2.0
2.6
|
L
 -8.7%
H
2.0
2.8
|
L
 15%
H
1.7
3.1
|
L
 46.5%
H
1.0
3.5
|
L
 -97.9%
H
1.0
119.4
|
L
 -100.0%
H
1.0
470400
|
| Aziyo Biologics Inc (Class A) |
|
-
|
1.0
|
L
 -2.0%
H
1.0
1.0
|
L
 -8.5%
H
1.0
1.1
|
L
 -4.0%
H
1.0
1.3
|
L
 -11.0%
H
1.0
1.3
|
L
 -49.0%
H
0.5
2.6
|
L
 -59.1%
H
0.5
2.8
|
L
 -90.7%
H
0.5
11.4
|
L
H
0.5
18.2
|
| Adagene Inc (ADR) |
|
224.6
|
3.4
|
L
 4.3%
H
3.2
3.5
|
L
 -10.1%
H
3.2
3.8
|
L
 -7.9%
H
3.1
4.3
|
L
 19.7%
H
2.9
4.8
|
L
 70.9%
H
1.3
4.8
|
L
 151.9%
H
1.1
4.8
|
L
 -75.1%
H
0.9
21.0
|
L
H
0.9
31.8
|
| Addex Therapeutics Ltd (ADR) |
|
7.9
|
6.2
|
L
 6.3%
H
6.2
6.2
|
L
 -6.3%
H
5.9
6.7
|
L
 -8.9%
H
5.9
7.1
|
L
 -13.1%
H
5.4
7.6
|
L
 -39.1%
H
5.4
12.1
|
L
 -54.5%
H
5
27.9
|
L
 -97.0%
H
5
229.6
|
L
H
5
750.4
|
| Akari Therapeutics PLC (ADR) |
|
23.6
|
15
|
L
 -2.9%
H
14.5
15.9
|
L
 11.7%
H
13.1
16.2
|
L
 140%
H
3.0
29.3
|
L
 49.4%
H
3.0
29.3
|
L
 -69.6%
H
3.0
52
|
L
 -88.4%
H
3.0
219.8
|
L
 -99.0%
H
3.0
1512
|
L
 -99.9%
H
3.0
17759.8
|
| Amarin Corp (ADR) |
|
312.2
|
14.9
|
L
 4.9%
H
14.2
15.3
|
L
 3.7%
H
13.6
15.3
|
L
 -1.1%
H
13.6
15.6
|
L
 5.9%
H
13.0
17
|
L
 17.1%
H
11.7
20.9
|
L
 1045.4%
H
0.4
20.9
|
L
 204.5%
H
0.4
20.9
|
L
 555.9%
H
0.4
26.1
|
| Argen X SE (ADR) |
|
54,974.0
|
884
|
L
 0.2%
H
870.2
898.7
|
L
 5.7%
H
793.2
899.3
|
L
 13.0%
H
775.6
899.3
|
L
 23.2%
H
661.9
899.3
|
L
 50.9%
H
510.1
934.6
|
L
 125.9%
H
327.7
934.6
|
L
 230.1%
H
249.5
934.6
|
L
H
17.3
934.6
|
| Ascendis Pharma A/S (ADR) |
|
13,090.9
|
213.2
|
L
 3.6%
H
204.3
215.4
|
L
 -2.6%
H
203.8
223.0
|
L
 -10.7%
H
203.8
250.0
|
L
 -11.4%
H
203.8
250.7
|
L
 23.2%
H
160.9
250.7
|
L
 131.2%
H
85.1
250.7
|
L
 63.0%
H
61.6
250.7
|
L
 1397.4%
H
12.3
250.7
|
| Alterity Therapeutics Ltd (ADR) |
|
77.8
|
4.3
|
L
 9.4%
H
4.0
5.0
|
L
 6.7%
H
3.9
5.0
|
L
 -7.9%
H
3.8
5.0
|
L
 25.1%
H
3.1
5.3
|
L
 -9.3%
H
2.7
7
|
L
 48.4%
H
1
7
|
L
 -70.2%
H
1
27.5
|
L
 -89.1%
H
1
66.9
|
| Autolus Therapeutics PLC (ADR) |
|
388.6
|
1.5
|
L
H
1.4
1.5
|
L
 -20.7%
H
1.4
1.8
|
L
 -7.0%
H
1.4
2.0
|
L
 -3.3%
H
1.2
2.0
|
L
 -37.6%
H
1.2
2.7
|
L
 -50%
H
1.1
7.5
|
L
 -78.7%
H
1.1
8.2
|
L
H
1.1
53.2
|
| Astrazeneca plc |
|
568,737.0
|
183.4
|
L
 1.0%
H
181.2
183.8
|
L
 2.1%
H
174.6
186.1
|
L
 0.3%
H
174.6
191.5
|
L
 -5.6%
H
174.6
207.3
|
L
 -2.6%
H
174.6
212.7
|
L
 -2.6%
H
174.6
212.7
|
L
 -2.6%
H
174.6
212.7
|
L
 -2.6%
H
174.6
212.7
|
| BridgeBio Pharma Inc |
|
13,255.9
|
67.7
|
L
 0.5%
H
65.8
69
|
L
 3.6%
H
62.5
69.5
|
L
 0.4%
H
62.5
71.7
|
L
 3.6%
H
62.5
84.8
|
L
 75.3%
H
38.6
84.9
|
L
 315.5%
H
14.8
84.9
|
L
 8.6%
H
5.0
84.9
|
L
H
5.0
84.9
|
| BioAtla Inc |
|
5.7
|
3.4
|
L
 3.9%
H
3.1
3.5
|
L
 -2.6%
H
3.1
3.8
|
L
 -28.9%
H
3.1
4.9
|
L
 -59.1%
H
3.1
10.3
|
L
 -85.7%
H
3.1
71.5
|
L
 -98.1%
H
3.1
201
|
L
 -99.8%
H
3.1
2591.5
|
L
H
3.1
3831.5
|
| BioCardia Inc |
|
12.8
|
0.9
|
L
 -6.5%
H
0.8
0.9
|
L
 -6.5%
H
0.8
1.8
|
L
 -22.5%
H
0.8
1.8
|
L
 -27.1%
H
0.8
1.8
|
L
 -60.4%
H
0.8
2.5
|
L
 -97.3%
H
0.8
43.8
|
L
 -98.8%
H
0.8
76.5
|
L
 -99.7%
H
0.8
2073.6
|
| Biocryst Pharma Inc |
|
2,117.2
|
8.3
|
L
 -1.2%
H
8.3
8.6
|
L
 -2.8%
H
8.1
8.6
|
L
 -3.4%
H
8.1
9.8
|
L
 -1.8%
H
7.8
10.3
|
L
 -24.6%
H
6
11.2
|
L
 -5.4%
H
4.0
11.3
|
L
 -51.1%
H
4.0
20.0
|
L
 114.7%
H
1.4
20.0
|
| BriaCell Therapeutics Corp |
|
26.7
|
3.1
|
L
 -0.7%
H
2.9
3.2
|
L
 -7.3%
H
2.9
3.5
|
L
 -26.7%
H
2.9
4.3
|
L
 -20.5%
H
2.9
4.7
|
L
 -99.1%
H
2.9
360
|
L
 -100.0%
H
2.9
11275.5
|
L
 -100.0%
H
2.9
18526.5
|
L
 -100.0%
H
2.9
83250
|
| Black Diamond Therapeutics Inc |
|
108.9
|
1.9
|
L
 2.7%
H
1.9
1.9
|
L
 -15.9%
H
1.8
2.3
|
L
 -36.5%
H
1.8
4.0
|
L
 -11.6%
H
1.8
4.0
|
L
 -26.4%
H
1.8
4.9
|
L
 -11.2%
H
1.2
7.7
|
L
 -85.5%
H
1.2
13.4
|
L
H
1.2
46.3
|
| Beam Therapeutics Inc |
|
3,134.7
|
30.5
|
L
 2.3%
H
29.0
31.3
|
L
 -2.2%
H
28.3
34.0
|
L
 -5.7%
H
25.9
34.4
|
L
 14.8%
H
21.6
34.4
|
L
 64.0%
H
15.6
36.4
|
L
 -8.9%
H
13.5
49.5
|
L
 -64.4%
H
13.5
138.5
|
L
H
13
138.5
|
| Biofrontera Inc |
|
11.3
|
0.9
|
L
 -5.4%
H
0.8
0.9
|
L
 -7.4%
H
0.8
1.1
|
L
 -23.5%
H
0.7
1.2
|
L
 2.3%
H
0.7
1.2
|
L
 46.7%
H
0.6
1.2
|
L
 -90.3%
H
0.5
13.4
|
L
H
0.5
292.6
|
L
H
0.5
292.6
|
| Biogen |
|
29,394.6
|
199.1
|
L
 3.4%
H
193.5
199.6
|
L
 3.6%
H
184.9
200.7
|
L
 2.9%
H
184.9
206.0
|
L
 7.7%
H
168.6
206.0
|
L
 49.6%
H
121.1
206.0
|
L
 -35.5%
H
110.0
319.8
|
L
 -49.6%
H
110.0
427.5
|
L
 -15.0%
H
110.0
468.6
|
| BioVie Inc |
|
12.6
|
1.7
|
L
H
1.6
1.8
|
L
 12.1%
H
1.4
1.8
|
L
 13.6%
H
1.3
1.8
|
L
 22.8%
H
1.2
1.8
|
L
 -84.5%
H
1.1
12.1
|
L
 -99.7%
H
1.1
645
|
L
 -99.9%
H
1.1
1910
|
L
 -99.9%
H
1.1
5625
|
| Biomea Fusion Inc |
|
82.4
|
1.1
|
L
 -0.9%
H
1.1
1.2
|
L
 -18.0%
H
1.1
1.5
|
L
 -26.0%
H
1.1
1.7
|
L
 -18.0%
H
1.1
2.2
|
L
 -54.2%
H
0.9
3.1
|
L
 -97.3%
H
0.9
43
|
L
 -94.4%
H
0.9
43.7
|
L
H
0.9
43.7
|
| Biomarin pharma Inc - Registered Shares |
|
11,193.1
|
57.9
|
L
 2.4%
H
56.9
58.1
|
L
 5.2%
H
53.0
58.1
|
L
 7.1%
H
49.3
58.1
|
L
 -5.3%
H
49.3
62.0
|
L
 2.2%
H
49.3
66.3
|
L
 -37.2%
H
49.3
99.6
|
L
 -26.5%
H
49.3
117.8
|
L
 -31.1%
H
49.3
131.9
|
| Bionano Genomics Inc |
|
13.3
|
1.2
|
L
 -0.9%
H
1.2
1.2
|
L
 -7.2%
H
1.2
1.4
|
L
 -10.1%
H
1.1
1.4
|
L
 3.6%
H
1.1
1.5
|
L
 -69.1%
H
1.1
5.5
|
L
 -84.1%
H
0.1
11.6
|
L
 -98.6%
H
0.1
84.8
|
L
H
0.1
156.9
|
| Benitec Biopharma Inc |
|
371.4
|
10.8
|
L
 3.0%
H
10.5
11
|
L
 -0.1%
H
10.2
11.3
|
L
 -12.0%
H
10.2
12.6
|
L
 -4.7%
H
10.0
14.3
|
L
 -32.4%
H
9.9
17.2
|
L
 177.9%
H
1.9
17.2
|
L
 -87.1%
H
1.9
86.2
|
L
 -96.7%
H
1.9
1371.3
|
| Bolt Biotherapeutics Inc |
|
8.9
|
4.6
|
L
 -2.1%
H
4.6
4.8
|
L
 -13.0%
H
4.5
5.4
|
L
 -1.1%
H
4.3
5.7
|
L
 7.4%
H
3.9
5.7
|
L
 -28.5%
H
3.9
7.4
|
L
 -86.1%
H
3.9
34.2
|
L
 -98.6%
H
3.9
385.7
|
L
H
3.9
861.4
|
| Bon Natural Life Ltd |
|
10.7
|
1.3
|
L
H
1.3
1.3
|
L
 5.6%
H
1.2
1.4
|
L
 10%
H
1.2
1.4
|
L
 -9.6%
H
1.1
1.6
|
L
 -20%
H
1.1
3.4
|
L
 -99.2%
H
1.1
192.5
|
L
 -100.0%
H
1.1
4400
|
L
 -100.0%
H
1.1
22532.5
|
| BioXcel Therapeutics Inc |
|
33.0
|
1.1
|
L
 -2.7%
H
1.1
1.1
|
L
 -10.1%
H
1.1
1.3
|
L
 -12.3%
H
1.1
1.4
|
L
 -27.7%
H
1.0
1.8
|
L
 -41.9%
H
1.0
8.1
|
L
 -94.8%
H
0.2
22.1
|
L
 -97.2%
H
0.2
39
|
L
H
0.2
71.5
|
| Blue Water Biotech Inc |
|
16.9
|
1.0
|
L
 -5.9%
H
0.9
1.0
|
L
 -16.7%
H
0.9
1.2
|
L
 150%
H
0.1
1.4
|
L
 93.9%
H
0.1
6.7
|
L
 1257.1%
H
0.1
6.7
|
L
 18.8%
H
0.1
6.7
|
L
H
0.1
90.9
|
L
H
0.1
90.9
|
| BeyondSpring Inc |
|
70.7
|
1.7
|
L
 1.2%
H
1.7
1.8
|
L
 -1.2%
H
1.6
1.8
|
L
 15.4%
H
1.2
1.8
|
L
 18.6%
H
1.2
1.9
|
L
 1.2%
H
1.2
3.4
|
L
 42.1%
H
0.7
4
|
L
 -85.2%
H
0.5
33
|
L
H
0.5
48.5
|
| Bicycle Therapeutics PLC (ADR) |
|
291.1
|
4.2
|
L
 1.5%
H
4.0
4.2
|
L
 -8.0%
H
4.0
4.5
|
L
 -13.3%
H
4.0
4.9
|
L
 -19.8%
H
4.0
5.5
|
L
 -51.2%
H
4.0
9.4
|
L
 -83.4%
H
4.0
28.9
|
L
 -86.1%
H
4.0
62.1
|
L
H
4.0
62.1
|
| Biodexa Pharma PLC (ADR) |
|
2.3
|
3.1
|
L
 -4.9%
H
3.1
3.3
|
L
 -6.6%
H
3.1
3.8
|
L
 -27.1%
H
3.1
4.1
|
L
 -31.6%
H
2.9
6.8
|
L
 -94.6%
H
2.9
66.5
|
L
 -100.0%
H
2.9
304375
|
L
 -100.0%
H
2.9
180500000
|
L
 -100.0%
H
2.9
10000000000
|
| BeiGene Ltd (ADR) |
|
28,567.1
|
268.2
|
L
 -1.0%
H
265.3
271.4
|
L
 -4.1%
H
265.3
283.8
|
L
 -14.1%
H
265.3
322.5
|
L
 -10.9%
H
265.3
328.4
|
L
 4.8%
H
239.3
385.2
|
L
 23.5%
H
127.0
385.2
|
L
 -22.9%
H
118.2
426.6
|
L
 736.7%
H
24.5
426.6
|
| Bioline Rx Ltd (ADR) |
|
14.0
|
3.2
|
L
 -1.2%
H
3.2
3.3
|
L
 -7.8%
H
3.0
3.5
|
L
 4.6%
H
2.5
4.0
|
L
 21.1%
H
2.2
4.0
|
L
 -44.1%
H
2.2
6.6
|
L
 -95.1%
H
0.1
101.2
|
L
 -97.2%
H
0.1
144.8
|
L
 -99.4%
H
0.1
1103.9
|
| Belite Bio Inc (ADR) |
|
5,668.8
|
141.4
|
L
 1.3%
H
137.0
144.8
|
L
 -3.8%
H
130
146.5
|
L
 -8.7%
H
130
158.6
|
L
 -18.4%
H
130
183.7
|
L
 137.0%
H
56.1
200
|
L
 855.5%
H
11
200
|
L
H
6
200
|
L
H
6
200
|
| Neuphoria Therapeutics Inc |
|
25.2
|
4.7
|
L
 -0.2%
H
4.5
4.9
|
L
 -12.1%
H
4.4
5.2
|
L
 -12.2%
H
4.4
5.5
|
L
 7.9%
H
3.8
5.5
|
L
 -32.2%
H
3.6
21.4
|
L
 109.0%
H
0.2
21.4
|
L
H
0.2
22
|
L
H
0.2
22
|
| BioNTech SE (ADR) |
|
21,874.5
|
86.5
|
L
 1.2%
H
85.0
87.1
|
L
 -5.7%
H
85.0
91.1
|
L
 -8.1%
H
85.0
97.4
|
L
 -14.8%
H
79.5
113.3
|
L
 -20.3%
H
79.5
124
|
L
 -20.6%
H
76.5
131.5
|
L
 -60.8%
H
76.5
464
|
L
H
12.5
464
|
| Biondvax Pharma Ltd (ADR) |
|
-
|
0.4
|
L
 -14.6%
H
0.3
0.4
|
L
 -30%
H
0.3
0.5
|
L
 -38.6%
H
0.3
0.6
|
L
 -55.1%
H
0.3
1.1
|
L
 -86.3%
H
0.3
3.5
|
L
 -75.4%
H
0.3
6.2
|
L
 -98.9%
H
0.3
99
|
L
 -98.9%
H
0.3
620
|
| Cabaletta Bio Inc |
|
525.0
|
3.2
|
L
 0.6%
H
3.0
3.2
|
L
 -12.3%
H
3.0
3.9
|
L
 -17.0%
H
3.0
4.1
|
L
 1.6%
H
2.5
4.2
|
L
 29.8%
H
1.3
4.2
|
L
 -73.9%
H
1.0
26.4
|
L
 -61.5%
H
0.6
26.4
|
L
H
0.6
26.4
|
| CalciMedica Inc |
|
14.4
|
0.9
|
L
 -5.2%
H
0.9
1.0
|
L
 8.3%
H
0.8
1.1
|
L
 44.4%
H
0.6
1.1
|
L
 24.7%
H
0.5
1.1
|
L
 -47.7%
H
0.5
7.2
|
L
 -82.7%
H
0.5
8.6
|
L
 -98.7%
H
0.5
98.8
|
L
H
0.5
530.3
|
| Capricor Therapeutics Inc |
|
1,506.3
|
26.0
|
L
 -0.6%
H
25.1
27.0
|
L
 -8.8%
H
25.1
28.5
|
L
 -14.4%
H
25.1
32.6
|
L
 -6.8%
H
25.1
36.8
|
L
 82.8%
H
4.3
40.4
|
L
 467.9%
H
2.7
40.4
|
L
 481.9%
H
2.6
40.4
|
L
 -24.6%
H
0.9
54
|
| Tvardi Therapeutics Inc |
|
26.1
|
2.8
|
L
 -2.5%
H
2.8
3.0
|
L
 -13.7%
H
2.8
3.3
|
L
 -33.5%
H
2.8
4.2
|
L
 -29.3%
H
2.8
4.3
|
L
 -90.3%
H
2.8
43.7
|
L
 -97.6%
H
2.8
160.2
|
L
 -99.4%
H
2.8
681.5
|
L
 -98.7%
H
2.8
1067.3
|
| Crescent Biopharma Inc |
|
-
|
18
|
L
 4.2%
H
17.3
18.2
|
L
 -8.7%
H
16.5
19.8
|
L
 -4.1%
H
16.5
22.5
|
L
 49.1%
H
9.9
27.4
|
L
 114.0%
H
7.9
27.4
|
L
 434.1%
H
3.3
27.4
|
L
 68.7%
H
0.9
27.4
|
L
 -68.3%
H
0.9
123.8
|
| C4 Therapeutics Inc |
|
395.8
|
3.6
|
L
 -0.3%
H
3.4
3.9
|
L
 -18.3%
H
3.4
4.6
|
L
 21.4%
H
3.0
4.6
|
L
 17.8%
H
2.3
4.6
|
L
 106.9%
H
1.4
4.6
|
L
 1.1%
H
1.1
11.9
|
L
 -91.2%
H
1.1
51.2
|
L
H
1.1
51.2
|
| Niagen Bioscience Inc |
|
279.6
|
3.5
|
L
 4.2%
H
3.4
3.5
|
L
 -2.8%
H
3.4
3.6
|
L
 -15.8%
H
3.4
4.2
|
L
 -30.6%
H
3.4
5.4
|
L
 -72.9%
H
3.4
14.7
|
L
 123.6%
H
1.3
14.7
|
L
 -66.7%
H
1.2
14.7
|
L
 -38.1%
H
1.2
23.7
|
| Cullinan Oncology Inc |
|
810.0
|
13.2
|
L
 -0.8%
H
12.5
13.8
|
L
 -18.7%
H
12.4
16.1
|
L
 -9.4%
H
12.4
16.7
|
L
 -16.3%
H
12.4
16.7
|
L
 45.2%
H
5.7
16.7
|
L
 1.4%
H
5.7
30.2
|
L
 -60.6%
H
5.7
34.4
|
L
H
5.7
59.9
|
| Compugen Ltd |
|
191.1
|
2.0
|
L
 -1.0%
H
2.0
2.1
|
L
 -17.9%
H
2.0
2.4
|
L
 -30.3%
H
2.0
3.1
|
L
 -2.9%
H
2.0
3.2
|
L
 16.1%
H
1.3
3.2
|
L
 59.1%
H
0.5
3.2
|
L
 -73.6%
H
0.5
9.2
|
L
 -70.2%
H
0.5
19.9
|
| Cognition Therapeutics Inc |
|
102.9
|
1.2
|
L
 -5.0%
H
1.1
1.2
|
L
 -8%
H
1.1
1.5
|
L
 -5.0%
H
1.1
1.5
|
L
 11.7%
H
0.6
1.5
|
L
 283.3%
H
0.3
3.8
|
L
 -61.7%
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
| Coherus Biosciences Inc |
|
219.0
|
1.4
|
L
H
1.4
1.5
|
L
 -9.6%
H
1.4
1.6
|
L
 -18.9%
H
1.4
2.1
|
L
 -22.0%
H
1.4
2.1
|
L
 71.1%
H
0.7
2.6
|
L
 -73.7%
H
0.7
5.6
|
L
 -89.5%
H
0.7
19.3
|
L
 -92.1%
H
0.7
32.0
|
| Cingulate Inc |
|
62.6
|
4.7
|
L
 2.7%
H
4.5
5.2
|
L
 29.2%
H
3.5
5.2
|
L
 -11.8%
H
3.2
5.3
|
L
 -27.7%
H
3.2
11.9
|
L
 6.7%
H
3.2
11.9
|
L
 379.4%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
| Clene Inc |
|
71.2
|
5.6
|
L
 4.5%
H
5.3
5.7
|
L
 -8.8%
H
5.3
6.2
|
L
 -23.5%
H
5.3
7.7
|
L
 3.9%
H
4.5
8.7
|
L
 31.1%
H
3.3
13.5
|
L
 -73.7%
H
2.3
21.8
|
L
 -97.6%
H
2.3
356.4
|
L
H
0.5
356.4
|
| Cellectar Biosciences Inc |
|
18.9
|
2.4
|
L
 -6.0%
H
2.3
2.6
|
L
 -20.5%
H
2.3
3.0
|
L
 -23.9%
H
2.3
3.3
|
L
 -14.5%
H
2.3
4.7
|
L
 -78.2%
H
2.3
14.0
|
L
 -95.5%
H
2.3
133.5
|
L
 -99.5%
H
2.3
465
|
L
 -100.0%
H
2.3
13740
|
| Clearmind Medicine Inc |
|
3.5
|
3.4
|
L
 -10.6%
H
3.3
3.6
|
L
 6.9%
H
2.8
4.6
|
L
 -38.5%
H
2.1
6.0
|
L
 -70.3%
H
2.1
15.2
|
L
 -99.1%
H
2.1
524
|
L
 -99.9%
H
2.1
8160
|
L
 -100.0%
H
2.1
7884000
|
L
H
2.1
7884000
|
| Compass Therapeutics Inc |
|
371.0
|
2.1
|
L
 2.0%
H
2.0
2.1
|
L
 -7.2%
H
2
2.2
|
L
 12.6%
H
1.8
2.5
|
L
 -62.6%
H
1.6
6.8
|
L
 -17.6%
H
1.6
6.9
|
L
 -32.0%
H
0.8
6.9
|
L
 -62.5%
H
0.8
6.9
|
L
H
0.8
11
|
| Cns Pharma Inc |
|
6.7
|
4.6
|
L
 -6.1%
H
4.6
4.9
|
L
 -8.8%
H
4.6
5.3
|
L
 -37.0%
H
4.6
7.6
|
L
 56.1%
H
1.9
10.5
|
L
 -63.2%
H
1.9
12.8
|
L
 -100.0%
H
1.9
4125000
|
L
 -100.0%
H
1.9
120600000
|
L
H
1.9
256050000
|
| Context Therapeutics Inc |
|
139.7
|
1.5
|
L
 -11.1%
H
1.5
1.7
|
L
 -45.5%
H
1.5
2.8
|
L
 -36.1%
H
1.5
3.1
|
L
 -51.3%
H
1.5
3.6
|
L
 130.3%
H
0.6
3.6
|
L
 16.0%
H
0.5
3.6
|
L
H
0.5
10.9
|
L
H
0.5
10.9
|
| Cocrystal Pharma Inc |
|
14.1
|
1.0
|
L
 1.0%
H
1
1.1
|
L
 -8.1%
H
1.0
1.1
|
L
 -29.2%
H
1.0
1.4
|
L
 1.0%
H
1.0
2.0
|
L
 -37.4%
H
0.9
2.7
|
L
 -61.4%
H
0.9
3.3
|
L
 -93.2%
H
0.9
17.9
|
L
 -99.5%
H
0.9
225.0
|
| Co-Diagnostics Inc |
|
16.6
|
4.5
|
L
 -10.9%
H
4.5
5.4
|
L
 -27.4%
H
4.4
9.1
|
L
 77.9%
H
1.3
13.5
|
L
 90.7%
H
1.3
13.5
|
L
 -50%
H
1.3
46.5
|
L
 -86.0%
H
1.3
66.9
|
L
 -98.2%
H
1.3
354.6
|
L
H
1.3
929.7
|
| Z Squared Inc |
|
531.3
|
10.3
|
L
 2.5%
H
9.7
10.9
|
L
 -2.2%
H
9.7
11.5
|
L
 -17.1%
H
8
13.0
|
L
 -21.7%
H
8
18.8
|
L
 15.4%
H
6.8
21.4
|
L
 -67.7%
H
2.3
37.4
|
L
 4.7%
H
2.3
242.6
|
L
H
2.3
242.6
|
| Cogent Biosciences Inc |
|
5,464.4
|
32.0
|
L
 2.6%
H
31.0
32.3
|
L
 -8.1%
H
30.9
34.6
|
L
 -7.9%
H
30.9
36.0
|
L
 -13.8%
H
30.9
39.4
|
L
 370.3%
H
6.6
43.7
|
L
 178.1%
H
3.7
43.7
|
L
 307.4%
H
3.7
43.7
|
L
H
1.2
70.6
|
| Collegium pharma Inc |
|
1,115.7
|
34.4
|
L
 3.4%
H
33.6
34.9
|
L
 8.2%
H
30.1
34.9
|
L
 -9.0%
H
30.1
37.8
|
L
 -7.8%
H
30.1
40.5
|
L
 13.9%
H
29.1
50.8
|
L
 56.8%
H
20.8
50.8
|
L
 53.0%
H
14.0
50.8
|
L
 107.2%
H
7.4
50.8
|
| Corcept Therapeutics Inc |
|
8,318.7
|
77.5
|
L
 5.7%
H
73.6
77.6
|
L
 10.0%
H
68.8
77.6
|
L
 48.2%
H
50.6
77.6
|
L
 128.8%
H
31.8
77.6
|
L
 11.3%
H
28.7
91
|
L
 222.3%
H
20.8
117.3
|
L
 260.1%
H
15.8
117.3
|
L
 1273.9%
H
5.0
117.3
|
| Cosmos Health Inc |
|
13.7
|
0.2
|
L
 -4.4%
H
0.2
0.3
|
L
 -12%
H
0.2
0.3
|
L
 -33.3%
H
0.2
0.3
|
L
 -40.5%
H
0.2
0.5
|
L
 -54.2%
H
0.2
1.3
|
L
 -93.7%
H
0.2
3.5
|
L
 -99.8%
H
0.2
194.3
|
L
 -99.8%
H
0.2
312.5
|
| Cumberland Pharma Inc |
|
85.7
|
5.7
|
L
 -2.4%
H
5.7
6
|
L
 0.4%
H
5.4
6.1
|
L
 22.2%
H
4.4
6.6
|
L
 63.4%
H
2.7
6.6
|
L
 -1.7%
H
1.9
6.6
|
L
 246.7%
H
1.0
7.3
|
L
 92.6%
H
1.0
7.5
|
L
 28.3%
H
1.0
8.0
|
| Catalyst Pharma Inc |
|
3,835.4
|
31.3
|
L
 0.2%
H
31.3
31.4
|
L
 0.2%
H
31.3
31.4
|
L
 0.6%
H
31.1
31.4
|
L
 29.3%
H
22.2
32.6
|
L
 21.1%
H
19.1
32.6
|
L
 164.2%
H
11.5
32.6
|
L
 457.7%
H
4.8
32.6
|
L
 4648.5%
H
0.6
32.6
|
| Corbus Pharma Holdings Inc |
|
142.7
|
7.7
|
L
 1.9%
H
7.5
7.9
|
L
 -0.7%
H
7.1
8.3
|
L
 -29.7%
H
7.1
12.9
|
L
 -3.9%
H
7.1
12.9
|
L
 -16.6%
H
6.7
20.6
|
L
 -17.4%
H
3.0
61.9
|
L
 -88.3%
H
2.1
68.7
|
L
 -91.9%
H
2.1
323.4
|
| Caribou Biosciences Inc |
|
182.5
|
1.8
|
L
H
1.8
1.9
|
L
 -24.3%
H
1.8
2.5
|
L
 -5.2%
H
1.8
2.5
|
L
 1.1%
H
1.7
2.5
|
L
 46.0%
H
1.0
3.5
|
L
 -58.8%
H
0.7
8.6
|
L
H
0.7
32.6
|
L
H
0.7
32.6
|
| Cardiol Therapeutics Inc (Class A) |
|
124.5
|
1.1
|
L
H
1.1
1.1
|
L
 -11.5%
H
1.1
1.2
|
L
 -18.2%
H
1.1
1.4
|
L
 11.3%
H
0.9
1.7
|
L
 -23.4%
H
0.9
1.7
|
L
 54.3%
H
0.7
3.1
|
L
 -66.1%
H
0.5
5.0
|
L
H
0.5
8.5
|
| Curis Inc |
|
17.5
|
0.5
|
L
 -4.3%
H
0.4
0.5
|
L
 -13.5%
H
0.4
0.5
|
L
 -19.6%
H
0.4
0.6
|
L
 -54.6%
H
0.4
1.1
|
L
 -81.0%
H
0.4
3.1
|
L
 -97.3%
H
0.4
18
|
L
 -99.8%
H
0.4
285.6
|
L
 -99.8%
H
0.4
372
|
| CorMedix Inc |
|
678.6
|
8.7
|
L
 1.3%
H
8.5
8.8
|
L
 2.4%
H
8.1
8.8
|
L
 9.2%
H
7.4
8.9
|
L
 33.9%
H
6.1
8.9
|
L
 -38.1%
H
6.1
17.4
|
L
 67.0%
H
2.6
17.4
|
L
 7.9%
H
2.6
17.4
|
L
 -33.5%
H
0.9
18.8
|
| Crinetics Pharma Inc |
|
3,687.2
|
35.0
|
L
 4.5%
H
33.5
35.1
|
L
 1.3%
H
32.3
35.1
|
L
 -6.7%
H
32.3
38.5
|
L
 -8.5%
H
32.3
43.6
|
L
 5.9%
H
25.8
58.0
|
L
 59.2%
H
15.8
62.5
|
L
 94.6%
H
15.2
62.5
|
L
H
10.6
62.5
|
| Cronos Grp Inc |
|
1,042.5
|
2.8
|
L
 0.7%
H
2.8
2.9
|
L
 -1.1%
H
2.7
2.9
|
L
 9.8%
H
2.6
2.9
|
L
 8.6%
H
2.4
3.3
|
L
 40.9%
H
1.8
3.4
|
L
 64.1%
H
1.6
3.4
|
L
 -68.8%
H
1.6
9.4
|
L
H
0.2
25.1
|
| CRISPR Therapeutics AG |
|
5,070.0
|
51.5
|
L
 -0.2%
H
49.6
53.1
|
L
 -5%
H
49.6
59
|
L
 -6.1%
H
46.9
59
|
L
 -8.9%
H
44.1
59.4
|
L
 23.0%
H
39.8
78.5
|
L
 -17.8%
H
30.0
91.1
|
L
 -56.7%
H
30.0
169.8
|
L
H
11.6
220.2
|
| Corvus Pharma Inc |
|
939.3
|
11.2
|
L
 0.2%
H
10.8
11.5
|
L
 -7.5%
H
10.8
12.0
|
L
 -28.2%
H
10.8
16.9
|
L
 -29.3%
H
10.8
19.7
|
L
 185.7%
H
3.6
27.0
|
L
 189.4%
H
1.1
27.0
|
L
 297.5%
H
0.6
27.0
|
L
 -16.3%
H
0.6
27.0
|
| Champions Oncology Inc |
|
80.4
|
5.8
|
L
 2.7%
H
5.7
6
|
L
 -0.9%
H
5.6
6
|
L
 -3.8%
H
5.6
6.4
|
L
 -1.4%
H
5.5
6.4
|
L
 -16.0%
H
5.5
9.6
|
L
 7.6%
H
3.6
12.0
|
L
 -37.6%
H
3.6
12.0
|
L
 137.3%
H
1.1
17.9
|
| CytomX Therapeutics Inc |
|
648.8
|
3.0
|
L
 1.4%
H
2.8
3.0
|
L
 -13.6%
H
2.8
3.4
|
L
 -25.1%
H
2.8
4.1
|
L
 -36.3%
H
2.8
8.2
|
L
 12.9%
H
1.7
8.2
|
L
 71.3%
H
0.4
8.2
|
L
 -57.3%
H
0.4
8.2
|
L
 -70.7%
H
0.4
35
|
| Cue Biopharma Inc |
|
127.9
|
30.4
|
L
 4.7%
H
27.9
31.5
|
L
 26.5%
H
24.8
32.6
|
L
 -13.0%
H
18.2
33.6
|
L
 238.2%
H
5.0
41.4
|
L
 58.3%
H
5.0
41.4
|
L
 -73.1%
H
5.0
146.7
|
L
 -92.5%
H
5.0
552.6
|
L
H
5.0
950.7
|
| Cadrenal Therapeutics Inc |
|
12.2
|
4.0
|
L
 -6.2%
H
4.0
4.4
|
L
 -16.0%
H
4.0
4.7
|
L
 -35.1%
H
4.0
6.3
|
L
 -52.3%
H
4.0
8.4
|
L
 -73.8%
H
4.0
16.0
|
L
 150%
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
| Cyclacel Pharma Inc |
|
5.0
|
0.9
|
L
 -18.2%
H
0.8
1.0
|
L
 -15.9%
H
0.8
2.8
|
L
 2.3%
H
0.8
2.8
|
L
 -5.3%
H
0.7
2.8
|
L
 -83.8%
H
0.7
19.9
|
L
 -100.0%
H
0.7
3168
|
L
 -100.0%
H
0.7
26028
|
L
 -100.0%
H
0.7
784800
|
| Cyclerion Therapeutics Inc |
|
13.0
|
3
|
L
 -0.3%
H
3.0
3.1
|
L
 -2.6%
H
3.0
3.1
|
L
 -3.2%
H
2.9
3.4
|
L
 112.8%
H
1.3
8.5
|
L
 -5.7%
H
1.0
8.5
|
L
 -31.2%
H
1.0
8.5
|
L
 -96.3%
H
1.0
97.2
|
L
H
1.0
457
|
| Cytokinetics Inc |
|
9,293.5
|
68.5
|
L
 0.8%
H
66.9
70.3
|
L
 -7.1%
H
66.9
73.6
|
L
 -11%
H
66.9
79.1
|
L
 13.3%
H
58.4
80.2
|
L
 111.9%
H
32.0
80.2
|
L
 79.8%
H
26.0
110
|
L
 215.1%
H
17.7
110
|
L
 714.9%
H
5.8
110
|
| Cellectis (ADR) |
|
300.8
|
3.0
|
L
 2.1%
H
2.9
3.1
|
L
 -14.1%
H
2.9
3.5
|
L
 -22.3%
H
2.9
4.2
|
L
 -16.0%
H
2.9
4.6
|
L
 112.1%
H
1.3
5.5
|
L
 50.3%
H
1.0
5.5
|
L
 -79.8%
H
1.0
16.5
|
L
 -90.9%
H
1.0
38.9
|
| Chemomab Therapeutics Ltd (ADR) |
|
12.5
|
1.7
|
L
 -4.4%
H
1.7
1.9
|
L
 -7.0%
H
1.7
2.0
|
L
 -2.3%
H
1.5
2.1
|
L
 -8.0%
H
1.5
2.2
|
L
 -67.3%
H
1.4
5.4
|
L
 -75.3%
H
1.4
10.2
|
L
 -97.8%
H
1.4
111.7
|
L
H
1.4
736
|
| Compass Pathways PLC (ADR) |
|
1,519.5
|
11.3
|
L
 -4.0%
H
10.8
12
|
L
 -20.7%
H
10.8
14.4
|
L
 13.6%
H
9.2
14.8
|
L
 71.1%
H
4.9
14.8
|
L
 134.6%
H
2.3
14.8
|
L
 39.7%
H
2.3
14.8
|
L
 -68.9%
H
2.3
49.5
|
L
H
2.3
61.7
|
| Centessa Pharma PLC (ADR) |
|
6,152.0
|
39.8
|
L
 0.2%
H
39.6
39.8
|
L
 -0.3%
H
39.6
40.0
|
L
 0.4%
H
39.5
40.0
|
L
 53.2%
H
25.1
40.3
|
L
 233.6%
H
11.6
40.3
|
L
 762.5%
H
4.5
40.3
|
L
 75.2%
H
2.9
40.3
|
L
H
2.9
40.3
|
| Connect Biopharma Holdings Ltd (ADR) |
|
118.1
|
2.1
|
L
 -3.6%
H
2.1
2.3
|
L
 -9.4%
H
2.1
2.5
|
L
 -10.2%
H
2.1
2.7
|
L
 -14.5%
H
2.1
3.8
|
L
 168.4%
H
0.8
3.8
|
L
 91.0%
H
0.5
3.8
|
L
 -86.6%
H
0.5
29.3
|
L
H
0.5
29.3
|
| Dare Bioscience Inc |
|
28.8
|
1.9
|
L
 3.8%
H
1.9
2.0
|
L
 -12.3%
H
1.9
2.2
|
L
 -30.2%
H
1.9
3.1
|
L
 25.5%
H
1.3
3.8
|
L
 -40%
H
1.3
9.2
|
L
 -83.8%
H
0.3
12
|
L
 -87.7%
H
0.3
30.1
|
L
 -99.3%
H
0.3
429.6
|
| Journey Medical Corp |
|
170.2
|
6.2
|
L
 3%
H
5.9
6.2
|
L
 1.5%
H
5.8
6.3
|
L
 21.9%
H
4.8
6.7
|
L
 -20.5%
H
4.3
8.5
|
L
 -16.4%
H
4.3
9.6
|
L
 245.3%
H
1.5
9.6
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
| Diffusion Pharma Inc |
|
-
|
2.9
|
L
 -0.7%
H
2.8
3
|
L
 -3.7%
H
2.8
3.2
|
L
 -26.8%
H
2.8
4.0
|
L
 -29.7%
H
2.8
5.1
|
L
 -62.1%
H
2.8
13.1
|
L
 -46.8%
H
2.8
14.4
|
L
 -95.0%
H
2.8
64.1
|
L
 -100.0%
H
2.8
17437.5
|
| DiaMedica Therapeutics Inc |
|
292.0
|
5.4
|
L
 -3.4%
H
5.3
5.9
|
L
 -7.2%
H
5.3
5.9
|
L
 -14.2%
H
5.3
6.6
|
L
 -29.7%
H
5.3
8.1
|
L
 30.9%
H
3.5
10.4
|
L
 67.8%
H
1.9
10.4
|
L
 -35.6%
H
1.1
10.4
|
L
 59.4%
H
1.1
13.8
|
| Denali Therapeutics Inc |
|
3,299.6
|
20.8
|
L
 6.4%
H
19.5
20.9
|
L
 1.9%
H
18.9
21.1
|
L
 6.0%
H
17.7
21.2
|
L
 5.6%
H
17.7
23.5
|
L
 41.4%
H
12.6
23.8
|
L
 -33.1%
H
10.6
33.3
|
L
 -71.4%
H
10.6
79.7
|
L
H
10.6
93.9
|
| Dominari Holdings Inc |
|
73.5
|
3.3
|
L
 2.5%
H
3.2
3.4
|
L
 -0.3%
H
3
3.5
|
L
 -10.7%
H
3
4.6
|
L
 9.1%
H
2.7
4.6
|
L
 -39.8%
H
2.7
8.4
|
L
 24.5%
H
0.8
13.6
|
L
 -82.3%
H
0.8
20.6
|
L
 -98.1%
H
0.8
308.4
|
| DarioHealth Corp |
|
55.1
|
7.5
|
L
 0.1%
H
7.2
7.7
|
L
 -2.2%
H
7.0
7.9
|
L
 -3.6%
H
7.0
8.8
|
L
 -22.4%
H
6.2
9.8
|
L
 -46.3%
H
5.9
17.7
|
L
 -91.0%
H
5.9
91.6
|
L
 -98.2%
H
5.9
476
|
L
 -99.6%
H
5.9
2200
|
| Dermata Therapeutics Inc |
|
4.8
|
1.2
|
L
 -0.8%
H
1.2
1.3
|
L
 -10.5%
H
1.2
1.4
|
L
 -4.8%
H
1.2
1.4
|
L
 -4%
H
1.1
1.8
|
L
 62.2%
H
0.6
7.1
|
L
 -37.2%
H
0.2
7.1
|
L
H
0.2
111.2
|
L
H
0.2
111.2
|
| Bright Minds Biosciences Inc |
|
665.3
|
67.8
|
L
 3.9%
H
66.0
70.0
|
L
 -16.3%
H
61.8
80.9
|
L
 -20.7%
H
61.8
92
|
L
 -11.8%
H
61.8
92.4
|
L
 145.6%
H
23.2
123.8
|
L
 2229.9%
H
0.9
123.8
|
L
 207.9%
H
0.9
123.8
|
L
H
0.9
123.8
|
| Design Therapeutics Inc |
|
658.9
|
10.6
|
L
 0.9%
H
10.3
10.8
|
L
 1.1%
H
9.9
11
|
L
 -25.8%
H
9.9
17.0
|
L
 5.0%
H
9.7
17.3
|
L
 163.1%
H
3.3
17.3
|
L
 88.7%
H
1.9
17.3
|
L
 -61.8%
H
1.9
28.5
|
L
H
1.9
50.5
|
| Precision Biosciences Inc |
|
177.0
|
6.9
|
L
 1.3%
H
6.7
7.2
|
L
 -2.3%
H
6
7.9
|
L
 -10.8%
H
6
8.6
|
L
 48.8%
H
4.5
8.6
|
L
 25.0%
H
3.5
8.8
|
L
 802.6%
H
0.3
19.4
|
L
 -41.6%
H
0.3
19.4
|
L
H
0.3
23.7
|
| Dyne Therapeutics Inc |
|
2,962.4
|
17.9
|
L
 6.6%
H
16.9
18
|
L
 -3.8%
H
16.6
18.8
|
L
 1.8%
H
15.9
19.6
|
L
 20.6%
H
15.0
21.4
|
L
 21.9%
H
8.1
25
|
L
 33.1%
H
6.4
47.5
|
L
 -10.4%
H
4.3
47.5
|
L
H
4.3
47.5
|
| DBV Tech (ADR) |
|
948.8
|
16.0
|
L
 0.2%
H
15.8
16.3
|
L
 -14.7%
H
15.8
18.3
|
L
 -18.8%
H
15.8
20.9
|
L
 -26.7%
H
15.8
24.1
|
L
 75.6%
H
8.5
26.2
|
L
 -15.6%
H
0.5
26.2
|
L
 -71.8%
H
0.5
64.7
|
L
 -95.2%
H
0.5
505.7
|
| Editas Medicine Inc |
|
406.7
|
2.7
|
L
 0.4%
H
2.5
2.7
|
L
 -20.7%
H
2.5
3.3
|
L
 -14.8%
H
2.4
3.9
|
L
 32.5%
H
2.0
3.9
|
L
 38.7%
H
1.7
4.5
|
L
 -72.4%
H
0.9
11.9
|
L
 -92.6%
H
0.9
73.0
|
L
 -92.3%
H
0.9
100.0
|
| Edesa Biotech Inc |
|
43.9
|
4.9
|
L
 -8.0%
H
4.6
5.6
|
L
 -26.2%
H
4.6
7.8
|
L
 -69.7%
H
4.6
17.1
|
L
 -24.2%
H
4.6
20.3
|
L
 170.0%
H
0.7
20.3
|
L
 -18.9%
H
0.7
20.3
|
L
 -87.3%
H
0.7
84
|
L
 -99.5%
H
0.7
1669.9
|
| Eledon Pharma Inc |
|
274.0
|
3.6
|
L
 -0.8%
H
3.4
3.7
|
L
 -5.6%
H
3.4
3.8
|
L
 -8.5%
H
3.4
4.1
|
L
 27.7%
H
2.7
4.2
|
L
 15.3%
H
1.4
4.6
|
L
 86.8%
H
1.1
5.4
|
L
 -57.3%
H
1.1
9
|
L
 -99.7%
H
1.1
1129.1
|
| Eloxx Pharmaceuticals Inc |
|
5.1
|
11.0
|
L
 170.5%
H
8.3
11.6
|
L
 170.5%
H
8.3
11.6
|
L
 170.5%
H
8.3
11.6
|
L
 170.5%
H
8.3
11.6
|
L
 170.5%
H
8.3
11.6
|
L
 79.6%
H
0
11.6
|
L
 -84.9%
H
0
101.2
|
L
 -94.3%
H
0
984
|
| Elicio Therapeutics Inc |
|
271.0
|
14.2
|
L
 4.8%
H
12.8
14.2
|
L
 17.2%
H
11.1
15.0
|
L
 43.3%
H
9.1
15.0
|
L
 22.1%
H
9.1
15.0
|
L
 81.4%
H
7.4
15.0
|
L
 -6.2%
H
3.0
16.1
|
L
 -89.2%
H
3.0
155.6
|
L
H
3.0
263
|
| Enliven Therapeutics Inc |
|
2,199.3
|
36.1
|
L
 7.4%
H
34.2
36.2
|
L
 -3.7%
H
33.5
38.0
|
L
 -11.4%
H
33.5
45.1
|
L
 22.7%
H
26.7
48.5
|
L
 74.1%
H
14.8
48.5
|
L
 58.9%
H
9.8
48.5
|
L
 -0.1%
H
3.9
48.5
|
L
H
3.9
250.8
|
| Climb Bio Inc |
|
637.9
|
11.1
|
L
 3.4%
H
10.4
11.5
|
L
 -5.6%
H
10.2
11.9
|
L
 -2.0%
H
9.3
12.5
|
L
 55.2%
H
5.9
12.5
|
L
 701.4%
H
1.2
12.5
|
L
 273.8%
H
1.1
12.5
|
L
H
1.1
29.7
|
L
H
1.1
29.7
|
| Enlivex Therapeutics Ltd |
|
166.3
|
0.7
|
L
 -2.8%
H
0.7
0.8
|
L
 -19.8%
H
0.7
0.9
|
L
 -10.4%
H
0.7
0.9
|
L
 -39.5%
H
0.7
1.3
|
L
 -28.9%
H
0.7
2.1
|
L
 -74.4%
H
0.7
4.6
|
L
 -92.5%
H
0.7
14.0
|
L
 -99.2%
H
0.7
86
|
| Enochian Biosciences Inc |
|
-
|
2.3
|
L
 -3.4%
H
2.3
2.4
|
L
 -22.6%
H
2.3
3.1
|
L
 593.9%
H
0.2
3.4
|
L
 895.7%
H
0.2
3.4
|
L
 638.7%
H
0.1
3.4
|
L
 209.5%
H
0.1
3.4
|
L
 -51.3%
H
0.1
13.8
|
L
 -8.4%
H
0.1
13.8
|
| Ensysce Biosciences Inc |
|
3.8
|
0.3
|
L
H
0.2
0.3
|
L
 -10.7%
H
0.2
0.3
|
L
 -28.6%
H
0.2
0.4
|
L
 -54.6%
H
0.2
0.7
|
L
 -89.5%
H
0.2
2.8
|
L
 -89.2%
H
0.1
9.9
|
L
 -100.0%
H
0.1
4108.8
|
L
H
0.1
5757.6
|
| Enanta Pharma Inc |
|
330.0
|
11.4
|
L
 2.5%
H
11.2
11.6
|
L
 -10.4%
H
10.9
13.2
|
L
 -26.0%
H
10.9
15.9
|
L
 -16.2%
H
10.9
15.9
|
L
 51.9%
H
6.4
17.2
|
L
 -56.5%
H
4.1
26.9
|
L
 -76.7%
H
4.1
102
|
L
 -52.8%
H
4.1
127.8
|
| Entera Bio Ltd |
|
60.1
|
1.2
|
L
 1.7%
H
1.2
1.2
|
L
 -3.9%
H
1.2
1.3
|
L
 -6.2%
H
1.2
1.4
|
L
 -2.4%
H
0.9
1.6
|
L
 -41.1%
H
0.9
3.2
|
L
 52.5%
H
0.5
3.4
|
L
 -68.1%
H
0.5
8.7
|
L
H
0.5
10.2
|
| Enveric Biosciences Inc |
|
5.9
|
1.6
|
L
 -8.6%
H
1.6
1.8
|
L
 -29.2%
H
1.6
2.4
|
L
 -43.9%
H
1.6
3.0
|
L
 -17.5%
H
1.6
7.9
|
L
 -89.7%
H
1.6
17.6
|
L
 -99.8%
H
1.6
766.8
|
L
 -100.0%
H
1.6
33660
|
L
 -100.0%
H
1.6
12150000
|
| Evolus Inc |
|
441.2
|
6.7
|
L
 0.3%
H
6.6
6.9
|
L
 2.8%
H
6.0
6.9
|
L
 5.4%
H
6.0
6.9
|
L
 21.2%
H
3.9
6.9
|
L
 -33.3%
H
3.9
10.6
|
L
 -21.9%
H
3.9
17.8
|
L
 -41.1%
H
3.9
17.8
|
L
H
2.9
39.5
|
| Equillium Inc |
|
170.7
|
2.7
|
L
 -2.5%
H
2.6
3.0
|
L
 -12.3%
H
2.2
3.5
|
L
 28.0%
H
1.8
3.5
|
L
 52.5%
H
1.6
3.5
|
L
 610.5%
H
0.3
3.5
|
L
 321.9%
H
0.3
3.5
|
L
 -64.7%
H
0.3
7.8
|
L
H
0.3
27.1
|
| Erasca Inc |
|
4,170.3
|
13.4
|
L
 4.2%
H
12.3
13.4
|
L
 -3.0%
H
11.8
14.6
|
L
 32.5%
H
9.8
15.0
|
L
 -13.3%
H
8.7
24.3
|
L
 738.1%
H
1.2
24.3
|
L
 393.0%
H
1.0
24.3
|
L
H
1.0
24.5
|
L
H
1.0
24.5
|
| Esperion Therapeutics Inc |
|
809.2
|
3.1
|
L
 -0.3%
H
3.1
3.2
|
L
 0.3%
H
3.1
3.2
|
L
H
3.1
3.2
|
L
 15.4%
H
1.8
3.3
|
L
 157.4%
H
1.0
4.2
|
L
 132.6%
H
0.7
4.2
|
L
 -86.1%
H
0.7
26.8
|
L
 -82.6%
H
0.7
82.7
|
| Eton Pharma Inc |
|
836.3
|
30.5
|
L
 1.9%
H
29.9
31.1
|
L
 6.5%
H
26.7
31.1
|
L
 3.0%
H
26.7
35.7
|
L
 81.7%
H
16.1
35.7
|
L
 81.3%
H
13.1
35.7
|
L
 684.8%
H
2.4
35.7
|
L
 383.8%
H
2.0
35.7
|
L
H
2.0
35.7
|
| Edgewise Therapeutics Inc |
|
3,664.6
|
34.1
|
L
 -2.2%
H
33.1
36.0
|
L
 -15.4%
H
33.1
40.4
|
L
 -3.6%
H
31.0
40.8
|
L
 22.4%
H
27.0
40.8
|
L
 123.5%
H
12.2
40.8
|
L
 231.0%
H
5.1
40.8
|
L
 27.2%
H
5.1
40.8
|
L
H
5.1
40.8
|
| Exelixis Inc |
|
13,319.3
|
53.0
|
L
 2.4%
H
52
53.3
|
L
 5.4%
H
48.1
53.3
|
L
 10.0%
H
48.1
53.3
|
L
 27.6%
H
40.5
53.3
|
L
 23.2%
H
33.8
53.3
|
L
 173.9%
H
18.6
53.3
|
L
 138.6%
H
14.9
53.3
|
L
 629.9%
H
7.2
53.3
|
| Hyperion DeFi Inc |
|
39.3
|
2.6
|
L
 -11.6%
H
2.6
2.9
|
L
 -32.9%
H
2.6
3.9
|
L
 -28.1%
H
2.6
4.1
|
L
 -16.7%
H
2.6
5.0
|
L
 -46.9%
H
2.1
17.2
|
L
 -98.9%
H
0.0
237.6
|
L
 -99.4%
H
0.0
530.4
|
L
H
0.0
859.2
|
| EyePoint Pharma Inc |
|
986.8
|
11.8
|
L
 2.8%
H
11.3
11.9
|
L
 -10.5%
H
11.3
13.2
|
L
 -13.8%
H
11.3
14.7
|
L
 -25.3%
H
11.3
16.1
|
L
 31.7%
H
7.9
19.1
|
L
 93.6%
H
3.9
31.0
|
L
 29.2%
H
2.2
31.0
|
L
 -66.9%
H
2.2
42.5
|
| Evaxion Biotech A/S (ADR) |
|
30.3
|
3.6
|
L
 -2.7%
H
3.5
3.8
|
L
 -6.9%
H
3.4
4.0
|
L
 -16.4%
H
3.4
4.5
|
L
 12.7%
H
3.0
4.8
|
L
 16.0%
H
2.1
12.2
|
L
 -73.7%
H
0.8
13.9
|
L
 -94.6%
H
0.8
250.4
|
L
H
0.8
250.4
|
| Evotec SE (ADR) |
|
976.8
|
2.8
|
L
 -2.1%
H
2.7
2.8
|
L
 -10.4%
H
2.7
3.0
|
L
 -10.4%
H
2.6
3.1
|
L
 -10.4%
H
2.3
3.4
|
L
 -32.1%
H
2.3
4.4
|
L
 -78.0%
H
2.3
13.5
|
L
 -87.4%
H
2.3
26.6
|
L
 21.7%
H
2.0
26.6
|
| Fate Therapeutics Inc |
|
221.5
|
1.9
|
L
 -0.5%
H
1.8
2.1
|
L
 -30.7%
H
1.8
2.8
|
L
 -20.5%
H
1.6
2.9
|
L
 42.9%
H
1.0
2.9
|
L
 18.8%
H
0.9
2.9
|
L
 -64.2%
H
0.7
8.8
|
L
 -97.6%
H
0.7
97.4
|
L
 5.0%
H
0.7
121.2
|
| Fortress Biotech Inc |
|
97.3
|
2.9
|
L
 2.8%
H
2.8
3.0
|
L
 14.0%
H
2.5
3
|
L
 22.6%
H
2.2
3
|
L
 -12.3%
H
2.2
3.4
|
L
 46.5%
H
1.7
4.5
|
L
 -66.3%
H
1.2
10.7
|
L
 -95.3%
H
1.2
67.4
|
L
 -93.3%
H
1.2
91.5
|
| Forte Biosciences Inc |
|
348.1
|
17
|
L
 8.5%
H
15.5
17.1
|
L
 -11.6%
H
15.5
19.4
|
L
 -29.2%
H
15.5
27.0
|
L
 -40.9%
H
15.5
35.8
|
L
 50.2%
H
9.1
35.8
|
L
 -31.6%
H
4.1
35.8
|
L
 -98.4%
H
4.1
1067.3
|
L
H
0.0
1349.8
|
| 4D Molecular Therapeutics Inc |
|
482.5
|
9.2
|
L
 6.8%
H
8.7
9.3
|
L
 -4.9%
H
8.4
10.5
|
L
 -9.0%
H
8.1
11.2
|
L
 8.8%
H
8.0
11.2
|
L
 112.2%
H
3.7
12.3
|
L
 -52.7%
H
2.2
36.3
|
L
 -65.4%
H
2.2
36.3
|
L
H
2.2
55.1
|
| Fennec Pharma Inc |
|
304.6
|
8.8
|
L
 -1.5%
H
8.6
9.3
|
L
 -11.2%
H
8.6
10
|
L
 26.6%
H
6.8
10.5
|
L
 13.9%
H
5.7
10.5
|
L
 4.0%
H
5.7
10.5
|
L
 1.7%
H
4.0
11.9
|
L
 25.8%
H
3.8
11.9
|
L
 260.9%
H
1.6
15.0
|
| Kyntra Bio Inc |
|
27.1
|
6.7
|
L
 0.9%
H
6.7
7.0
|
L
 -3.0%
H
6.6
7.0
|
L
 -3.7%
H
6.6
7.2
|
L
 -2.2%
H
6.3
7.7
|
L
 -14.5%
H
4.9
12.6
|
L
 -98.5%
H
4.5
455.3
|
L
 -98.9%
H
4.5
753.1
|
L
 -98.6%
H
4.5
1713.8
|
| Foghorn Therapeutics Inc |
|
227.2
|
3.9
|
L
 4.3%
H
3.7
3.9
|
L
 -2.8%
H
3.5
4.1
|
L
 -12.8%
H
3.5
4.6
|
L
 -33.0%
H
3.5
5.8
|
L
 -13.2%
H
3.3
7.0
|
L
 -52.2%
H
2.7
10.2
|
L
 -64.5%
H
2.7
24.3
|
L
H
2.7
28.3
|
| Q32 Bio Inc |
|
201.6
|
11.9
|
L
 -1.2%
H
11.6
12.6
|
L
 2.0%
H
11.1
14.9
|
L
 121.4%
H
5.0
14.9
|
L
 153.0%
H
4.4
14.9
|
L
 525.8%
H
1.3
14.9
|
L
 -39.9%
H
1.3
53.8
|
L
 -90.4%
H
1.3
160.2
|
L
H
1.3
572.4
|
| ZeroStack Corp |
|
11.5
|
4.8
|
L
 -0.2%
H
4.8
4.8
|
L
 -0.4%
H
4.5
5.2
|
L
 -13.6%
H
3.7
5.9
|
L
 -29%
H
3.7
9.7
|
L
 -81.0%
H
3.7
47
|
L
 -96.7%
H
3.7
213.7
|
L
 -99.8%
H
3.7
16731
|
L
H
3.7
16731
|
| Frequency Therapeutics Inc |
|
-
|
10.9
|
L
 3.3%
H
10.5
11.3
|
L
 -15.4%
H
10.5
12.7
|
L
 -9.2%
H
9.1
14.0
|
L
 -2.2%
H
9.1
15.6
|
L
 -25.0%
H
5.2
55.9
|
L
 -43.9%
H
5.2
55.9
|
L
 -97.7%
H
5.2
545
|
L
H
5.2
2918.5
|
| Fulcrum Therapeutics Inc |
|
234.5
|
3.5
|
L
 2.3%
H
3.4
3.6
|
L
 -45.2%
H
2.8
3.7
|
L
 -49.8%
H
2.8
7.5
|
L
 -56.9%
H
2.8
8.4
|
L
 -51.5%
H
2.8
15.7
|
L
 10.7%
H
2.3
15.7
|
L
 -61.5%
H
2.3
33.1
|
L
H
2.3
33.1
|
| First Wave BioPharma Inc |
|
9.9
|
6.4
|
L
 2.4%
H
5.7
6.5
|
L
 -6.3%
H
5.6
6.9
|
L
 86.3%
H
3.0
6.9
|
L
 189.6%
H
1.9
6.9
|
L
 1125%
H
0.4
6.9
|
L
 -77.3%
H
0.4
60
|
L
 -100.0%
H
0.4
38639.2
|
L
H
0.4
235200
|
| Galectin Therapeutics Inc |
|
158.7
|
2.4
|
L
 0.4%
H
2.4
2.5
|
L
 -7.7%
H
2.3
2.6
|
L
 14.8%
H
2.1
3.1
|
L
 -22.3%
H
2.0
3.5
|
L
 82.6%
H
1.3
7.1
|
L
 56.5%
H
0.7
7.1
|
L
 -40.0%
H
0.7
7.1
|
L
 62.8%
H
0.5
9.5
|
| Gain Therapeutics Inc |
|
70.4
|
1.7
|
L
 -2.4%
H
1.6
1.7
|
L
 -15.8%
H
1.6
1.9
|
L
 -9.3%
H
1.5
2.1
|
L
 -45.9%
H
1.5
3.1
|
L
 -14.1%
H
1.4
4.3
|
L
 -65.6%
H
0.9
5.3
|
L
 -84.5%
H
0.9
10.9
|
L
H
0.9
17.9
|
| CytoMed Therapeutics Ltd |
|
13.5
|
1.1
|
L
 -0.9%
H
1.0
1.1
|
L
H
1.0
1.3
|
L
 46.2%
H
0.7
1.4
|
L
 8.6%
H
0.7
1.4
|
L
 -44.4%
H
0.7
3.7
|
L
 -58.8%
H
0.7
9.3
|
L
H
0.7
9.3
|
L
H
0.7
9.3
|
| Geron Corp |
|
718.5
|
1.1
|
L
 -0.9%
H
1.1
1.2
|
L
 -7.4%
H
1.1
1.2
|
L
 -19.4%
H
1.1
1.5
|
L
 -26.8%
H
1.1
1.8
|
L
 -30%
H
1.0
2.0
|
L
 -69.6%
H
1.0
5.3
|
L
 -24.3%
H
1.0
5.3
|
L
 -62.0%
H
0.8
7.0
|
| GH Research PLC |
|
1,396.2
|
20.4
|
L
 1.1%
H
19.8
21.6
|
L
 -18.0%
H
19.7
25.9
|
L
 -5%
H
19.7
25.9
|
L
 27.8%
H
12.8
25.9
|
L
 62.8%
H
11.3
25.9
|
L
 59.7%
H
5.1
25.9
|
L
H
5.1
30.4
|
L
H
5.1
30.4
|
| Gilead Sciences |
|
155,817.0
|
125.5
|
L
 -2.0%
H
123.2
129
|
L
 -4.3%
H
123.2
131.7
|
L
 -4.4%
H
123.2
137.5
|
L
 -12.8%
H
123.2
149.4
|
L
 11.6%
H
104.5
157.3
|
L
 60.1%
H
62.1
157.3
|
L
 85.9%
H
57.2
157.3
|
L
 43.6%
H
56.6
157.3
|
| Galmed Pharma Ltd |
|
3.4
|
0.5
|
L
 10.6%
H
0.5
0.6
|
L
 -28.8%
H
0.4
0.8
|
L
 -14.8%
H
0.4
0.8
|
L
 -21.2%
H
0.4
1.3
|
L
 -65.6%
H
0.4
2.3
|
L
 -99.0%
H
0.2
65.6
|
L
 -99.9%
H
0.2
642.6
|
L
 -99.9%
H
0.2
4870.8
|
| Greenwich LifeSciences Inc |
|
326.3
|
22.2
|
L
 2.7%
H
21.4
22.6
|
L
 -22.0%
H
20.9
27.4
|
L
 -2.8%
H
20.9
29.9
|
L
 -3.7%
H
20.5
30.3
|
L
 130.1%
H
7.8
34.1
|
L
 92.6%
H
7.6
34.1
|
L
 -39.8%
H
6.8
49.0
|
L
H
3.3
158.1
|
| Galecto Inc |
|
1,290.2
|
21.0
|
L
 0.2%
H
20.1
22.2
|
L
 -15.7%
H
20.1
25.5
|
L
 -13.3%
H
20.1
26.5
|
L
 -27.5%
H
16.5
30.4
|
L
 537.1%
H
2.5
38.3
|
L
 839.9%
H
0.5
38.3
|
L
 319.2%
H
0.5
38.3
|
L
H
0.5
38.3
|
| Monte Rosa Therapeutics Inc |
|
1,403.2
|
16.6
|
L
 -2.3%
H
16.2
17.8
|
L
 -15.6%
H
16.1
19.4
|
L
 -14.3%
H
16.1
21.3
|
L
 -6.7%
H
14.2
21.6
|
L
 231.5%
H
4.1
25.8
|
L
 150.9%
H
2.4
25.8
|
L
H
2.4
45.6
|
L
H
2.4
45.6
|
| GlycoMimetics Inc |
|
1,161.6
|
18
|
L
 4.2%
H
17.3
18.2
|
L
 -8.7%
H
16.5
19.8
|
L
 -4.1%
H
16.5
22.5
|
L
 49.1%
H
9.9
27.4
|
L
 -7.2%
H
8.7
27.4
|
L
 -90%
H
8.7
353
|
L
 -93.3%
H
8.7
416
|
L
 -97.9%
H
8.7
2605
|
| Genelux Corp |
|
133.6
|
3.0
|
L
 1.7%
H
2.9
3.0
|
L
 0.3%
H
2.9
3.2
|
L
 -4.2%
H
2.7
3.3
|
L
 10.0%
H
2.3
3.3
|
L
 16.4%
H
2.3
8.5
|
L
 -89.5%
H
1.6
41.0
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
| Genprex Inc |
|
7.2
|
0.7
|
L
 -1.5%
H
0.6
0.7
|
L
 -12%
H
0.6
0.8
|
L
 -24.1%
H
0.6
0.9
|
L
 -66.2%
H
0.6
2.1
|
L
 127.6%
H
0.1
13.0
|
L
 -26.7%
H
0.1
13.0
|
L
 -83.1%
H
0.1
13.0
|
L
H
0.1
19.5
|
| Gossamer Bio Inc |
|
78.2
|
0.2
|
L
 -5.9%
H
0.2
0.2
|
L
 -20%
H
0.2
0.2
|
L
 -51.5%
H
0.2
0.4
|
L
 -68%
H
0.2
0.6
|
L
 -88.0%
H
0.2
3.9
|
L
 -87.3%
H
0.2
3.9
|
L
 -98.2%
H
0.2
15.2
|
L
H
0.2
27.2
|
| Geovax Labs Inc |
|
6.7
|
1.3
|
L
 -4.5%
H
1.2
1.5
|
L
 -42.1%
H
1.2
2.3
|
L
 -23.4%
H
1.2
4.4
|
L
 -28.5%
H
1.0
4.4
|
L
 -95.4%
H
1.0
34.8
|
L
 -99.4%
H
1.0
276.8
|
L
 -99.9%
H
1.0
2812.5
|
L
 -100.0%
H
1.0
379518072.3
|
| Graphite Bio Inc |
|
395.4
|
6.8
|
L
 1.0%
H
6.5
7.0
|
L
 -8.7%
H
6.5
7.4
|
L
 -32.5%
H
6.5
10.6
|
L
 -41.8%
H
6.5
12.7
|
L
 -78.8%
H
6.5
50.4
|
L
 -95.3%
H
6.5
413
|
L
H
6.5
1666
|
L
H
6.5
1666
|
| GT Biopharma Inc |
|
15.1
|
0.4
|
L
H
0.4
0.4
|
L
 -4.6%
H
0.4
0.5
|
L
 10.5%
H
0.3
0.5
|
L
 -10.6%
H
0.3
0.5
|
L
 -84.3%
H
0.3
3.9
|
L
 16.7%
H
0.2
10.7
|
L
 -97.7%
H
0.2
19.7
|
L
 -100.0%
H
0.2
2295
|
| Galapagos NV (ADR) |
|
1,862.9
|
28.3
|
L
 1.6%
H
27.9
28.3
|
L
 2.7%
H
26.9
28.4
|
L
 -1.1%
H
26.4
28.7
|
L
 -14.1%
H
26.4
33.8
|
L
 2.0%
H
26.4
37.8
|
L
 -34.1%
H
22.4
44.3
|
L
 -62.4%
H
22.4
81.1
|
L
 -52.4%
H
22.4
274.0
|
| Genmab (ADR) |
|
15,409.7
|
25.1
|
L
 1.2%
H
24.7
25.2
|
L
 -1.4%
H
23.6
25.3
|
L
 -5.0%
H
23.6
27.4
|
L
 -7.2%
H
23.6
29.4
|
L
 13.1%
H
20.2
35.4
|
L
 -35.4%
H
17.2
42.7
|
L
 -39.6%
H
17.2
49.1
|
L
 32.3%
H
12.1
49.1
|
| Genenta Science SpA (ADR) |
|
37.7
|
1.6
|
L
 -11.1%
H
1.6
1.9
|
L
 -3.0%
H
1.5
2.6
|
L
 154.0%
H
0.6
2.6
|
L
 86.1%
H
0.6
2.6
|
L
 -60%
H
0.6
10
|
L
 -68%
H
0.6
10
|
L
H
0.6
13.1
|
L
H
0.6
13.1
|
| Grifols SA (ADR) - Level III |
|
4,995.4
|
7.3
|
L
 0.1%
H
7.3
7.5
|
L
 -5.2%
H
7.3
7.8
|
L
 -9.4%
H
7.3
8.2
|
L
 -14.6%
H
7.3
8.8
|
L
 -16.8%
H
7.3
11.1
|
L
 -16.6%
H
5.3
12.2
|
L
 -57.2%
H
5.3
19.1
|
L
 -57.6%
H
5.3
25.7
|
| Halozyme Therapeutics Inc |
|
8,478.5
|
71.5
|
L
 1.1%
H
70.2
72.3
|
L
 4.9%
H
65.6
72.3
|
L
 11.5%
H
63.5
73.9
|
L
 6.1%
H
61.3
73.9
|
L
 31.8%
H
51.1
82.2
|
L
 109.3%
H
32.8
82.2
|
L
 81.1%
H
29.9
82.2
|
L
 676.1%
H
7.7
82.2
|
| HCW Biologics Inc |
|
8.5
|
1.2
|
L
 -18.6%
H
1.1
1.4
|
L
 -43%
H
1.1
2.1
|
L
 257.6%
H
0.3
4.0
|
L
 90.3%
H
0.3
4.0
|
L
 -80.5%
H
0.3
7.4
|
L
 -98.6%
H
0.2
100.8
|
L
H
0.2
311
|
L
H
0.2
311
|
| Hillstream BioPharma Inc |
|
31.5
|
2.7
|
L
 1.1%
H
2.7
3.0
|
L
 -4.3%
H
2.1
3.0
|
L
 -11.3%
H
2.1
3.9
|
L
 -40.2%
H
2.1
4.8
|
L
 77.5%
H
1.1
9.1
|
L
 -69.9%
H
1.1
132.8
|
L
H
1.1
132.8
|
L
H
1.1
132.8
|
| Hoth Therapeutics Inc |
|
28.6
|
1.3
|
L
 -7.9%
H
1.2
1.4
|
L
 -4.5%
H
1.2
2.5
|
L
 91.0%
H
0.5
2.5
|
L
 29.3%
H
0.5
2.5
|
L
 -1.5%
H
0.5
2.5
|
L
 -60%
H
0.5
3.8
|
L
 -96.9%
H
0.5
43.8
|
L
H
0.5
347
|
| Werewolf Therapeutics Inc |
|
18.5
|
0.4
|
L
H
0.4
0.4
|
L
 -19.2%
H
0.4
0.5
|
L
 -44.1%
H
0.4
0.7
|
L
 -39.7%
H
0.4
1.1
|
L
 -73.2%
H
0.4
2.4
|
L
 -89.1%
H
0.4
8.2
|
L
 -96.8%
H
0.4
21.7
|
L
H
0.4
24.0
|
| Harmony Biosciences Holdings Inc |
|
1,974.1
|
34.1
|
L
 5.3%
H
32.7
34.2
|
L
 7.2%
H
30.7
34.2
|
L
 10.0%
H
29.3
34.2
|
L
 20.4%
H
26.3
35.0
|
L
 -4.2%
H
25.5
40.9
|
L
 -5.3%
H
18.6
41.6
|
L
 3.0%
H
18.6
62.1
|
L
H
18.6
62.1
|
| Harrow Health Inc |
|
1,247.2
|
33.5
|
L
 1.1%
H
33.2
34.4
|
L
 -1.9%
H
32.5
35.2
|
L
 -12.5%
H
28.5
39.8
|
L
 -8.0%
H
28.5
42.1
|
L
 13.1%
H
28.5
54.9
|
L
 63.1%
H
7.6
59.2
|
L
 270.5%
H
5.4
59.2
|
L
 734.4%
H
1.4
59.2
|
| Heron Therapeutics Inc |
|
75.7
|
0.4
|
L
 -11.1%
H
0.4
0.5
|
L
 -51.8%
H
0.4
0.7
|
L
 -66.9%
H
0.4
1.1
|
L
 -58.8%
H
0.4
1.3
|
L
 -81.0%
H
0.4
2.3
|
L
 -66.4%
H
0.4
3.9
|
L
 -97.1%
H
0.4
16.6
|
L
 -98.0%
H
0.4
42.9
|
| Quantum BioPharma Ltd (Class B) (Sub Voting) |
|
24.9
|
3.9
|
L
 -4.0%
H
3.6
4.1
|
L
 -25.9%
H
3.6
5.5
|
L
 -20.3%
H
3.6
10.8
|
L
 11.1%
H
2.1
10.8
|
L
 -74.8%
H
2.1
38.3
|
L
 -94.9%
H
2.1
109.2
|
L
 -96.9%
H
2.1
136.5
|
L
H
2.1
11431.9
|
| Humacyte Inc |
|
308.6
|
1.4
|
L
 0.7%
H
1.3
1.5
|
L
 -4.1%
H
1.3
1.5
|
L
 31.1%
H
0.8
1.5
|
L
 25.2%
H
0.6
1.5
|
L
 -46.3%
H
0.6
2.8
|
L
 -67.3%
H
0.6
10.0
|
L
 -87.4%
H
0.6
17.5
|
L
H
0.6
17.5
|
| HUTCHMED (China) Ltd (ADR) |
|
1,827.8
|
10.6
|
L
 -2.0%
H
10.4
10.9
|
L
 -6.8%
H
10.4
11.7
|
L
 -19.0%
H
10.4
13.1
|
L
 -23.3%
H
10.4
15.8
|
L
 -30.8%
H
10.4
19.5
|
L
 -10.5%
H
10.4
21.9
|
L
 -65.1%
H
7.4
43.9
|
L
 -24.2%
H
7.4
43.9
|
| ImmunityBio Inc |
|
7,593.3
|
7.3
|
L
 1.1%
H
6.9
7.4
|
L
 0.1%
H
6.8
7.5
|
L
 -14.8%
H
6.8
8.7
|
L
 -16.4%
H
6.5
9.5
|
L
 130.2%
H
2.0
12.4
|
L
 144.9%
H
1.3
12.4
|
L
 -53.5%
H
1.2
16.0
|
L
H
1.2
40.8
|
| Immucell Corp |
|
88.4
|
9.8
|
L
 0.7%
H
9.6
9.8
|
L
 1.0%
H
9.3
10.2
|
L
 21.4%
H
8.1
10.8
|
L
 48.0%
H
6
10.8
|
L
 49.6%
H
4.5
10.8
|
L
 89.0%
H
3.3
10.8
|
L
 -0.1%
H
3.3
11.0
|
L
 43.7%
H
3.3
13.2
|
| Ideaya Biosciences Inc |
|
2,466.3
|
28.1
|
L
 -10.8%
H
27.9
32.0
|
L
 -3.0%
H
27.7
32.0
|
L
 -0.9%
H
27.7
32.0
|
L
 -15.4%
H
27.7
38.1
|
L
 29.2%
H
20.5
39.3
|
L
 9.9%
H
13.5
47.7
|
L
 28.5%
H
8.1
47.7
|
L
H
3.0
47.7
|
| InflaRx N.V. |
|
244.5
|
1.7
|
L
 -2.9%
H
1.6
1.8
|
L
 -27.2%
H
1.6
2.3
|
L
 -35.7%
H
1.6
2.9
|
L
 71.1%
H
0.8
3.0
|
L
 100%
H
0.7
3.0
|
L
 -58.5%
H
0.7
4.7
|
L
 -45.0%
H
0.7
7.3
|
L
H
0.7
53.1
|
| ImageneBio Inc |
|
62.6
|
5.6
|
L
 -1.4%
H
5.6
5.6
|
L
 1.5%
H
5.4
5.9
|
L
 4.9%
H
5.1
6.0
|
L
 -5.0%
H
3.9
6.6
|
L
 -67.4%
H
3.9
18
|
L
 -93.2%
H
3.9
88.6
|
L
 -97.0%
H
3.9
211.2
|
L
H
3.9
451.3
|
| Inhibikase Therapeutics Inc |
|
220.5
|
1.7
|
L
 3.1%
H
1.6
1.7
|
L
 -2.3%
H
1.6
1.7
|
L
 -18.9%
H
1.5
2.1
|
L
 -11.2%
H
1.5
2.1
|
L
 -14.8%
H
1.3
2.3
|
L
 -59.9%
H
0.8
4.3
|
L
 -95.2%
H
0.8
38.5
|
L
H
0.8
70.8
|
| Illumina Inc |
|
24,212.5
|
160.0
|
L
 1.3%
H
155.6
161.1
|
L
 -2.7%
H
155.6
177.2
|
L
 12.8%
H
138.1
177.2
|
L
 28.4%
H
115.3
177.2
|
L
 93.6%
H
82.6
177.2
|
L
 -21.1%
H
68.7
212.5
|
L
 -63.1%
H
68.7
526
|
L
 10.2%
H
68.7
555.8
|
| IM Cannabis Corp |
|
1.6
|
0.3
|
L
 -16.7%
H
0.2
0.3
|
L
 -21.9%
H
0.2
0.3
|
L
 4.2%
H
0.2
0.4
|
L
 -66.7%
H
0.2
1.1
|
L
 -90.9%
H
0.2
3.8
|
L
 -96.4%
H
0.2
8.1
|
L
 -99.9%
H
0.2
381
|
L
H
0.2
697.8
|
| Immix Biopharma Inc |
|
570.2
|
8.0
|
L
 1.8%
H
7.8
8.2
|
L
 -13.1%
H
7.7
9.3
|
L
 -17.9%
H
7.7
10.8
|
L
 -13.8%
H
7.7
11.6
|
L
 238.0%
H
1.9
11.6
|
L
 294.6%
H
1.3
11.6
|
L
H
0.7
11.6
|
L
H
0.7
11.6
|
| Immunome Inc |
|
2,082.7
|
18.4
|
L
 -1.2%
H
18.1
19.2
|
L
 -11.5%
H
18.1
20.7
|
L
 -18.1%
H
18.1
24.0
|
L
 -12.6%
H
18.1
24.9
|
L
 101.4%
H
8.0
27.7
|
L
 280.0%
H
4.5
31.0
|
L
 0.9%
H
2.1
31.0
|
L
H
2.1
63.8
|
| Imunon Inc |
|
8.5
|
2.0
|
L
 0.5%
H
2.0
2.1
|
L
 -6.1%
H
2.0
2.2
|
L
 -25.7%
H
2.0
2.8
|
L
 -37.7%
H
2.0
3.3
|
L
 -90.8%
H
2.0
31.8
|
L
 -89.6%
H
2.0
54.8
|
L
 -99.3%
H
2.0
348.8
|
L
 -100.0%
H
2.0
4504.5
|
| Immuneering Corp (Class A) |
|
260.7
|
4.0
|
L
 2.5%
H
3.9
4.1
|
L
 -10.4%
H
3.9
4.7
|
L
 -22.8%
H
3.9
6.9
|
L
 -24.4%
H
3.9
6.9
|
L
 89.2%
H
1.7
10.1
|
L
 -60.7%
H
1
11.9
|
L
H
1
34.0
|
L
H
1
34.0
|
| Immatics N.V |
|
1,251.9
|
9.2
|
L
 -0.7%
H
9.0
9.5
|
L
 -17.8%
H
9.0
11.1
|
L
 -19.4%
H
9.0
11.9
|
L
 -7.1%
H
9.0
11.9
|
L
 53.4%
H
5.1
12.4
|
L
 -15.1%
H
3.3
13.8
|
L
 -24.7%
H
3.3
16.3
|
L
H
3.3
18.4
|
| Immunic Inc |
|
167.0
|
12.3
|
L
 1.7%
H
11.7
13.1
|
L
 -19.0%
H
11.7
15.2
|
L
 5.4%
H
10.9
15.8
|
L
 -0.3%
H
8.5
15.8
|
L
 55.6%
H
5.1
15.8
|
L
 -31.9%
H
5.1
31.1
|
L
 -91.7%
H
5.1
151.2
|
L
 -99.6%
H
5.1
3900
|
| Immunovant Inc |
|
6,489.8
|
31.6
|
L
 2.6%
H
30.2
31.7
|
L
 -3.8%
H
30.2
32.9
|
L
 9.2%
H
25.8
36.3
|
L
 18.6%
H
22.8
36.3
|
L
 88.5%
H
14.3
36.3
|
L
 48.8%
H
12.7
45.6
|
L
 203.1%
H
3.1
45.6
|
L
H
3.1
53.8
|
| IN8bio Inc |
|
13.9
|
1.5
|
L
 0.7%
H
1.4
1.5
|
L
 -16.2%
H
1.4
1.7
|
L
 -8.2%
H
1.4
1.9
|
L
 -15.7%
H
1.3
2.1
|
L
 -65.2%
H
1.2
3.7
|
L
 -39.8%
H
0.1
4.2
|
L
H
0.1
10.3
|
L
H
0.1
10.3
|
| Inhibrx Inc |
|
4,221.4
|
89.1
|
L
 0.0%
H
85.7
93.3
|
L
 -10.3%
H
85.5
99.4
|
L
 -33.7%
H
85.5
151.0
|
L
 28.8%
H
57.3
155.3
|
L
 540.1%
H
13.3
155.3
|
L
 262.6%
H
10.8
155.3
|
L
 267.7%
H
7.7
155.3
|
L
H
7.7
155.3
|
| Incyte |
|
20,623.5
|
103.2
|
L
 2.6%
H
101.5
104.2
|
L
 8.0%
H
92.2
106.4
|
L
 4.7%
H
92.2
106.4
|
L
 7.6%
H
89.3
106.4
|
L
 50.1%
H
66.7
112.3
|
L
 67.8%
H
50.3
112.3
|
L
 21.7%
H
50.3
112.3
|
L
 24.5%
H
50.3
153.2
|
| Indaptus Therapeutics Inc |
|
228.7
|
2.0
|
L
 -3.8%
H
1.9
2.7
|
L
 5.2%
H
1.8
6.0
|
L
 7.5%
H
0.9
6.0
|
L
 9.2%
H
0.9
6.0
|
L
 494.1%
H
0.3
13.4
|
L
 -3.8%
H
0.3
13.4
|
L
 -86.7%
H
0.3
28.8
|
L
 -99.5%
H
0.3
8800
|
| Indivior PLC |
|
4,522.5
|
38.3
|
L
 2.3%
H
37.5
38.8
|
L
 9.7%
H
32.4
38.8
|
L
 -3.1%
H
32.4
39.7
|
L
 18.6%
H
27.7
41
|
L
 171.9%
H
13.4
41
|
L
 77.1%
H
7.3
41
|
L
 1608.0%
H
2.0
41
|
L
 1126.3%
H
0.4
41
|
| MiNK Therapeutics Inc |
|
58.9
|
11.8
|
L
 4.2%
H
11.3
12.0
|
L
 -4.5%
H
11.0
13.4
|
L
 7.1%
H
9.5
13.4
|
L
 15.0%
H
8.5
16.9
|
L
 62.8%
H
6.8
76
|
L
 -47.2%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
| InMed Pharma Inc |
|
5.1
|
1.5
|
L
 -0.7%
H
1.5
1.6
|
L
 -1.9%
H
1.5
1.7
|
L
 135.4%
H
0.6
2.0
|
L
 66.3%
H
0.6
2.0
|
L
 -46.7%
H
0.6
5.5
|
L
 -94.4%
H
0.6
41.6
|
L
 -99.9%
H
0.6
1755
|
L
 -99.9%
H
0.6
32175
|
| INmune Bio Inc |
|
32.4
|
1.2
|
L
 -1.6%
H
1.2
1.3
|
L
 -12.2%
H
1.2
1.5
|
L
 -14.7%
H
1.2
1.8
|
L
 -8.3%
H
1.1
1.8
|
L
 -84.0%
H
1.1
11.6
|
L
 -85.5%
H
1.1
14.7
|
L
 -91.9%
H
1.1
30.4
|
L
H
1.1
30.4
|
| Inovio Pharma Inc |
|
90.5
|
1.1
|
L
 0.9%
H
1.1
1.1
|
L
 -14.1%
H
1.1
1.3
|
L
 -24.7%
H
1.1
1.6
|
L
 -36.8%
H
1.0
1.8
|
L
 -51.5%
H
1.0
3.0
|
L
 100%
H
0.3
14.8
|
L
 -87.2%
H
0.3
14.8
|
L
 -90.2%
H
0.3
33.8
|
| Insmed Inc |
|
21,467.2
|
99.0
|
L
 5.2%
H
95.4
99.6
|
L
 -6.6%
H
92.1
105.3
|
L
 -2.3%
H
92.1
122.9
|
L
 -29.3%
H
92.1
166.2
|
L
 34.5%
H
70.6
212.8
|
L
 394.5%
H
18.8
212.8
|
L
 267.8%
H
16.0
212.8
|
L
 724.6%
H
9.0
212.8
|
| Innoviva Inc |
|
1,663.6
|
22.5
|
L
 0.9%
H
22.3
22.7
|
L
 4.8%
H
21.3
22.9
|
L
 -1.5%
H
21.2
23.5
|
L
 2.3%
H
21.2
24.5
|
L
 4.5%
H
16.5
25.1
|
L
 64.3%
H
12.2
25.1
|
L
 80.2%
H
10.6
25.1
|
L
 96.5%
H
7.6
25.1
|
| Ionis Pharma Inc |
|
12,325.3
|
74.6
|
L
 1.4%
H
73.5
75.8
|
L
 -1.1%
H
72.0
76.0
|
L
 -1.5%
H
71.9
79.2
|
L
 0.7%
H
68.9
79.2
|
L
 111.3%
H
34.8
86.7
|
L
 79.1%
H
24.0
86.7
|
L
 102.2%
H
24.0
86.7
|
L
 245.8%
H
20.5
86.7
|
| Iovance Biotherapeutics Inc |
|
1,732.4
|
3.9
|
L
 -3%
H
3.8
4.1
|
L
 -2.0%
H
3.8
4.6
|
L
 7.2%
H
3.3
4.6
|
L
 -24.4%
H
3.2
5.6
|
L
 89.3%
H
1.7
5.6
|
L
 -51.5%
H
1.6
18.3
|
L
 -81.2%
H
1.6
28
|
L
 -51.6%
H
1.6
54.2
|
| Century Therapeutics Inc |
|
398.6
|
2.2
|
L
 4.3%
H
2.1
2.2
|
L
 -6.4%
H
2.0
2.4
|
L
 -3.5%
H
2.0
2.5
|
L
 -13.7%
H
1.9
3.0
|
L
 256.5%
H
0.4
3.0
|
L
 -35.2%
H
0.3
5.5
|
L
H
0.3
32.9
|
L
H
0.3
32.9
|
| Disc Medicine Inc |
|
2,610.5
|
68.3
|
L
 3.9%
H
65.2
69.0
|
L
 -5.0%
H
64.7
72.8
|
L
 0.1%
H
63.8
72.8
|
L
 11.7%
H
57.7
72.8
|
L
 36.6%
H
40
99.5
|
L
 73.1%
H
25.6
99.5
|
L
 -36.8%
H
11.6
123
|
L
H
11.6
190.9
|
| Ironwood Pharma Inc (Class A) |
|
530.1
|
3.2
|
L
 -2.1%
H
3.1
3.4
|
L
 -6.9%
H
3.1
3.5
|
L
 -23.7%
H
3.1
4.4
|
L
 -8%
H
3.0
4.9
|
L
 427.9%
H
0.6
5.8
|
L
 -72.2%
H
0.5
15.7
|
L
 -71.9%
H
0.5
15.7
|
L
 -70.8%
H
0.5
17.7
|
| Invivyd Inc |
|
291.7
|
1.0
|
L
 -2.9%
H
1.0
1.1
|
L
 -18.9%
H
1.0
1.2
|
L
 -34%
H
1.0
1.6
|
L
 -45%
H
1.0
2.0
|
L
H
0.5
3.1
|
L
 -26.7%
H
0.4
5.2
|
L
H
0.4
78.8
|
L
H
0.4
78.8
|
| I-Mab (ADR) |
|
183.3
|
1.6
|
L
 1.9%
H
1.5
1.6
|
L
 -7.0%
H
1.5
1.8
|
L
 -27.7%
H
1.5
2.2
|
L
 -54.6%
H
1.5
3.6
|
L
 -35.1%
H
1.5
6.8
|
L
 -50%
H
0.6
6.8
|
L
 -97.9%
H
0.6
85.4
|
L
H
0.6
85.4
|
| Immunocore Holdings PLC (ADR) |
|
1,450.7
|
28.5
|
L
 2.6%
H
28.1
29.2
|
L
 -2.1%
H
27.7
29.8
|
L
 -3.6%
H
27.7
30.2
|
L
 -13.4%
H
27.6
33.9
|
L
 -23.4%
H
27.6
40.7
|
L
 -50.7%
H
23.2
77.0
|
L
 -28.0%
H
18.4
77.0
|
L
H
18.4
77.0
|
| Immutep Ltd (ADR) |
|
54.5
|
0.4
|
L
H
0.4
0.4
|
L
 -7.5%
H
0.4
0.4
|
L
 -17.8%
H
0.4
0.6
|
L
 -86.6%
H
0.3
1.1
|
L
 -80.1%
H
0.3
3.5
|
L
 -82.0%
H
0.3
3.5
|
L
 -92.3%
H
0.3
5
|
L
 -89.7%
H
0.3
8.0
|
| Immuron Ltd (ADR) |
|
9.7
|
1.2
|
L
 -0.8%
H
1.1
1.2
|
L
 -15.6%
H
1.1
1.4
|
L
 48.8%
H
0.8
1.6
|
L
 35.2%
H
0.7
1.6
|
L
 -30%
H
0.7
2.4
|
L
 -39.9%
H
0.7
6.0
|
L
 -75.5%
H
0.7
6.0
|
L
H
0.7
29.0
|
| Innate Pharma (ADR) |
|
166.2
|
1.8
|
L
 0.6%
H
1.8
1.8
|
L
 -0.6%
H
1.7
1.9
|
L
 25.5%
H
1.3
2.6
|
L
 10.6%
H
1.2
2.6
|
L
 -18.4%
H
1.2
2.6
|
L
 -46.7%
H
1.2
3.6
|
L
 -53.7%
H
1.2
12.0
|
L
H
1.2
12.0
|
| Inventiva (ADR) |
|
829.5
|
4.0
|
L
 1.5%
H
3.7
4.0
|
L
 -16.8%
H
3.7
4.7
|
L
 -26.1%
H
3.7
6.1
|
L
 -35.2%
H
3.7
6.8
|
L
 10.3%
H
2.9
8.0
|
L
 5.6%
H
1.5
8.0
|
L
 -73.7%
H
1.5
16.9
|
L
H
1.5
19.1
|
| Jaguar Health Inc |
|
2.0
|
2.8
|
L
 3.3%
H
2.6
2.8
|
L
 -13.8%
H
2.6
3.3
|
L
 -6%
H
2.6
4.1
|
L
 -86.4%
H
2.5
21.2
|
L
 -98.0%
H
2.5
142.5
|
L
 -100.0%
H
2.5
37800
|
L
 -100.0%
H
2.5
26932500
|
L
 -100.0%
H
2.5
880621875
|
| Janux Therapeutics Inc |
|
830.6
|
13.6
|
L
 0.8%
H
13.3
13.9
|
L
 -5.5%
H
13.2
14.3
|
L
 -4.0%
H
13.2
14.9
|
L
 -1.6%
H
13.0
16.6
|
L
 -48.0%
H
12.1
35.3
|
L
 2.9%
H
5.7
71.7
|
L
H
5.7
71.7
|
L
H
5.7
71.7
|
| Jazz Pharma PLC |
|
14,380.0
|
229.2
|
L
 -1.2%
H
228.5
239.2
|
L
 -1.5%
H
224.2
242.0
|
L
 1.5%
H
221.3
243.3
|
L
 25.9%
H
177.6
243.3
|
L
 106.2%
H
105
243.3
|
L
 79.6%
H
95.5
243.3
|
L
 28.1%
H
95.5
243.3
|
L
 47.9%
H
86.9
243.3
|
| Jasper Therapeutics Inc |
|
13.2
|
0.5
|
L
H
0.4
0.5
|
L
 -11.3%
H
0.4
0.6
|
L
 -49.5%
H
0.4
1.0
|
L
 -65.9%
H
0.4
1.4
|
L
 -92.2%
H
0.4
7.2
|
L
 -70.4%
H
0.4
31.0
|
L
H
0.4
31.0
|
L
H
0.4
31.0
|
| Kala Pharma Inc |
|
43.7
|
2.4
|
L
 2.6%
H
2.2
2.4
|
L
 6.8%
H
2.0
2.6
|
L
 -40.7%
H
2.0
4.0
|
L
 -83.1%
H
2.0
25.5
|
L
 -98.9%
H
2.0
1030
|
L
 -99.7%
H
2.0
1030
|
L
 -100.0%
H
2.0
16943.3
|
L
H
2.0
66943.3
|
| KalVista Pharma Inc |
|
1,437.0
|
27.0
|
L
H
27.0
27
|
L
 0.2%
H
26.9
27
|
L
 1.0%
H
26.7
27
|
L
 66.3%
H
15.1
27
|
L
 88.0%
H
9.8
27
|
L
 170.2%
H
7.2
27
|
L
 -7.1%
H
4.1
30.7
|
L
 48.3%
H
4.1
45
|
| Kamada Ltd |
|
417.6
|
7.2
|
L
H
7.1
7.3
|
L
 -6.0%
H
7.1
7.6
|
L
 -15.3%
H
7.1
8.7
|
L
 -18.3%
H
7.1
9.1
|
L
 5.7%
H
6.5
9.4
|
L
 40.6%
H
4.1
9.4
|
L
 22.7%
H
3.7
9.4
|
L
 95.1%
H
3.6
13.3
|
| Kiniksa Pharma Ltd (Class A) |
|
3,746.9
|
48.7
|
L
 -0.7%
H
48.5
50.7
|
L
 0.6%
H
46.1
50.7
|
L
 -16.9%
H
46.1
59.9
|
L
 5.5%
H
41.5
59.9
|
L
 61.1%
H
26.3
59.9
|
L
 224.0%
H
13.6
59.9
|
L
 243.2%
H
7.4
59.9
|
L
H
5.0
59.9
|
| Kodiak Sciences Inc |
|
1,943.7
|
31.1
|
L
 4.9%
H
29.2
31.1
|
L
 -15.9%
H
29.2
36.7
|
L
 -24.3%
H
29.2
45.2
|
L
 24.9%
H
21
47.8
|
L
 636.0%
H
3.4
47.8
|
L
 255.0%
H
1.4
47.8
|
L
 -60.4%
H
1.4
132.0
|
L
H
1.4
171.2
|
| Kiora Pharma Inc |
|
11.5
|
2.6
|
L
 0.4%
H
2.5
2.7
|
L
 -7.5%
H
2.5
2.8
|
L
 5.7%
H
2.4
2.9
|
L
 30.8%
H
1.8
2.9
|
L
 -15.9%
H
1.8
3.4
|
L
 219.8%
H
0.4
5.6
|
L
 -98.5%
H
0.4
257.2
|
L
 -99.9%
H
0.4
2340
|
| Karyopharm Therapeutics Inc |
|
196.9
|
8.7
|
L
 2.2%
H
8.4
9
|
L
 -11.5%
H
8.4
9.8
|
L
 0.6%
H
6.9
10.2
|
L
 -0.9%
H
5
10.2
|
L
 93.5%
H
3.7
11.0
|
L
 -75.2%
H
0.6
35.3
|
L
 -93.9%
H
0.6
221.0
|
L
 -93.8%
H
0.6
444.2
|
| Keros Therapeutics Inc |
|
199.3
|
10.1
|
L
 0.7%
H
9.9
10.3
|
L
 -7.6%
H
9.9
11.1
|
L
 -16.6%
H
9.8
12.2
|
L
 -10.9%
H
9.8
12.6
|
L
 -33.1%
H
9.8
22.6
|
L
 -79.4%
H
9.1
73
|
L
 -80.4%
H
9.1
73
|
L
H
9.1
88.8
|
| Krystal Biotech Inc |
|
9,131.4
|
309.8
|
L
 2.7%
H
302.3
311
|
L
 3.9%
H
285.1
312.8
|
L
 1.3%
H
285.1
319.5
|
L
 22.1%
H
242
319.5
|
L
 126.2%
H
128.0
319.5
|
L
 142.0%
H
94.0
319.5
|
L
 374.9%
H
38.9
319.5
|
L
H
8.0
319.5
|
| TuHURA Biosciences Inc |
|
128.6
|
2.0
|
L
 -1.0%
H
2.0
2.1
|
L
 -9.8%
H
1.9
2.3
|
L
 -15.1%
H
1.9
2.8
|
L
 34.7%
H
1.3
3.4
|
L
 -28.1%
H
0.4
3.9
|
L
 -98.3%
H
0.2
196
|
L
 -99.9%
H
0.2
4987.5
|
L
 -100.0%
H
0.2
190225
|
| Pasithea Therapeutics Corp |
|
19.4
|
0.6
|
L
H
0.5
0.6
|
L
 -19.4%
H
0.5
0.7
|
L
 -27.5%
H
0.5
0.8
|
L
 -27.5%
H
0.5
1.0
|
L
 -34.8%
H
0.3
2.1
|
L
 20.8%
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
| Kura Oncology Inc |
|
782.1
|
8.8
|
L
 2.9%
H
8.6
9.0
|
L
 -2.5%
H
8.4
9.2
|
L
 -6.5%
H
8.4
11.5
|
L
 -1.7%
H
7.5
11.5
|
L
 30.9%
H
5.5
12.5
|
L
 -35.7%
H
5.4
24.2
|
L
 -58.7%
H
5.4
24.2
|
L
 187.9%
H
2.5
43
|
| Kymera Therapeutics Inc |
|
6,326.4
|
76.9
|
L
 4%
H
73.1
77.3
|
L
 -2.0%
H
69.5
78.9
|
L
 -10.7%
H
69.5
89.5
|
L
 -7.9%
H
69.5
90.1
|
L
 61.5%
H
36.7
103
|
L
 229.0%
H
9.6
103
|
L
 58.4%
H
9.6
103
|
L
H
9.6
103
|
| Kazia Therapeutics Ltd (ADR) |
|
130.5
|
11.4
|
L
 0.2%
H
10.9
11.9
|
L
 -9.1%
H
10.6
13.1
|
L
 -20.9%
H
10.6
15.2
|
L
 38.4%
H
6.8
15.2
|
L
 102.1%
H
4.9
17.4
|
L
 -82.7%
H
2.9
79
|
L
 -97.8%
H
2.9
614
|
L
 -97.2%
H
2.9
792.5
|
| Lexaria Bioscience Corp |
|
16.6
|
0.7
|
L
 3.1%
H
0.7
0.7
|
L
 8.1%
H
0.6
0.7
|
L
 9.8%
H
0.6
0.7
|
L
 -19.3%
H
0.6
1.1
|
L
 -31.6%
H
0.5
1.6
|
L
 -13.0%
H
0.5
6.9
|
L
 -90.5%
H
0.5
12.5
|
L
 -78.7%
H
0.5
76.2
|
| Lifecore Biomedical Inc |
|
212.3
|
5.7
|
L
 1.6%
H
5.4
5.7
|
L
 16.7%
H
4.8
5.9
|
L
 18.2%
H
4.2
5.9
|
L
 -18.7%
H
3.6
7.2
|
L
 -17.4%
H
3.6
9.0
|
L
 -32.5%
H
3.6
11.5
|
L
 -55.5%
H
1.5
12.7
|
L
 -50.4%
H
1.5
15.6
|
| Lifevantage Corp |
|
119.9
|
9.5
|
L
 -11.2%
H
9.3
11.4
|
L
 0.7%
H
7.5
11.7
|
L
 77.9%
H
4.9
11.7
|
L
 94.7%
H
3.9
11.7
|
L
 -24.1%
H
3.9
15
|
L
 102.1%
H
3.9
27.4
|
L
 14.7%
H
3.0
27.4
|
L
 -32.7%
H
2.9
27.4
|
| Ligand Pharma Inc (Class B) |
|
4,875.6
|
243.3
|
L
 2.3%
H
237
245
|
L
 5.9%
H
227.8
245
|
L
 9.9%
H
205.2
245
|
L
 20.5%
H
188.7
247.4
|
L
 129.5%
H
103.4
247.4
|
L
 227.5%
H
49.3
247.4
|
L
 218.1%
H
46.8
247.4
|
L
 218.6%
H
36.9
247.4
|
| Longeveron Inc (Class A) |
|
24.3
|
0.8
|
L
 2.7%
H
0.7
0.8
|
L
H
0.7
0.8
|
L
 -8.3%
H
0.7
0.9
|
L
 60.4%
H
0.5
1.2
|
L
 -37.4%
H
0.5
1.8
|
L
 -97.8%
H
0.5
43.0
|
L
 -98.8%
H
0.5
450
|
L
H
0.5
450
|
| Atyr Pharma Inc |
|
45.1
|
0.5
|
L
 4.6%
H
0.4
0.5
|
L
 -16.4%
H
0.4
0.6
|
L
 -51.6%
H
0.4
1.0
|
L
 -43.9%
H
0.4
1.1
|
L
 -91.5%
H
0.4
7.3
|
L
 -79.6%
H
0.4
7.3
|
L
 -90.2%
H
0.4
13.1
|
L
 -99.0%
H
0.4
90.9
|
| Lixte biotech Holdings Inc |
|
119.4
|
6.9
|
L
 3.3%
H
6.8
7.4
|
L
 -4.7%
H
6.1
7.5
|
L
 33.1%
H
4.1
7.5
|
L
 181.6%
H
2.4
7.5
|
L
 416.5%
H
0.6
7.5
|
L
 24.2%
H
0.6
9.5
|
L
 -76.3%
H
0.6
49.5
|
L
 -28.4%
H
0.6
110.4
|
| Lipocine Inc |
|
16.9
|
2.1
|
L
 0.5%
H
2.0
2.1
|
L
 -10.1%
H
2.0
2.3
|
L
 -13.5%
H
2.0
2.4
|
L
 -74.8%
H
1.8
9.3
|
L
 -35.3%
H
1.8
12.4
|
L
 -53.7%
H
1.8
12.4
|
L
 -90.4%
H
1.8
32.1
|
L
 -98.6%
H
1.8
163.0
|
| Leap Therapeutics Inc |
|
72.4
|
0.7
|
L
 -4.2%
H
0.6
0.8
|
L
 -35.2%
H
0.5
1.3
|
L
 -42.9%
H
0.5
1.4
|
L
 33.3%
H
0.5
1.4
|
L
 74.4%
H
0.2
3.7
|
L
 -89.9%
H
0.2
7.3
|
L
 -96.1%
H
0.2
41.7
|
L
H
0.2
102.5
|
| Liquidia Corp |
|
5,692.3
|
64.0
|
L
 0.2%
H
61.7
66.0
|
L
 9.0%
H
53.1
66.8
|
L
 51.3%
H
39.6
66.8
|
L
 77.7%
H
34.2
66.8
|
L
 252.9%
H
11.9
66.8
|
L
 650.4%
H
5.7
66.8
|
L
 2219.2%
H
2.3
66.8
|
L
H
2.3
66.8
|
| Larimar Therapeutics Inc |
|
363.6
|
3.5
|
L
 12.9%
H
3.1
3.5
|
L
 -0.3%
H
3.0
3.5
|
L
 -11.8%
H
3.0
4.2
|
L
 -33.0%
H
3.0
6
|
L
 30.6%
H
2.2
6.4
|
L
 -0.3%
H
1.6
13.7
|
L
 -57.9%
H
1.5
15.3
|
L
 -95.7%
H
1.5
148.3
|
| Lisata Therapeutics Inc |
|
31.5
|
3.5
|
L
 -0.6%
H
3.4
3.5
|
L
 -3.4%
H
3.3
3.7
|
L
 9.8%
H
3.0
3.7
|
L
 -17.2%
H
2.8
5.1
|
L
 28.6%
H
1.8
5.1
|
L
 -19.2%
H
1.8
5.1
|
L
 -85.4%
H
1.8
25.2
|
L
 -95.8%
H
1.8
174.8
|
| Lantern Pharma Inc |
|
48.6
|
3.8
|
L
 1.6%
H
3.6
4.2
|
L
 1.9%
H
3.3
4.2
|
L
 81.4%
H
2
4.2
|
L
 41.1%
H
1.1
4.2
|
L
 14.8%
H
1.1
5.7
|
L
 -30.6%
H
1.1
12.0
|
L
 -75.3%
H
1.1
16.3
|
L
H
1.1
24.8
|
| Lexicon Pharma Inc |
|
835.1
|
1.9
|
L
H
1.8
1.9
|
L
 -9.2%
H
1.8
2.1
|
L
 -6%
H
1.8
2.5
|
L
 9.9%
H
1.5
2.5
|
L
 144.2%
H
0.6
2.5
|
L
 -38.0%
H
0.3
3.7
|
L
 -61.1%
H
0.3
6.3
|
L
 -87.2%
H
0.3
19.6
|
| Lyell Immunopharma Inc |
|
296.3
|
12.7
|
L
 3.2%
H
12.1
13.0
|
L
 -26.0%
H
11.7
17.2
|
L
 -34.3%
H
11.7
20.7
|
L
 -43.5%
H
11.7
27.8
|
L
 -0.5%
H
8.5
45
|
L
 -79.4%
H
7.7
79.4
|
L
H
7.7
396.8
|
L
H
7.7
396.8
|
| Legend Biotech Corp (ADR) |
|
6,220.4
|
33.5
|
L
 6.3%
H
31.3
33.5
|
L
 31.3%
H
25.3
37.5
|
L
 19.1%
H
24.3
37.5
|
L
 76.5%
H
16.7
37.5
|
L
 -4.3%
H
16.2
45.3
|
L
 -51.4%
H
16.2
77.3
|
L
 -13.9%
H
16.2
77.3
|
L
H
16.2
77.3
|
| Mustang Bio Inc |
|
5.6
|
0.7
|
L
 5.7%
H
0.7
0.8
|
L
 -3.9%
H
0.6
0.8
|
L
 5.7%
H
0.6
0.8
|
L
 -17.8%
H
0.6
1.0
|
L
 -40.3%
H
0.5
7
|
L
 -99.8%
H
0.1
408.5
|
L
 -100.0%
H
0.1
3045
|
L
H
0.1
10012.5
|
| Microbot Medical Inc |
|
122.2
|
1.8
|
L
H
1.8
1.9
|
L
 -8.1%
H
1.8
2.0
|
L
 -14.6%
H
1.7
2.3
|
L
 -23.5%
H
1.7
2.9
|
L
 -35.2%
H
1.6
4.7
|
L
 -31.6%
H
0.8
4.7
|
L
 -75.7%
H
0.8
9.6
|
L
 -97.1%
H
0.8
403.7
|
| Moleculin Biotech Inc |
|
12.9
|
2.4
|
L
 -2.4%
H
2.4
2.5
|
L
 -8.7%
H
2.3
2.7
|
L
 -2.4%
H
2
3.0
|
L
 15.9%
H
1.8
3.0
|
L
 -85.6%
H
1.8
24
|
L
 -99.0%
H
1.8
3318.8
|
L
 -99.8%
H
1.8
3318.8
|
L
 -100.0%
H
1.8
19417.5
|
| Seres Therapeutics Inc |
|
61.3
|
6.3
|
L
 0.8%
H
6.2
7.0
|
L
 -17.2%
H
6.0
8.0
|
L
 -17.8%
H
6.0
8.1
|
L
 -30.7%
H
6.0
9.6
|
L
 -23.1%
H
6.0
30.0
|
L
 13.0%
H
0.4
30.0
|
L
 -67.9%
H
0.4
30.0
|
L
 -81.5%
H
0.4
38.5
|
| Madrigal Pharma Inc |
|
10,995.0
|
476.9
|
L
 2.1%
H
470.8
480.5
|
L
 -0.9%
H
445.2
497.8
|
L
 -6.5%
H
445.2
547.2
|
L
 10.2%
H
418.7
572.2
|
L
 71.4%
H
275
615
|
L
 77.2%
H
119.8
615
|
L
 351.3%
H
52.3
615
|
L
 3628.6%
H
6.6
615
|
| MediWound Ltd |
|
183.8
|
14.3
|
L
 0.6%
H
14.1
14.4
|
L
 3.5%
H
13.5
14.7
|
L
 -13.7%
H
13.5
17.1
|
L
 -16.0%
H
13.5
18.1
|
L
 -33.8%
H
13.5
22.0
|
L
 48.0%
H
7.1
24
|
L
 -44.8%
H
7.1
43.5
|
L
 -74.8%
H
7.1
60.1
|
| MEI Pharma Inc |
|
25.9
|
0.8
|
L
H
0.7
0.8
|
L
 -20.8%
H
0.7
0.9
|
L
 -37.7%
H
0.7
1.3
|
L
 -33.3%
H
0.7
1.3
|
L
 -65.1%
H
0.7
9
|
L
 -89.6%
H
0.7
9
|
L
 -98.8%
H
0.7
71
|
L
 -97.4%
H
0.7
102.8
|
| Macrogenics Inc |
|
248.5
|
3.9
|
L
 0.8%
H
3.9
4.1
|
L
 -5.6%
H
3.8
4.5
|
L
 30.3%
H
2.9
4.6
|
L
 75.3%
H
2.3
4.6
|
L
 119.7%
H
1.2
4.6
|
L
 -24.8%
H
1.0
21.9
|
L
 -82.7%
H
1.0
29.2
|
L
 -85.8%
H
1.0
36.5
|
| Mangoceuticals Inc |
|
5.8
|
0.3
|
L
 -5.6%
H
0.3
0.4
|
L
 -19.1%
H
0.3
0.4
|
L
 -17.1%
H
0.3
0.6
|
L
 -8.1%
H
0.2
0.6
|
L
 -83.3%
H
0.2
2.8
|
L
 -79.3%
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
| Magenta Therapeutics Inc |
|
-
|
84.6
|
L
 4.1%
H
78.6
84.8
|
L
 -5.5%
H
78.6
90.0
|
L
 -2.5%
H
78.6
93.6
|
L
 29.7%
H
75.5
96.5
|
L
 348.7%
H
16.6
96.5
|
L
 634.1%
H
9.9
96.5
|
L
 -55.1%
H
5.1
195.5
|
L
H
5.1
336
|
| MeiraGTx Holdings PLC |
|
852.9
|
9.2
|
L
 1.3%
H
8.9
9.5
|
L
 -6.0%
H
8.9
9.8
|
L
 -6.2%
H
8.9
10.7
|
L
 31.6%
H
6.9
11.9
|
L
 53.5%
H
6.0
11.9
|
L
 14.6%
H
3.5
11.9
|
L
 -38.5%
H
3.5
24.9
|
L
H
3.5
30.2
|
| Mirum Pharma Inc |
|
5,822.5
|
95.5
|
L
 2.0%
H
91.8
97
|
L
 -0.9%
H
90.6
97.2
|
L
 -10.9%
H
90.6
115.0
|
L
 10.6%
H
84.3
115.0
|
L
 105.9%
H
45.4
115.0
|
L
 228.7%
H
23.1
115.0
|
L
 480.8%
H
12.8
115.0
|
L
H
6.5
115.0
|
| Milestone Pharma Inc |
|
150.6
|
1.2
|
L
 -1.6%
H
1.2
1.3
|
L
 -11.0%
H
1.2
1.4
|
L
 -37.0%
H
1.2
2.0
|
L
 -23.4%
H
1
2.3
|
L
 -30.1%
H
1
3.1
|
L
 -69.8%
H
0.6
4.1
|
L
 -77.4%
H
0.6
9.9
|
L
H
0.6
28.0
|
| MoonLake Immunotherapeutics (Class A) |
|
1,310.4
|
17.8
|
L
 -1.1%
H
17.4
18.9
|
L
 -5.4%
H
17.4
18.9
|
L
 4.3%
H
15.8
21
|
L
 -1.9%
H
15.8
21
|
L
 -62.0%
H
6.0
62.8
|
L
 -39.0%
H
6.0
65.0
|
L
 76.2%
H
4.3
65.0
|
L
H
4.3
65.0
|
| Mineralys Therapeutics Inc |
|
2,131.7
|
24.2
|
L
 7.5%
H
22.9
24.4
|
L
 -22.3%
H
22.3
30.7
|
L
 -18.1%
H
22.3
32.1
|
L
 -9.1%
H
22.3
32.1
|
L
 50%
H
12.6
47.7
|
L
 57.6%
H
5.9
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
| Mannkind Corp |
|
1,103.0
|
3.6
|
L
 5.3%
H
3.4
3.6
|
L
 1.1%
H
3.3
3.6
|
L
 1.4%
H
2.9
3.9
|
L
 36.8%
H
2.2
4.3
|
L
 -18.5%
H
2.2
6.5
|
L
 -13.3%
H
2.2
7.6
|
L
 -7.8%
H
2.2
7.6
|
L
 -30.7%
H
0.7
7.6
|
| Mind Medicine Inc |
|
2,503.1
|
23.0
|
L
 -0.3%
H
21.7
23.8
|
L
 -4.6%
H
21.7
25.2
|
L
 4.1%
H
19.3
25.2
|
L
 30.0%
H
17.1
26.3
|
L
 194.6%
H
6.3
26.3
|
L
 507.1%
H
2.4
26.3
|
L
 -58.8%
H
2.1
60.6
|
L
H
0.0
154.8
|
| Medicinova Inc |
|
62.5
|
1.3
|
L
 -2.3%
H
1.3
1.3
|
L
 -7.3%
H
1.3
1.4
|
L
 -9.3%
H
1.3
1.5
|
L
 -6.6%
H
1.3
1.6
|
L
 -9.9%
H
1.2
2.0
|
L
 -41.2%
H
1.1
2.7
|
L
 -70.4%
H
1.1
5.1
|
L
 -81.5%
H
1.1
14.5
|
| Monopar Therapeutics Inc |
|
406.2
|
60.6
|
L
 0.0%
H
58.3
62.2
|
L
 -5.9%
H
57.7
64.8
|
L
 -4.6%
H
54.2
68.8
|
L
 5.2%
H
50.1
68.8
|
L
 63.4%
H
29.2
105
|
L
 1218.0%
H
1.4
105
|
L
 108.7%
H
1.4
105
|
L
H
1.4
240
|
| Marker Therapeutics Inc |
|
23.5
|
1.4
|
L
 -3.4%
H
1.4
1.5
|
L
 -7.2%
H
1.4
1.5
|
L
 -3.4%
H
1.4
1.6
|
L
 2.2%
H
1.2
1.8
|
L
 -20.3%
H
0.8
4.1
|
L
 -32.2%
H
0.8
9.7
|
L
 -95.6%
H
0.7
36.5
|
L
 -98.0%
H
0.7
135.5
|
| Moderna |
|
18,938.6
|
47.7
|
L
 0.3%
H
45.4
48.4
|
L
 3.6%
H
43.9
51.9
|
L
 -12.2%
H
43.9
59.5
|
L
 -9.1%
H
43.7
59.5
|
L
 73.8%
H
22.3
59.6
|
L
 -61.8%
H
22.3
170.5
|
L
 -77.6%
H
22.3
497.5
|
L
H
11.5
497.5
|
| Maravai LifeSciences Holdings Inc (Class A) |
|
752.3
|
5.1
|
L
 1.2%
H
4.9
5.2
|
L
 7.4%
H
4.7
5.2
|
L
 5.2%
H
4
5.2
|
L
 43.7%
H
2.8
5.2
|
L
 113.4%
H
2.0
5.2
|
L
 -62.3%
H
1.7
14.9
|
L
 -87.8%
H
1.7
63.6
|
L
H
1.7
63.6
|
| Mannatech Inc |
|
10.8
|
5.6
|
L
 -0.7%
H
5.4
5.9
|
L
 4.3%
H
5.2
6.1
|
L
 -1.9%
H
3.8
6.1
|
L
 -16.6%
H
3.8
8.5
|
L
 -47.6%
H
3.8
12.5
|
L
 -55.3%
H
3.8
16.5
|
L
 -78.2%
H
3.8
49.1
|
L
 -74.0%
H
3.8
49.1
|
| MaxCyte Inc |
|
127.5
|
1.2
|
L
 3.5%
H
1.2
1.2
|
L
 -2.5%
H
1.1
1.3
|
L
 41.7%
H
0.8
1.3
|
L
 52.6%
H
0.7
1.3
|
L
 -44.7%
H
0.6
2.4
|
L
 -73.4%
H
0.6
5.5
|
L
 -79.7%
H
0.6
17.4
|
L
H
0.6
17.4
|
| TNF Pharma Inc |
|
29.8
|
3.8
|
L
 0.3%
H
3.5
3.9
|
L
 -9.8%
H
3.5
4.3
|
L
 0.5%
H
3.5
5.5
|
L
 -15.8%
H
3.1
5.5
|
L
 -77.4%
H
2.5
33.6
|
L
 -99.9%
H
2.5
6387
|
L
 -100.0%
H
2.5
29850
|
L
 -99.9%
H
2.5
29850
|
| Mainz Biomed N.V. |
|
46.4
|
2.0
|
L
 -2.9%
H
1.9
2.1
|
L
 -8.5%
H
1.9
3.1
|
L
 466.7%
H
0.3
4.9
|
L
 145.8%
H
0.3
4.9
|
L
 -1.9%
H
0.3
4.9
|
L
 -99.0%
H
0.3
208.4
|
L
H
0.3
1200
|
L
H
0.3
1200
|
| Mesoblast Ltd (ADR) |
|
1,846.2
|
14.3
|
L
 3.5%
H
13.9
14.5
|
L
 -3.9%
H
13.7
15.1
|
L
 -3.1%
H
13.7
15.6
|
L
 -9.9%
H
13.3
16.9
|
L
 21.1%
H
9.9
21.5
|
L
 305.7%
H
1.0
22
|
L
 87.6%
H
1.0
22
|
L
 104.3%
H
1.0
22
|
| Molecular Partners AG (ADR) |
|
145.5
|
3.9
|
L
 -1.8%
H
3.7
3.9
|
L
 -1.8%
H
3.7
4.1
|
L
 -5.4%
H
3.7
4.4
|
L
 -22.4%
H
3.7
5.3
|
L
 2.1%
H
3.4
5.4
|
L
 -44.0%
H
3.3
12.7
|
L
 -84.1%
H
3.3
32.0
|
L
 -85.5%
H
3.3
32.0
|
| Mereo Biopharma Grp PLC (ADR) |
|
49.5
|
0.3
|
L
 3.3%
H
0.3
0.3
|
L
H
0.3
0.4
|
L
 24%
H
0.2
0.4
|
L
 -20.5%
H
0.2
0.4
|
L
 -88.7%
H
0.2
3.1
|
L
 -77.0%
H
0.2
5.0
|
L
 -90.5%
H
0.2
5.0
|
L
H
0.2
8.5
|
| Natural Alternatives Intl Inc |
|
15.7
|
2.5
|
L
 -0.8%
H
2.5
2.6
|
L
 -0.8%
H
2.4
2.7
|
L
 -6.4%
H
2.4
2.8
|
L
 -8.4%
H
2.4
3.3
|
L
 -26.9%
H
2.3
5.0
|
L
 -66.8%
H
2.3
7.8
|
L
 -81.7%
H
2.3
19.9
|
L
 -79.1%
H
2.3
19.9
|
| NewAmsterdam Pharma Co NV |
|
3,551.5
|
30.4
|
L
 -1.8%
H
29.6
32.0
|
L
 -4.4%
H
29.6
33.4
|
L
 -21.6%
H
29.6
42.2
|
L
 1.7%
H
27.9
42.2
|
L
 50.8%
H
17.6
42.2
|
L
 160.5%
H
5.6
42.2
|
L
 210%
H
5.6
42.2
|
L
H
5.6
42.2
|
| Nature`s Sunshine Products Inc |
|
354.2
|
20.1
|
L
 1.9%
H
19.8
20.5
|
L
 -3.2%
H
19.4
21.3
|
L
 -16.9%
H
19.4
24.2
|
L
 -19.6%
H
19.4
28
|
L
 38.8%
H
13.0
28.1
|
L
 67.1%
H
10.8
28.1
|
L
 -0.5%
H
7.9
28.1
|
L
 82.3%
H
5.5
28.1
|
| Nautilus biotech Inc |
|
298.6
|
2.4
|
L
 0.9%
H
2.3
2.4
|
L
 -15.2%
H
2.3
2.8
|
L
 -12.3%
H
2.3
3.2
|
L
 -4.9%
H
2.2
4.3
|
L
 205.2%
H
0.6
4.3
|
L
 -25.4%
H
0.6
4.7
|
L
 -78.0%
H
0.6
12.4
|
L
H
0.6
25.9
|
| Neurocrine Biosciences Inc |
|
16,614.9
|
165.2
|
L
 1.3%
H
160.9
166.4
|
L
 2.6%
H
154.1
169.6
|
L
 8.5%
H
150.3
169.6
|
L
 29.0%
H
125.1
169.6
|
L
 31.8%
H
122.1
169.6
|
L
 75.7%
H
84.2
169.6
|
L
 70.3%
H
71.9
169.6
|
L
 218.0%
H
37.3
169.6
|
| Minerva Neurosciences Inc |
|
220.8
|
4.7
|
L
 2.4%
H
4.6
4.9
|
L
 -2.1%
H
4.5
5.2
|
L
 -19.4%
H
4.3
6.1
|
L
 -21.1%
H
4.3
8.8
|
L
 157.6%
H
1.6
12.5
|
L
 -31.8%
H
1.2
13.5
|
L
 -80.5%
H
1.2
25.1
|
L
 -94.3%
H
1.2
121.7
|
| Nektar Therapeutics |
|
1,899.8
|
56.2
|
L
 -0.7%
H
54.1
58.9
|
L
 -12.0%
H
54.1
63
|
L
 -31.3%
H
54.1
81.0
|
L
 -20.5%
H
54.1
109
|
L
 462.9%
H
8.0
109
|
L
 524.8%
H
6.2
109
|
L
 -77.3%
H
6.2
290.6
|
L
 -76.6%
H
6.2
1670.4
|
| Nkarta Inc |
|
175.3
|
2.5
|
L
 2.1%
H
2.3
2.5
|
L
 -22.0%
H
2.3
3.2
|
L
 -23.2%
H
2.3
3.3
|
L
 -2%
H
2.0
3.7
|
L
 29.0%
H
1.6
3.7
|
L
 -48.1%
H
1.3
16.2
|
L
 -90.1%
H
1.3
40.6
|
L
H
1.3
79.2
|
| NLS Pharmaceutics Ltd |
|
17.1
|
3.2
|
L
 -2.2%
H
3.0
3.3
|
L
 -8.9%
H
2.8
3.4
|
L
 -5.7%
H
2.8
3.7
|
L
 14.4%
H
1.8
5.1
|
L
 -86.2%
H
1.8
30.8
|
L
 -99.1%
H
1.2
612
|
L
 -99.8%
H
1.2
1492
|
L
H
1.2
2940
|
| Neoleukin Therapeutics Inc |
|
-
|
28.8
|
L
 0.7%
H
24.9
29.9
|
L
 4.6%
H
24.9
29.9
|
L
 -6.4%
H
24.9
34.0
|
L
 30.0%
H
18.2
34.0
|
L
 32.0%
H
14.7
37.3
|
L
 82.3%
H
12.2
37.3
|
L
 -86.7%
H
7.5
220
|
L
 -81.9%
H
7.5
399.4
|
| 9 Meters Biopharma Inc |
|
-
|
9.1
|
L
 1.6%
H
9.0
9.2
|
L
 0.4%
H
8.8
9.2
|
L
 2.5%
H
8.5
9.3
|
L
 13.3%
H
7.0
9.3
|
L
 33.7%
H
6.2
9.3
|
L
 1060.3%
H
0.0
9.3
|
L
 -69.2%
H
0.0
31
|
L
H
0.0
1010
|
| MetaVia Inc |
|
9.8
|
1.9
|
L
 -14.9%
H
1.7
2.0
|
L
 -30.8%
H
1.7
2.8
|
L
 73.4%
H
1.0
4.3
|
L
 21.9%
H
1.0
4.3
|
L
 -75.2%
H
1.0
19.0
|
L
 -95.7%
H
1.0
74.3
|
L
 -100.0%
H
1.0
17344.8
|
L
H
1.0
1424940
|
| Nurix Therapeutics Inc |
|
1,617.3
|
15.6
|
L
H
14.7
17.0
|
L
 -10.1%
H
14.2
18.2
|
L
 -5.3%
H
14.2
18.2
|
L
 3.6%
H
14.0
18.2
|
L
 22.4%
H
8.2
22.5
|
L
 44.3%
H
4.2
29.6
|
L
 -50.5%
H
4.2
37.4
|
L
H
4.2
52.4
|
| NeuroSense Therapeutics Ltd |
|
27.4
|
0.8
|
L
 1.3%
H
0.7
0.8
|
L
 -6.2%
H
0.7
0.8
|
L
 -13.6%
H
0.7
0.9
|
L
 -12.6%
H
0.6
1.1
|
L
 -57.5%
H
0.6
2.6
|
L
 -60.2%
H
0.4
2.6
|
L
H
0.4
8.2
|
L
H
0.4
8.2
|
| NRX Pharma Inc |
|
165.6
|
3.9
|
L
 -10.6%
H
3.7
4.4
|
L
 -16.2%
H
3.5
5.1
|
L
 25.7%
H
2.7
5.1
|
L
 127.7%
H
1.6
5.1
|
L
 18.4%
H
1.6
5.1
|
L
 -26.8%
H
1.1
54
|
L
 -97.7%
H
1.1
262.4
|
L
H
1.1
769.9
|
| Intellia Therapeutics Inc |
|
1,801.0
|
12.9
|
L
 -4.5%
H
12.5
14.3
|
L
 -6.1%
H
12.5
15.5
|
L
 -8.5%
H
11.8
15.6
|
L
 -4.1%
H
11.6
17.0
|
L
 59.3%
H
8.0
28.3
|
L
 -70.3%
H
5.9
47.5
|
L
 -83.7%
H
5.9
202.7
|
L
 -54.5%
H
5.9
202.7
|
| Nuvalent Inc (Class A) |
|
9,736.5
|
123.3
|
L
 39.3%
H
122.8
123.6
|
L
 32.5%
H
87.3
123.6
|
L
 17.1%
H
87.3
123.6
|
L
 24.0%
H
87.3
123.6
|
L
 58.0%
H
71.1
123.6
|
L
 190.1%
H
38.8
123.6
|
L
H
7.1
123.6
|
L
H
7.1
123.6
|
| Novavax Inc |
|
1,425.7
|
8.7
|
L
 0.6%
H
8.4
8.9
|
L
 -17.5%
H
8.4
10.6
|
L
 -14.2%
H
8.4
11.6
|
L
 -13.1%
H
7.6
11.6
|
L
 16.4%
H
6.1
12.0
|
L
 12.7%
H
3.5
23.9
|
L
 -95.6%
H
3.5
277.8
|
L
 -93.5%
H
3.5
331.7
|
| Nuvectis Pharma Inc |
|
260.0
|
9.8
|
L
 4.0%
H
9.4
9.9
|
L
 0.5%
H
9.2
10.0
|
L
 -15.9%
H
9.2
13.3
|
L
 9.4%
H
7.2
13.3
|
L
 10.7%
H
5.6
13.3
|
L
 -44.1%
H
4.4
18.7
|
L
H
3.1
20.9
|
L
H
3.1
20.9
|
| Nextcure Inc |
|
8.4
|
2.3
|
L
 -16.5%
H
2.3
2.9
|
L
 -31.1%
H
2.3
3.7
|
L
 -76.1%
H
2.3
11.1
|
L
 -81.2%
H
2.3
14.4
|
L
 -60.8%
H
2.3
15.7
|
L
 -89.0%
H
2.3
30.8
|
L
 -97.6%
H
2.3
110.2
|
L
H
2.3
1308
|
| NuCana PLC (ADR) |
|
8.2
|
2.0
|
L
 -3.9%
H
2.0
2.1
|
L
 -9.2%
H
1.9
2.2
|
L
 -6.6%
H
1.8
2.4
|
L
 -8.8%
H
1.3
2.4
|
L
 -99.9%
H
1.3
8000
|
L
 -100.0%
H
1.3
950000
|
L
 -100.0%
H
1.3
3319720
|
L
H
1.3
32000000
|
| Ocugen Inc |
|
419.8
|
1.2
|
L
 -1.6%
H
1.2
1.3
|
L
 -9.5%
H
1.2
1.4
|
L
 -17.9%
H
1.2
1.6
|
L
 -23.0%
H
1.2
2.7
|
L
 17.0%
H
0.9
2.7
|
L
 169.6%
H
0.3
2.7
|
L
 -87.8%
H
0.3
17.7
|
L
 -99.0%
H
0.2
268.2
|
| Oculis Holding AG |
|
663.1
|
11.0
|
L
 2.5%
H
10.7
11.8
|
L
 -24.3%
H
10.5
14
|
L
 -66.4%
H
10.5
34.5
|
L
 -59.3%
H
10.5
34.5
|
L
 -44.9%
H
10.5
34.5
|
L
 -4.5%
H
9.1
34.5
|
L
 6.7%
H
6.3
34.5
|
L
H
6.3
34.5
|
| Ocular Therapeutix Inc |
|
1,854.6
|
8.5
|
L
 3.8%
H
8.1
8.5
|
L
 -5.2%
H
8.1
8.9
|
L
 -12.2%
H
7.9
9.7
|
L
 -17.5%
H
7.4
10.3
|
L
 -6.1%
H
6.2
16.4
|
L
 11.3%
H
2
16.4
|
L
 -43.3%
H
2
16.4
|
L
 24.6%
H
2
24.3
|
| Opus Genetics Inc |
|
336.9
|
4.1
|
L
 1.2%
H
3.9
4.1
|
L
 -1.0%
H
3.9
4.7
|
L
 -18.2%
H
3.9
5.2
|
L
 -16.6%
H
3.9
5.8
|
L
 292.3%
H
0.9
5.8
|
L
 3.0%
H
0.7
5.8
|
L
 -28.5%
H
0.7
7
|
L
 -97.1%
H
0.7
340.8
|
| Insight Molecular Diagnostics Inc |
|
188.9
|
5.9
|
L
 2.3%
H
5.6
6.3
|
L
 -5.0%
H
5.2
6.9
|
L
 16.8%
H
4.7
6.9
|
L
 7.3%
H
2.4
6.9
|
L
 97.0%
H
2.3
8.5
|
L
 36.0%
H
1.9
8.5
|
L
 -93.9%
H
1.9
125
|
L
 -93.1%
H
1.9
159
|
| OKYO Pharma Ltd - Ordinary Shares - New |
|
80.8
|
1.5
|
L
 -3.1%
H
1.5
1.6
|
L
 -9.9%
H
1.5
1.8
|
L
 -5.5%
H
1.5
1.8
|
L
 -7.2%
H
1.4
1.8
|
L
 -19.0%
H
1.4
3.4
|
L
 6.2%
H
0.8
3.4
|
L
H
0.8
7
|
L
H
0.8
7
|
| Olema Pharma Inc |
|
912.8
|
10.5
|
L
 4.9%
H
10.1
10.7
|
L
 -17.8%
H
9.9
12.6
|
L
 -29.9%
H
9.9
15.6
|
L
 -51.5%
H
9.9
18.6
|
L
 134.3%
H
3.9
36.3
|
L
 59.5%
H
2.9
36.3
|
L
 -62.7%
H
2
36.3
|
L
H
2
60.3
|
| Omeros Corp |
|
721.6
|
10.0
|
L
 1.2%
H
9.6
10.0
|
L
 -7%
H
9.6
10.8
|
L
 -29.4%
H
9.6
14.9
|
L
 -13.6%
H
9.6
15.3
|
L
 164.5%
H
3.0
17.7
|
L
 31.7%
H
0.9
17.7
|
L
 -37.1%
H
0.9
17.7
|
L
 -9.5%
H
0.9
27.1
|
| Oncolytics Biotech Inc |
|
96.7
|
0.8
|
L
 -3.6%
H
0.8
0.9
|
L
 -23.6%
H
0.8
1.1
|
L
 -9.0%
H
0.8
1.2
|
L
 -23.6%
H
0.8
1.2
|
L
 125%
H
0.4
1.5
|
L
 -48.7%
H
0.3
3.4
|
L
 -72.7%
H
0.3
3.4
|
L
 -78.6%
H
0.3
8.5
|
| Traws Pharma Inc |
|
19.8
|
1.3
|
L
 -4.4%
H
1.3
1.4
|
L
 -10.9%
H
1.3
1.5
|
L
 -39.9%
H
1.3
3.2
|
L
 -18.1%
H
1
3.2
|
L
 -20.6%
H
1
3.3
|
L
 -95.5%
H
1.0
31.3
|
L
 -99.2%
H
1.0
200
|
L
 -100.0%
H
1.0
45956.3
|
| VivoSim Labs Inc |
|
3.4
|
1.2
|
L
H
1.1
1.2
|
L
 -7.8%
H
1.1
1.4
|
L
 -14.4%
H
1.1
1.4
|
L
 -35.0%
H
1.1
2.0
|
L
 -35.3%
H
1.1
5.3
|
L
 -94.3%
H
0.3
24.6
|
L
 -98.8%
H
0.3
118.7
|
L
 -99.8%
H
0.3
1197.6
|
| ORIC Pharma Inc |
|
828.1
|
8
|
L
 6.2%
H
7.4
8.0
|
L
 -10.9%
H
7.3
8.3
|
L
 -9.6%
H
7.3
9.2
|
L
 -41.7%
H
7.2
13.0
|
L
 -14.2%
H
7.2
14.9
|
L
 52.4%
H
3.9
16.7
|
L
 -59.7%
H
2.4
26.7
|
L
H
2.4
40.8
|
| Oramed Pharma Inc |
|
149.4
|
3.7
|
L
 0.3%
H
3.6
3.8
|
L
 -6.2%
H
3.6
4.0
|
L
 -10.8%
H
3.6
5.0
|
L
 11.3%
H
3.2
5.0
|
L
 64.4%
H
2.0
5.0
|
L
 -9.0%
H
1.7
5.0
|
L
 -73.6%
H
1.7
31.5
|
L
 -54.7%
H
1.7
31.5
|
| Outlook Therapeutics Inc |
|
104.0
|
0.7
|
L
 -2.8%
H
0.7
0.8
|
L
 -16.7%
H
0.7
0.9
|
L
 218.2%
H
0.2
0.9
|
L
 70.7%
H
0.2
0.9
|
L
 -63.2%
H
0.2
3.0
|
L
 -99.9%
H
0.2
744
|
L
 -99.9%
H
0.2
1308
|
L
H
0.2
17568
|
| Ovid Therapeutics Inc |
|
451.7
|
2.4
|
L
 2.5%
H
2.3
2.5
|
L
 -5.5%
H
2.3
2.6
|
L
 -13.6%
H
2.3
2.9
|
L
 26.7%
H
1.8
3.1
|
L
 656.3%
H
0.3
3.1
|
L
 -31.1%
H
0.2
4.1
|
L
 -45.5%
H
0.2
4.6
|
L
H
0.2
15.9
|
| Phibro Animal Health Corp (Class A) |
|
1,324.4
|
32.7
|
L
 2.8%
H
32.0
32.9
|
L
 9.3%
H
28.3
34.0
|
L
 -18.4%
H
28.3
39.9
|
L
 -31.9%
H
28.3
60.1
|
L
 35.6%
H
22.9
60.1
|
L
 135.6%
H
9.4
60.1
|
L
 11.1%
H
9.4
60.1
|
L
 68.8%
H
9.4
60.1
|
| Palisade Bio Inc |
|
293.7
|
1.7
|
L
 -2.9%
H
1.6
1.8
|
L
 -18.8%
H
1.6
2.1
|
L
 -6.1%
H
1.6
2.2
|
L
 3.7%
H
1.5
2.9
|
L
 141.4%
H
0.5
2.9
|
L
 -93.0%
H
0.4
36.6
|
L
 -99.9%
H
0.4
3427.5
|
L
 -100.0%
H
0.4
594000
|
| Passage Bio Inc |
|
17.9
|
5.6
|
L
 1.8%
H
5.4
5.9
|
L
 -4.8%
H
5.4
6.1
|
L
 32.3%
H
4.2
6.1
|
L
 -33.7%
H
3.9
12.1
|
L
 -34.2%
H
3.9
20
|
L
 -71.6%
H
3.9
35.8
|
L
 -98.0%
H
3.9
322.8
|
L
H
3.9
764.6
|
| Paranovus Entertainment Tech Ltd (Class A) |
|
1.1
|
1.0
|
L
 8.5%
H
1.0
26.7
|
L
 -8.9%
H
0.9
26.7
|
L
 -17.7%
H
0.9
26.7
|
L
 -93.0%
H
0.9
28.4
|
L
 -99.9%
H
0.9
1488
|
L
 -100.0%
H
0.9
5808
|
L
 -100.0%
H
0.9
43920
|
L
H
0.9
146400
|
| Puma biotech Inc |
|
358.8
|
7.1
|
L
 2.9%
H
6.9
7.1
|
L
 -1.0%
H
6.8
7.2
|
L
 -5.9%
H
6.6
7.5
|
L
 16.5%
H
5.8
7.9
|
L
 89.5%
H
3.0
7.9
|
L
 100.9%
H
2.1
7.9
|
L
 -38.3%
H
1.6
11.9
|
L
 -80.1%
H
1.6
136.9
|
| Pacira BioSciences Inc |
|
913.3
|
23.2
|
L
 1.5%
H
23
23.7
|
L
 1.1%
H
22
23.7
|
L
 0.3%
H
21.9
25.2
|
L
 5.5%
H
21.2
27.1
|
L
 -10.6%
H
18.8
27.6
|
L
 -37.3%
H
11.2
41.7
|
L
 -61.8%
H
11.2
82.2
|
L
 -50.7%
H
11.2
82.2
|
| Processa Pharma Inc |
|
5.6
|
2.0
|
L
 -15.7%
H
1.9
2.6
|
L
 -19.4%
H
1.9
3
|
L
 -25.3%
H
1.9
3.4
|
L
 -27.9%
H
1.9
3.5
|
L
 -72.9%
H
1.8
19.6
|
L
 -99.4%
H
1.8
450
|
L
 -99.9%
H
1.8
4495.5
|
L
 -100.0%
H
1.8
17937.5
|
| Vaxcyte Inc |
|
6,769.4
|
46.9
|
L
 1.2%
H
46.1
47.6
|
L
 -4.2%
H
45.6
49.2
|
L
 -11.6%
H
45.6
54.7
|
L
 -20.9%
H
45.6
63.3
|
L
 26.7%
H
29.1
65
|
L
 -8.0%
H
27.7
121.1
|
L
 94.8%
H
16.8
121.1
|
L
H
15.5
121.1
|
| PDS biotech Corp |
|
57.5
|
1.0
|
L
 3%
H
1.0
1.0
|
L
 -9.7%
H
1.0
1.3
|
L
 -17.6%
H
1.0
1.6
|
L
 53.7%
H
0.5
1.6
|
L
 -39.1%
H
0.5
1.9
|
L
 -82.3%
H
0.5
6.9
|
L
 -90.8%
H
0.5
17.9
|
L
 -99.5%
H
0.5
355.4
|
| PepGen Inc |
|
95.5
|
1.4
|
L
 2.2%
H
1.3
1.4
|
L
 -6.1%
H
1.3
1.5
|
L
 -21.6%
H
1.3
1.8
|
L
 -75.7%
H
1.3
6.7
|
L
 -8%
H
1.0
7.8
|
L
 -91.6%
H
0.9
19.3
|
L
H
0.9
20
|
L
H
0.9
20
|
| Precigen Inc |
|
1,322.7
|
3.7
|
L
 3.9%
H
3.6
3.8
|
L
 -10.0%
H
3.5
4.1
|
L
 -11.9%
H
3.5
4.9
|
L
 11.8%
H
3.0
4.9
|
L
 147.3%
H
1.4
5.5
|
L
 194.4%
H
0.7
5.5
|
L
 -48.5%
H
0.7
8.7
|
L
 -86%
H
0.7
32.9
|
| Phathom Pharma Inc |
|
783.2
|
9.8
|
L
 -1.8%
H
9.8
10.2
|
L
 6.3%
H
8.8
10.7
|
L
 -19.2%
H
8.8
13.4
|
L
 -8.0%
H
8.8
13.7
|
L
 10.1%
H
7.6
18.3
|
L
 -20.2%
H
2.2
19.7
|
L
 -71.8%
H
2.2
37.2
|
L
H
2.2
64.5
|
| Phio Pharma Corp |
|
12.5
|
1.1
|
L
 -0.9%
H
1.1
1.1
|
L
 -4.4%
H
1.1
1.1
|
L
 0.9%
H
1.1
1.2
|
L
 -6.9%
H
1.0
1.4
|
L
 -63.5%
H
0.8
4.2
|
L
 -96.1%
H
0.6
30.5
|
L
 -99.5%
H
0.6
266.8
|
L
 -100.0%
H
0.6
194238
|
| Pharvaris NV |
|
2,208.2
|
31.6
|
L
 0.0%
H
30.3
32.2
|
L
 8.6%
H
28.5
32.2
|
L
 5.0%
H
28.3
33.3
|
L
 22.0%
H
25.0
33.3
|
L
 88.3%
H
16
33.3
|
L
 251.1%
H
8.8
33.3
|
L
 55.0%
H
1.8
33.3
|
L
H
1.8
42.9
|
| Pliant Therapeutics Inc |
|
73.7
|
1.2
|
L
 3.5%
H
1.1
1.2
|
L
 -0.8%
H
1.1
1.2
|
L
 -2.5%
H
1.1
1.3
|
L
 -10.5%
H
1.1
1.4
|
L
 -27.0%
H
1.1
2.0
|
L
 -94.8%
H
1.1
24.7
|
L
 -96.2%
H
1.1
36.6
|
L
H
1.1
43.9
|
| Pluri Inc |
|
25.7
|
2.4
|
L
 3.0%
H
2.3
2.6
|
L
 -1.2%
H
2.3
2.6
|
L
 -31.6%
H
2.2
3.9
|
L
 -27.4%
H
2.2
3.9
|
L
 -49.9%
H
2.2
6.0
|
L
 -66.2%
H
0.7
8.6
|
L
 -92.9%
H
0.7
36.4
|
L
 -98.1%
H
0.7
169.6
|
| PharmaCyte Biotech Inc |
|
7.5
|
0.7
|
L
H
0.7
0.7
|
L
 -12.5%
H
0.7
0.8
|
L
 -7.9%
H
0.7
1.0
|
L
 -6.7%
H
0.6
1.0
|
L
 -31.4%
H
0.6
1.5
|
L
 -78.0%
H
0.6
3.2
|
L
 -96.5%
H
0.6
21.5
|
L
 -99.3%
H
0.6
253.4
|
| Praxis Precision Medicines Inc |
|
6,978.9
|
250.3
|
L
 -1.2%
H
244.2
266.6
|
L
 -25.3%
H
244.2
321.8
|
L
 -24.2%
H
244.2
366.5
|
L
 -19.4%
H
244.2
366.5
|
L
 461.8%
H
37.2
366.5
|
L
 1552.3%
H
12.6
366.5
|
L
 -18.3%
H
11.9
366.5
|
L
H
11.9
914.3
|
| PainReform Ltd |
|
1.2
|
1.4
|
L
 -2.7%
H
1.3
1.5
|
L
 -29.7%
H
1.3
2.1
|
L
 -26.8%
H
1.3
5.4
|
L
 -45.8%
H
1.3
5.4
|
L
 -31.1%
H
0.6
5.4
|
L
 -94.9%
H
0.2
158.5
|
L
 -99.2%
H
0.2
470.4
|
L
H
0.2
471
|
| Prelude Therapeutics Inc |
|
313.8
|
3.9
|
L
 2.6%
H
3.8
4.0
|
L
 3.1%
H
3.4
4.2
|
L
 -18.9%
H
3.4
5.1
|
L
 22.0%
H
2.8
5.5
|
L
 282.5%
H
0.8
5.5
|
L
 -28.9%
H
0.6
6.8
|
L
 -87.4%
H
0.6
43.6
|
L
H
0.6
95.4
|
| Prime Medicine Inc |
|
520.2
|
2.9
|
L
 -2.7%
H
2.8
3.1
|
L
 -15.3%
H
2.8
3.6
|
L
 -10.3%
H
2.7
3.6
|
L
 -28.2%
H
2.7
4.4
|
L
 70.4%
H
1.4
6.9
|
L
 -80.8%
H
1.1
15.8
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
| ProKidney Corp Ordinary |
|
342.7
|
1.7
|
L
 -2.3%
H
1.6
1.8
|
L
 -9.7%
H
1.6
2.0
|
L
 -10.2%
H
1.5
2.0
|
L
 -27.4%
H
1.5
2.6
|
L
 70.4%
H
0.5
7.1
|
L
 -85.5%
H
0.5
13.5
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
| ProQR Therapeutics NV |
|
154.9
|
1.5
|
L
 -3.9%
H
1.4
1.6
|
L
 3.5%
H
1.4
1.6
|
L
 -7.0%
H
1.4
1.7
|
L
 -17.4%
H
1.4
2.2
|
L
 -23.0%
H
1.3
3.1
|
L
 -16.5%
H
1.1
4.6
|
L
 -77.7%
H
0.5
9.1
|
L
 -70.2%
H
0.5
24
|
| Prothena Corporation plc |
|
443.4
|
8.5
|
L
 -1.1%
H
8.3
8.9
|
L
 -11.7%
H
8.3
9.6
|
L
 -21.1%
H
8.3
10.9
|
L
 -11.7%
H
8.3
11.8
|
L
 56.6%
H
5.0
11.8
|
L
 -87.9%
H
4.3
77.1
|
L
 -78.5%
H
4.3
79.8
|
L
 -82.7%
H
4.3
79.8
|
| Alpha Compute Corp |
|
6.4
|
0.3
|
L
 -6.9%
H
0.3
0.3
|
L
 -27.0%
H
0.3
0.3
|
L
 12.5%
H
0.2
0.6
|
L
 -27.0%
H
0.2
0.6
|
L
 -96.8%
H
0.2
13.8
|
L
 -99.6%
H
0.2
79
|
L
 -100.0%
H
0.2
899.5
|
L
 -99.9%
H
0.2
1310
|
| Plus Therapeutics Inc |
|
37.9
|
5.5
|
L
 -0.5%
H
5.1
5.8
|
L
 -3.5%
H
5.1
6.0
|
L
 -10.1%
H
5.1
7.3
|
L
 -23.8%
H
2.9
8.2
|
L
 -32.5%
H
2.9
23.4
|
L
 -93.8%
H
2.9
90.5
|
L
 -99.5%
H
2.9
1106.3
|
L
 -100.0%
H
2.9
453750
|
| PTC Therapeutics Inc |
|
6,111.7
|
73.7
|
L
 4.0%
H
71.3
74.3
|
L
 -0.2%
H
67.5
74.3
|
L
 0.0%
H
67.2
77.9
|
L
 17.3%
H
62.1
79.9
|
L
 41.3%
H
43.2
87.5
|
L
 73.1%
H
17.5
87.5
|
L
 76.3%
H
17.5
87.5
|
L
 833.8%
H
4.0
87.5
|
| Protagonist Therapeutics Inc |
|
6,808.6
|
105.9
|
L
 8%
H
98.1
106.5
|
L
 11.5%
H
92.8
106.5
|
L
 6.6%
H
92.8
106.5
|
L
 15.0%
H
90.6
107.8
|
L
 94.7%
H
49.4
107.8
|
L
 260.6%
H
13.7
107.8
|
L
 182.8%
H
6.9
107.8
|
L
H
4.5
107.8
|
| Pulmatrix Inc |
|
5.0
|
1.4
|
L
 -2.8%
H
1.3
1.4
|
L
 -0.7%
H
1.2
1.6
|
L
 6.2%
H
1.2
1.6
|
L
 -31.7%
H
1.2
2.5
|
L
 -84.5%
H
1.2
9.2
|
L
 -50%
H
1.2
10.4
|
L
 -93.0%
H
1.2
23.4
|
L
 -99.7%
H
1.2
1396
|
| Polypid Ltd |
|
87.6
|
4.6
|
L
 -1.1%
H
4.4
4.8
|
L
 -9.9%
H
4.4
5.2
|
L
 4.3%
H
4.2
5.2
|
L
 9.1%
H
4.0
5.2
|
L
 39.8%
H
2.8
5.2
|
L
 -62.8%
H
2.3
13.2
|
L
 -98.4%
H
2.3
289.2
|
L
H
2.3
583.5
|
| Pyxis Oncology Inc |
|
107.7
|
1.7
|
L
 0.6%
H
1.6
1.8
|
L
 -5.0%
H
1.6
1.9
|
L
 -38.0%
H
1.6
2.9
|
L
 24.1%
H
1.3
2.9
|
L
 25.9%
H
1.0
5.6
|
L
 -42.8%
H
0.8
6.9
|
L
H
0.8
19
|
L
H
0.8
19
|
| Pharming Grp N.V. (ADR) |
|
889.2
|
12.6
|
L
 -1.6%
H
12.3
12.7
|
L
 -3.9%
H
12.0
13.2
|
L
 -3%
H
11.8
13.8
|
L
 -18.5%
H
11.8
18.4
|
L
 6.2%
H
9.5
21.3
|
L
 13.3%
H
6.7
21.3
|
L
 4.0%
H
6.1
21.3
|
L
H
6.1
22.0
|
| Purple Biotech Ltd (ADR) |
|
2.8
|
3.0
|
L
 2.4%
H
2.8
3.1
|
L
H
2.8
3.1
|
L
 -27.4%
H
2.5
4.2
|
L
 -37.5%
H
2.5
5
|
L
 -88.6%
H
2.5
29
|
L
 -100.0%
H
2.5
7200
|
L
 -100.0%
H
2.5
23280
|
L
 -100.0%
H
2.5
192404.2
|
| AIxCrypto Holdings Inc |
|
25.9
|
1.3
|
L
 -0.8%
H
1.3
1.4
|
L
 -2.3%
H
1.2
1.4
|
L
 -6.6%
H
1.2
1.5
|
L
 16.4%
H
1.0
1.7
|
L
 -65.9%
H
0.9
8.8
|
L
 -97.6%
H
0.1
63
|
L
 -99.9%
H
0.1
1560
|
L
 -100.0%
H
0.1
468750
|
| Qilian Intl Holding Grp ltd (Class A) |
|
68.2
|
0.3
|
L
 6.3%
H
0.3
0.4
|
L
 6.3%
H
0.3
0.4
|
L
 17.2%
H
0.3
0.5
|
L
 -67.3%
H
0.3
1.1
|
L
 -97.4%
H
0.3
17.2
|
L
 -91.6%
H
0.3
17.2
|
L
 -98.6%
H
0.3
24.7
|
L
H
0.3
110
|
| Quince Therapeutics Inc |
|
19.0
|
1.0
|
L
 -3%
H
1.0
1.0
|
L
 -12.6%
H
1.0
1.2
|
L
 -24.2%
H
0.8
1.4
|
L
 -4.9%
H
0.8
3.8
|
L
 -91.7%
H
0.8
45.5
|
L
 -93.9%
H
0.8
45.5
|
L
 -99.8%
H
0.8
1219.8
|
L
H
0.8
1219.8
|
| uniQure NV |
|
1,668.8
|
26.5
|
L
 -2%
H
25.7
27.5
|
L
 -6.2%
H
25.7
31
|
L
 -4.3%
H
24
31
|
L
 85.4%
H
13.2
31
|
L
 53.2%
H
8.7
71.5
|
L
 27.3%
H
3.7
71.5
|
L
 -28.4%
H
3.7
71.5
|
L
 107.5%
H
3.7
82.5
|
| Quoin Pharma Ltd (ADR) |
|
9.9
|
5.0
|
L
 8.3%
H
4.5
5
|
L
 3.8%
H
4.1
5.1
|
L
 -16.5%
H
4.1
6.4
|
L
 -42.9%
H
4.1
10.8
|
L
 -43.9%
H
4.1
41.8
|
L
 -99.9%
H
4.1
8400
|
L
 -100.0%
H
4.1
3003840
|
L
H
4.1
3003840
|
| Rain Oncology Inc |
|
76.0
|
2.1
|
L
 -4.6%
H
2.0
2.2
|
L
 -9.9%
H
2.0
2.3
|
L
 64.6%
H
1.3
2.8
|
L
 -25.4%
H
1.3
3.8
|
L
 -43.4%
H
1.3
8.5
|
L
 62.0%
H
0.8
9.2
|
L
 -89.2%
H
0.8
22.2
|
L
H
0.8
23.9
|
| Rani Therapeutics Holdings Inc |
|
91.0
|
0.8
|
L
 -3.6%
H
0.8
0.9
|
L
 -10%
H
0.8
0.9
|
L
 -16.5%
H
0.8
1.1
|
L
 -37.7%
H
0.7
1.4
|
L
 44.6%
H
0.4
3.9
|
L
 -83.6%
H
0.4
8.8
|
L
 -99.6%
H
0.4
36.3
|
L
H
0.4
224.5
|
| Ultragenyx Pharmaceutical Inc |
|
2,244.6
|
22.8
|
L
 5.6%
H
22.0
23.0
|
L
 -0.3%
H
21.3
23.5
|
L
 -12.8%
H
21.3
27.4
|
L
 7.3%
H
18.3
27.4
|
L
 -38.7%
H
18.3
42.4
|
L
 -55.8%
H
18.3
60.4
|
L
 -75.6%
H
18.3
105.5
|
L
 -68.0%
H
18.3
179.7
|
| Rocket Pharmaceuticals Inc |
|
289.4
|
2.7
|
L
 -1.9%
H
2.5
2.8
|
L
 -12.3%
H
2.5
3.0
|
L
 -27%
H
2.5
3.8
|
L
 -39.9%
H
2.5
5.5
|
L
 -13.4%
H
2.4
5.5
|
L
 -88.7%
H
2.2
32.5
|
L
 -94.3%
H
2.2
49.7
|
L
 -92.6%
H
2.2
67.5
|
| Regeneron Pharma |
|
64,599.7
|
616.2
|
L
 0.8%
H
611.0
628.9
|
L
 2.6%
H
591.5
640.8
|
L
 -13.8%
H
591.5
730.6
|
L
 -18.9%
H
591.5
788.7
|
L
 24.9%
H
494.4
821.1
|
L
 -17.9%
H
476.5
1211.2
|
L
 21.7%
H
476.5
1211.2
|
L
 58.4%
H
271.4
1211.2
|
| Replimune Grp Inc |
|
763.0
|
9.2
|
L
 3.0%
H
8.4
9.3
|
L
 2.7%
H
8.4
10.9
|
L
 127.0%
H
3.6
10.9
|
L
 14.5%
H
1.5
10.9
|
L
 -11.0%
H
1.5
13.2
|
L
 -59.0%
H
1.5
24.8
|
L
 -71.8%
H
1.5
40.2
|
L
H
1.5
54.9
|
| Revelation Biosciences Inc |
|
4.1
|
1.0
|
L
 3.0%
H
1
1.1
|
L
 -4.6%
H
1.0
1.1
|
L
 8.3%
H
0.9
1.1
|
L
 -19.4%
H
0.9
1.4
|
L
 -89.9%
H
0.9
12.9
|
L
 -100.0%
H
0.9
6796.8
|
L
 -100.0%
H
0.9
2276064
|
L
H
0.9
2276064
|
| Regencell Bioscience Holdings Ltd |
|
10,043.1
|
20.3
|
L
 -5.1%
H
19.1
21.9
|
L
 -16.0%
H
19.1
25.1
|
L
 -30.6%
H
19.1
30
|
L
 -13.0%
H
19.1
40
|
L
 12.5%
H
9.4
83.6
|
L
 3073.4%
H
0.1
83.6
|
L
H
0.1
83.6
|
L
H
0.1
83.6
|
| Repligen Corp |
|
7,340.3
|
130.1
|
L
 3.8%
H
127.4
132.2
|
L
 5.7%
H
117.6
132.2
|
L
 5.4%
H
101.0
132.2
|
L
 8.5%
H
101.0
141.5
|
L
 1.4%
H
101.0
175.8
|
L
 -20.8%
H
101.0
211.1
|
L
 -28.7%
H
101.0
327.3
|
L
 425.8%
H
21.1
327.3
|
| Regenxbio Inc |
|
327.8
|
6.3
|
L
 3.4%
H
6.1
6.5
|
L
 -11.2%
H
6.0
7.2
|
L
 -39.9%
H
5.5
11.4
|
L
 -26.7%
H
5.5
11.4
|
L
 -34.0%
H
5.5
16.2
|
L
 -68.7%
H
5.0
28.8
|
L
 -83.1%
H
5.0
46.5
|
L
 -50.4%
H
5.0
85.1
|
| Rigel Pharma |
|
568.4
|
30.7
|
L
 2.1%
H
30.1
31.1
|
L
 2.9%
H
28.5
31.1
|
L
 18.0%
H
25.5
33.0
|
L
 6.4%
H
25.0
33.2
|
L
 43.0%
H
18.1
52.2
|
L
 1796.3%
H
0.7
52.2
|
L
 669.9%
H
0.6
52.2
|
L
 1143.7%
H
0.6
52.2
|
| Relay Therapeutics Inc |
|
3,070.8
|
14.1
|
L
 3.2%
H
13.2
14.1
|
L
 -1.2%
H
12.9
17.5
|
L
 10.4%
H
11.6
17.5
|
L
 42.5%
H
9.3
17.5
|
L
 319.4%
H
3.0
17.5
|
L
 26.3%
H
1.8
17.5
|
L
 -59.6%
H
1.8
38.6
|
L
H
1.8
64.4
|
| Relmada Therapeutics Inc |
|
657.7
|
6.3
|
L
 9.6%
H
5.6
6.3
|
L
 -8.5%
H
5.6
6.8
|
L
 -14.3%
H
5.6
7.7
|
L
 40.9%
H
5.6
8
|
L
 646.4%
H
0.5
8
|
L
 123.1%
H
0.2
8
|
L
 -79.4%
H
0.2
38.7
|
L
 -39.7%
H
0.2
54
|
| TransCode Therapeutics Inc |
|
4.7
|
5.0
|
L
 -2.2%
H
4.9
5.2
|
L
 -8.5%
H
3.8
6.3
|
L
 -32.0%
H
3.8
7.5
|
L
 -48.1%
H
3.8
10.3
|
L
 -30.3%
H
3.8
21.0
|
L
 -100.0%
H
3.8
118272
|
L
H
3.8
5174400
|
L
H
3.8
5174400
|
| RenovoRx Inc |
|
38.8
|
0.9
|
L
 -3.4%
H
0.9
0.9
|
L
 -6.5%
H
0.9
1.0
|
L
H
0.8
1.0
|
L
 8.9%
H
0.8
1.3
|
L
 -38.1%
H
0.7
1.5
|
L
 -55.9%
H
0.6
3.3
|
L
H
0.6
16.7
|
L
H
0.6
16.7
|
| Roivant Sciences Ltd |
|
20,894.8
|
29.1
|
L
 2.0%
H
28.3
29.3
|
L
 -0.1%
H
27.9
29.6
|
L
 1.7%
H
27.9
32.8
|
L
 0.9%
H
26.0
32.8
|
L
 158.7%
H
10.7
32.8
|
L
 203.2%
H
8.2
32.8
|
L
 194.6%
H
2.5
32.8
|
L
H
2.5
32.8
|
| Royalty Pharma PLC (Class A) |
|
24,659.3
|
55.6
|
L
 1.4%
H
54.4
55.8
|
L
 0.8%
H
53.9
56.5
|
L
 9.5%
H
50.5
56.5
|
L
 22.5%
H
44.7
56.5
|
L
 64.7%
H
33.4
56.5
|
L
 61.1%
H
24.1
56.5
|
L
 19.8%
H
24.1
56.5
|
L
H
24.1
56.5
|
| Revolution Medicines Inc |
|
31,793.8
|
149.6
|
L
 0.7%
H
146.5
151.5
|
L
 -8.6%
H
146.5
162.8
|
L
 5.5%
H
141
166.5
|
L
 52.0%
H
91.5
166.5
|
L
 264.0%
H
34
166.5
|
L
 502.1%
H
15.5
166.5
|
L
 363.1%
H
14.1
166.5
|
L
H
14.1
166.5
|
| Recursion Pharma Inc (Class A) |
|
1,709.1
|
3.2
|
L
 -3.0%
H
3.1
3.5
|
L
 -15.0%
H
3.1
4.0
|
L
 -3.0%
H
2.8
4.0
|
L
 -6.9%
H
2.8
4.0
|
L
 -41.4%
H
2.8
7.2
|
L
 -64.8%
H
2.8
16.7
|
L
 -89.2%
H
2.8
42.8
|
L
H
2.8
42.8
|
| Rhythm Pharma Inc |
|
6,026.6
|
87.9
|
L
 2.3%
H
84.7
90.1
|
L
 0.0%
H
82.9
90.1
|
L
 -6.7%
H
82.9
97.4
|
L
 -6.1%
H
74.5
100
|
L
 29%
H
60.7
122.2
|
L
 399.2%
H
15.5
122.2
|
L
 364.6%
H
3.0
122.2
|
L
H
3.0
122.2
|
| Rezolute Inc |
|
375.5
|
3.9
|
L
 -4.4%
H
3.7
4.1
|
L
 8.0%
H
3.6
4.7
|
L
 21.5%
H
2.8
4.7
|
L
 25.4%
H
2.3
4.7
|
L
 -12.0%
H
1.1
11.5
|
L
 97.0%
H
0.7
11.5
|
L
 -67.2%
H
0.7
17.4
|
L
 -91.4%
H
0.7
100
|
| Redhill Biopharma (ADR) |
|
4.2
|
0.8
|
L
 -21.6%
H
0.8
0.9
|
L
 -20%
H
0.8
1.1
|
L
 -20.8%
H
0.8
1.1
|
L
 -13.0%
H
0.7
1.1
|
L
 -59.8%
H
0.7
3.3
|
L
 -98.3%
H
0.7
82
|
L
 -100.0%
H
0.7
11180
|
L
 -100.0%
H
0.7
16540
|
| SAB Biotherapeutics Inc |
|
256.9
|
3.4
|
L
 -1.2%
H
3.4
3.5
|
L
 -2.3%
H
3.3
3.5
|
L
 -18.3%
H
3.3
4.3
|
L
 -11.4%
H
3.3
5.2
|
L
 85.6%
H
1.6
6.6
|
L
 265.2%
H
0.4
6.6
|
L
 -66.1%
H
0.4
12.9
|
L
H
0.4
12.9
|
| Sana biotech Inc |
|
784.8
|
2.8
|
L
 4.8%
H
2.6
2.9
|
L
 -12.2%
H
2.6
3.3
|
L
 -19.7%
H
2.6
3.8
|
L
 -10.5%
H
2.6
4.1
|
L
 -0.7%
H
2.4
6.6
|
L
 -57.9%
H
1.3
12
|
L
 -88.7%
H
1.3
26.6
|
L
H
1.3
44.6
|
| Filana Therapeutics Inc |
|
68.6
|
1.4
|
L
 -0.7%
H
1.4
1.5
|
L
 -4.7%
H
1.3
1.5
|
L
 9.2%
H
1.2
1.6
|
L
 -30.1%
H
1.2
2.5
|
L
 -35.2%
H
1.2
5.0
|
L
 -94.2%
H
1.2
42.2
|
L
 -97.9%
H
1.2
146.2
|
L
 -90.9%
H
0.8
146.2
|
| Sunshine Biopharma Inc |
|
3.7
|
2.3
|
L
 -6.2%
H
2.1
2.4
|
L
 -4.6%
H
2.1
3.1
|
L
 -78.3%
H
2.1
23.2
|
L
 -79.5%
H
2.1
23.2
|
L
 -84.9%
H
2.1
24.3
|
L
 -100.0%
H
2.1
12900
|
L
 -100.0%
H
2.1
712000
|
L
 -100.0%
H
2.1
45037037.0
|
| Scilex Holding Co |
|
49.5
|
7.0
|
L
 1.9%
H
6.8
7.2
|
L
 -11.9%
H
6.8
7.9
|
L
 -10.0%
H
5.6
9.7
|
L
 -17.0%
H
4.2
12.3
|
L
 11.6%
H
4.2
34.3
|
L
 6.0%
H
0.2
34.3
|
L
 -29.1%
H
0.2
34.3
|
L
H
0.2
34.3
|
| Scynexis Inc |
|
43.3
|
4.4
|
L
 -2.0%
H
4.3
4.8
|
L
 -18.2%
H
4.3
5.4
|
L
 -40.5%
H
4.3
7.3
|
L
 -31.9%
H
4.3
9.1
|
L
 -40.6%
H
4.3
10.5
|
L
 -79.0%
H
4.3
31.0
|
L
 -93.5%
H
4.3
69.2
|
L
 -98.7%
H
4.3
440.8
|
| Seer Inc (Class A) |
|
92.9
|
1.7
|
L
 -5.6%
H
1.7
1.8
|
L
 -10.1%
H
1.7
1.9
|
L
 -9.6%
H
1.7
1.9
|
L
 -5.1%
H
1.7
2.1
|
L
 -25.9%
H
1.7
2.4
|
L
 -64.5%
H
1.5
5.7
|
L
 -94.7%
H
1.5
45.9
|
L
H
1.5
86.6
|
| Selecta Biosciences Inc |
|
1,060.8
|
6.9
|
L
 16.9%
H
6.6
9.3
|
L
 -1.0%
H
5.8
9.3
|
L
 -20.8%
H
5.8
9.3
|
L
H
5.6
9.3
|
L
 -38.0%
H
5.6
15.6
|
L
 -33.2%
H
5.6
15.6
|
L
 -33.2%
H
5.6
15.6
|
L
 -33.2%
H
5.6
15.6
|
| Shuttle Pharma Holdings Inc |
|
2.6
|
0.5
|
L
 -6.3%
H
0.4
0.5
|
L
 -15.1%
H
0.4
0.5
|
L
 -34.8%
H
0.4
0.7
|
L
 -51.1%
H
0.4
1.2
|
L
 -90.2%
H
0.4
6.2
|
L
 -99.8%
H
0.4
254
|
L
H
0.4
25252
|
L
H
0.4
25252
|
| SIGA Tech Inc |
|
314.9
|
4.4
|
L
 1.4%
H
4.3
4.4
|
L
 -1.1%
H
4.2
4.5
|
L
 -8.5%
H
4.1
4.9
|
L
 -24.3%
H
4.1
5.8
|
L
 -27.2%
H
4.1
9.6
|
L
 -24.7%
H
4.1
12.8
|
L
 -33.4%
H
4.1
27.0
|
L
 367.0%
H
0.8
27.0
|
| SILO Pharma Inc |
|
7.0
|
6.5
|
L
 3.2%
H
6.1
6.7
|
L
 1857.6%
H
0.3
6.7
|
L
 1515%
H
0.3
6.7
|
L
 1857.6%
H
0.3
6.7
|
L
 1013.8%
H
0.2
6.7
|
L
 191.0%
H
0.2
6.7
|
L
 -55.4%
H
0.2
496
|
L
 -87.1%
H
0.2
496
|
| Solid Biosciences Inc |
|
646.8
|
6.6
|
L
 2.5%
H
6.3
6.8
|
L
 -8.6%
H
6.3
7.5
|
L
 -9.6%
H
6
7.9
|
L
 -2.7%
H
6
8.9
|
L
 44.7%
H
3.8
8.9
|
L
 4.0%
H
1.8
15.1
|
L
 -89.2%
H
1.8
73.7
|
L
H
1.8
822.6
|
| Sol-Gel Tech Ltd |
|
249.2
|
76.2
|
L
 -4.7%
H
73.0
81.0
|
L
 8.3%
H
70.3
81.0
|
L
 7.6%
H
62.5
81.5
|
L
 -6.6%
H
61.9
96
|
L
 952.8%
H
6.8
98.0
|
L
 2128.7%
H
0.3
98.0
|
L
 646.5%
H
0.3
98.0
|
L
H
0.3
98.0
|
| SELLAS Life Sciences Grp Inc |
|
1,510.1
|
7.7
|
L
 -3.8%
H
7.5
8.1
|
L
 -15.3%
H
7.5
9.2
|
L
 53.3%
H
5.0
9.5
|
L
 38.9%
H
4.0
9.5
|
L
 377.0%
H
1.4
9.5
|
L
 354.4%
H
0.5
9.5
|
L
 -33.4%
H
0.5
15.1
|
L
 -100.0%
H
0.5
74703
|
| Summit Therapeutics Inc |
|
11,091.4
|
14.3
|
L
 1.3%
H
14.0
14.7
|
L
 -9.0%
H
13.8
15.5
|
L
 -21.0%
H
13.8
19.4
|
L
 -5.4%
H
13.8
29.2
|
L
 -30.6%
H
13.8
31.0
|
L
 676.6%
H
1.5
36.9
|
L
 86.6%
H
0.7
36.9
|
L
 67.5%
H
0.7
36.9
|
| Syndax Pharma Inc |
|
1,567.5
|
17.7
|
L
 4.3%
H
17.1
18.1
|
L
 -6.2%
H
16.7
19
|
L
 -17.7%
H
16.7
22.7
|
L
 -19.9%
H
16.7
25.6
|
L
 54.5%
H
8.6
25.6
|
L
 -17.0%
H
8.6
25.6
|
L
 -9.0%
H
8.6
29.9
|
L
 24.2%
H
3.4
29.9
|
| Soligenix Inc |
|
6.4
|
0.4
|
L
 2.4%
H
0.4
0.5
|
L
 -47.6%
H
0.4
0.8
|
L
 48.3%
H
0.3
1.1
|
L
 -63.9%
H
0.3
1.4
|
L
 -77.7%
H
0.3
6.2
|
L
 -96.3%
H
0.3
85.3
|
L
 -99.8%
H
0.3
321.6
|
L
 -100.0%
H
0.3
2040.1
|
| Sonoma Pharma Inc |
|
3.9
|
1.1
|
L
 1.8%
H
1.1
1.2
|
L
 -5.9%
H
1.1
1.3
|
L
 -7.5%
H
1
1.3
|
L
 -53.4%
H
0.9
2.9
|
L
 -66.6%
H
0.9
6.9
|
L
 14.4%
H
0.1
6.9
|
L
 -85.6%
H
0.1
13.4
|
L
 -97.5%
H
0.1
74.2
|
| Synaptogenix Inc |
|
27.8
|
3.7
|
L
 -3.4%
H
3.6
4.1
|
L
 -11.6%
H
3.6
4.3
|
L
 -42.6%
H
3.6
6.9
|
L
 -6.3%
H
3.6
7.2
|
L
 54.4%
H
3.0
12.0
|
L
 332.6%
H
0.1
12.0
|
L
 -46.9%
H
0.1
14.5
|
L
H
0.1
14.5
|
| Sensei Biotherapeutics Inc |
|
16.9
|
12.6
|
L
 -2.9%
H
12.4
13.2
|
L
 -36.2%
H
12.4
20.6
|
L
 -46.0%
H
12.4
24.4
|
L
 -57.9%
H
12.4
36.1
|
L
 83.6%
H
5.6
36.8
|
L
 -53.9%
H
5
38.8
|
L
 -94.8%
H
5
260
|
L
H
5
530
|
| Senti Biosciences Inc |
|
28.3
|
0.9
|
L
 -3.2%
H
0.9
1
|
L
 -7.1%
H
0.9
1.1
|
L
 -8.1%
H
0.9
1.1
|
L
 -5.2%
H
0.8
1.2
|
L
 -76.3%
H
0.8
3.8
|
L
 -91.0%
H
0.8
16.9
|
L
 -9%
H
0.7
87.7
|
L
H
0.7
87.7
|
| Spruce Biosciences Inc |
|
134.9
|
49.0
|
L
 -0.6%
H
46.7
52.2
|
L
 -3.3%
H
46.7
54.3
|
L
 -13.2%
H
46.7
59.2
|
L
 -12.2%
H
46.7
80
|
L
 457.8%
H
7.3
240
|
L
 -71.9%
H
4.3
446.3
|
L
 -94.9%
H
4.3
976.5
|
L
H
4.3
2670
|
| SciSparc Ltd |
|
5.3
|
9.3
|
L
 -10.7%
H
8.4
10.0
|
L
 -12.1%
H
8.4
15.8
|
L
 49.0%
H
4
15.8
|
L
 67.2%
H
3.0
15.8
|
L
 -84.2%
H
3.0
80.1
|
L
 -99.7%
H
3.0
3145.0
|
L
H
3.0
41769
|
L
H
3.0
41769
|
| Spero Therapeutics Inc |
|
148.8
|
2.6
|
L
 -6.2%
H
2.5
2.8
|
L
 -9.2%
H
2.5
3.1
|
L
 0.4%
H
2.4
3.1
|
L
 11.7%
H
2.2
3.1
|
L
 2.8%
H
1.8
3.2
|
L
 42.8%
H
0.5
3.2
|
L
 -83.5%
H
0.5
19.9
|
L
H
0.5
23.6
|
| ARS Pharma Inc |
|
934.4
|
9.4
|
L
 4.7%
H
8.9
9.5
|
L
 -0.2%
H
8.4
9.5
|
L
 7.7%
H
7.0
9.9
|
L
 3.9%
H
7.0
9.9
|
L
 -35.1%
H
6.7
18.9
|
L
 38.6%
H
2.6
18.9
|
L
 -68.2%
H
2.6
35.6
|
L
H
2.6
63.4
|
| SeqLL Inc |
|
43.1
|
0.9
|
L
 11.7%
H
0.8
0.9
|
L
 -41.1%
H
0.7
1.5
|
L
 -42.7%
H
0.7
1.7
|
L
 -70.2%
H
0.7
4.6
|
L
 -64.3%
H
0.7
5.3
|
L
 115%
H
0.3
35.4
|
L
H
0.2
35.4
|
L
H
0.2
35.4
|
| Sarepta Therapeutics Inc |
|
1,677.6
|
15.9
|
L
 2.2%
H
15.4
16.3
|
L
 -9.8%
H
15.4
17.6
|
L
 -20.4%
H
15.4
21.0
|
L
 -4.9%
H
15.4
23.9
|
L
 -63.1%
H
10.4
43.9
|
L
 -87.4%
H
10.4
173.3
|
L
 -80.0%
H
10.4
173.3
|
L
 -18.3%
H
10.4
181.8
|
| Scholar Rock Holding Corp |
|
5,461.8
|
45.6
|
L
 4.1%
H
43.7
45.7
|
L
 -3.8%
H
43.3
47.0
|
L
 -5.8%
H
43.3
52.2
|
L
 0.6%
H
38.8
52.2
|
L
 33.2%
H
27.1
52.2
|
L
 556.8%
H
5.9
52.2
|
L
 62.1%
H
4.3
52.2
|
L
H
4.3
70
|
| Surrozen Inc |
|
249.6
|
21.5
|
L
 3.9%
H
20.6
22.0
|
L
 -13.0%
H
20.5
25.7
|
L
 -25.8%
H
20.5
31.8
|
L
 -20.5%
H
20.5
35
|
L
 152.9%
H
8
35
|
L
 3424.6%
H
0.3
35
|
L
H
0.3
35
|
L
H
0.3
35
|
| Stoke Therapeutics Inc |
|
1,829.2
|
29.4
|
L
 1.3%
H
28.6
30.1
|
L
 -3.6%
H
28.5
31.1
|
L
 -10.7%
H
28.0
34.4
|
L
 -17.2%
H
28.0
40.2
|
L
 163.6%
H
10.9
40.2
|
L
 131.4%
H
3.4
40.2
|
L
 -27.2%
H
3.4
41.6
|
L
H
3.4
71.6
|
| Sutro Biopharma Inc |
|
427.4
|
25.8
|
L
 1.5%
H
24.4
27.4
|
L
 -8.7%
H
23.6
30.9
|
L
 -35.9%
H
23.6
43.9
|
L
 2.0%
H
19.1
43.9
|
L
 204.1%
H
6.7
43.9
|
L
 -49.6%
H
5.2
61.3
|
L
 -86.2%
H
5.2
237
|
L
H
5.2
283
|
| Shattuck Labs Inc |
|
327.4
|
4.3
|
L
 9.5%
H
4.0
4.7
|
L
 -24.4%
H
3.3
5.7
|
L
 -37.7%
H
3.3
7.3
|
L
 -28.7%
H
3.3
8.3
|
L
 274.6%
H
0.7
8.3
|
L
 45.7%
H
0.7
11.8
|
L
 -86.0%
H
0.7
31.2
|
L
H
0.7
60.5
|
| Supernus Pharma Inc |
|
2,650.1
|
45.7
|
L
 2.7%
H
44.7
45.8
|
L
 2.0%
H
43.5
45.8
|
L
 -11.4%
H
43.5
52.4
|
L
 -15.2%
H
43.5
56
|
L
 37.7%
H
30.8
59.7
|
L
 28.3%
H
22
59.7
|
L
 52.0%
H
22
59.7
|
L
 132.8%
H
13.1
61.3
|
| Savara Inc |
|
1,010.3
|
4.9
|
L
 -2.6%
H
4.7
5.1
|
L
 -4.3%
H
4.7
5.4
|
L
 -5.7%
H
4.7
5.4
|
L
 -6.5%
H
4.7
6.2
|
L
 102.1%
H
2.0
7
|
L
 67.1%
H
1.9
7
|
L
 170.9%
H
1.0
7
|
L
 -80.4%
H
0.7
49.6
|
| China SXT Pharma Inc |
|
7.0
|
1.6
|
L
 0.7%
H
1.5
1.7
|
L
 -7.1%
H
1.4
1.9
|
L
 -9.8%
H
1.4
1.9
|
L
 -23.5%
H
1.3
2.6
|
L
 -25.4%
H
0.0
7.0
|
L
 -71.9%
H
0.0
9.4
|
L
 -95.9%
H
0.0
57
|
L
H
0.0
2335
|
| 60 Degrees Pharma Inc |
|
3.7
|
1.4
|
L
 -2.8%
H
1.4
1.5
|
L
 -4.8%
H
1.4
1.6
|
L
 -9.7%
H
1.4
1.6
|
L
 -32.2%
H
1.3
3.6
|
L
 -88.1%
H
1.3
12.2
|
L
H
1.3
2076
|
L
H
1.3
2076
|
L
H
1.3
2076
|